<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2026-01-05 09:24:43 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena L. Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>94</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, Sara Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/046a4759f61fd2ed00479ddd2426526fb3c7aa64" target='_blank'>
              Myeloid reprogramming by poly(I:C) recruits progenitor-exhausted CD8+ T cells and sensitizes rhabdoid tumors to PD-1 blockade
              </a>
            </td>
          <td>
            Valeria Manriquez, Sofia Cavada-Silva, Kévin Beccaria, L. L. Niborski, Amaury Leruste, W. Richer, Mathias Vandenbogaert, Zhi-Yan Han, C. Sedlik, Jordan Denizeau, Jeremy Mesple, Zoé Fusilier, L. Laëtitia Lesage, Jérémie Goldstein, Yohan Gerber-Ferder, Stéphanie Fitte-Duval, Federico Marziali, R. Mena-Osuna, Jimena Tosello-Boari, Rachida Bouarich-Bourimi, Maria Florencia Pacini, Y. Missolo-Koussou, Mylène Bohec, Sylvain Baulande, Philippe Benaroch, J. Helft, Hélène D Moreau, J. Waterfall, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="ABSTRACT Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. HPV-negative HNSCC, arising in diverse upper airway mucosal niches, is particularly aggressive, with poor 5-y survival and a limited response to immune checkpoint inhibitors. A deeper understanding of the tumor-localized immune landscape is essential to uncover actionable immunotherapeutic targets. Here, we integrated two single-cell RNA sequencing (scRNA-seq) datasets from 29 samples totaling nearly 300,000 immune cells to dissect immune rewiring during tumor progression and lymph node metastasis in HPV-negative HNSCC. We identified distinct shifts in adaptive immune cell populations across 14 peripheral blood mononuclear cell (PBMC) and 21 tumor-infiltrating immune cell (TIC) states. Notably, TICs exhibited enriched interferon response and immunomodulatory gene signatures, in contrast to PBMCs, indicating tumor-specific immune imprinting. Ligand–receptor analysis revealed that immunosuppressive crosstalk between macrophages and cytotoxic cells was associated with advanced disease. To spatially validate these transcriptional states, we conducted multiplexed immunofluorescence profiling on nine locally invasive HPV-negative HNSCCs, all from the ventrolateral tongue mucosa. Spatial proteomics confirmed peritumoral enrichment of activated (CD107a+, ICOS+) NK and CD8+ T cells and intratumoral accumulation of exhausted (PD-1+, PD-L1+) phenotypes, mirroring pseudotime trajectories inferred from scRNA-seq. These findings highlight spatially localized cytotoxic cell exhaustion as a key immune evasion mechanism in HPV-negative HNSCC and underscore the value of integrating spatial and single-cell data to reveal therapeutic vulnerabilities.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e184d6ff5ae8303f9ef6f76673a4a076479b44fb" target='_blank'>
              Single-cell landscape of peripheral and tumor-infiltrating immune cells in HPV-negative HNSCC
              </a>
            </td>
          <td>
            Rômulo Gonçalves Agostinho Galvani, Adolfo Alexis Rojas Hidalgo, Carlos Alberto Biagi-Junior, B. Matuck, Jelte Martinus Maria Krol, Brittany T. Rupp, Nikhil V. Kumar, Khoa L. A. Huynh, Jinze Liu, Siddharth Sheth, Vinicius Maracaja-Coutinho, K. Byrd, Patricia Severino
          </td>
          <td>2025-12-30</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e10756da93e249564dafc2b41fce10c7b1ebac2e" target='_blank'>
              Dual PD-L1/TIGIT blockade induces PNAd⁺ HEV-like vessels and CD62L⁺ lymphocyte recruitment, driving rhabdoid tumor rejection
              </a>
            </td>
          <td>
            Stéphanie Fitte-Duval, Sofia Cavada Silva, R. Mena-Osuna, Owen Hoare, L. L. Niborski, Jordan Denizeau, Laëtitia Lesage, W. Richer, C. Sedlik, Kévin Beccaria, Maëva Veyssière, Rachida Bouarich-Bourimi, Jérémie Goldstein, Federico Marziali, Jimena Tosello Boari, J. Masliah-Planchon, Zhi-Yan Han, Dario Rocha, Mylène Bohec, Sylvain Baulande, J. Waterfall, Valeria Manriquez, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48deb9a97772c3939779b0a727ea3595d2e4a10f" target='_blank'>
              PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
              </a>
            </td>
          <td>
            Teresa Dinter, Sebastian Mackowiak, Zachary J. Rogers, Vidit Bhandarkar, Molly Carney, Yiming J. Zhang, D. Morgan, Lorelai Pop, Fiona Chatterjee, E. Lutz, Yajit Jain, Adityanarayanan Radhakrishnan, Eric Lander, K. Dane Wittrup, J. C. Love, Alexander Meissner, Stefani Spranger
          </td>
          <td>2025-11-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6a060eabfcbbb0a36b483e2912054f711b0272" target='_blank'>
              Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
              </a>
            </td>
          <td>
            Mehdi Chaib, M. Aminu, Shelley M Herbrich, Mahshid Arabi, Yue Xuan, Akshay V. Basi, Anna Casasent, Marc D. Macaluso, Kenneth H. Hu, Matthew M. Gubin, Xi Chen, James J. Mancuso, Sreyashi Basu, Sonali Jindal, Jared K. Burks, S. Watowich, Jia Wu, James P. Allison, Padmanee Sharma
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Tumor-specific CD8+ T lymphocytes play a critical role in anticancer immunity but frequently become dysfunctional and exhausted within the immunosuppressive tumor microenvironment. Although immune checkpoint inhibitors can restore T-cell activity, resistance to these treatments remains a significant challenge. Therefore, understanding the transcriptional and regulatory mechanisms underlying CD8+ T-cell exhaustion is crucial for the development of effective therapies. We developed two murine models of acquired immune checkpoint inhibitor resistance through prolonged anti-PD1 treatment. To gain insight into CD8+ T-cell exhaustion, we performed single-cell multiomics analysis, including both scRNA-seq and scATAC-seq, to capture gene expression profiles and chromatin accessibility. Moreover, we collected three external datasets to validate the results in silico. We further assessed the therapeutic potential of Runx2 through marker expression and cytotoxicity assays. Our single-cell analysis revealed distinct T-cell subsets, including early and terminally exhausted populations, along with their exhaustion trajectories. Runx2 was identified as a key transcription factor associated with CD8+ T-cell exhaustion in both models and correlated with immunotherapy response in clinical data. Additionally, functional marker expression and cytotoxicity assays demonstrated that inhibiting Runx2 improved CD8+ T-cell cytotoxicity. These findings highlight the role of Runx2 as a crucial regulator of CD8+ T-cell exhaustion in the context of prolonged immune checkpoint inhibitor treatment. Targeting Runx2 may provide a novel strategy to overcome immune checkpoint inhibitor resistance and enhance therapeutic efficacy, offering promising avenues for combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4efed637bde0b584b5806d223ee2a3f6b51d5e91" target='_blank'>
              Transcriptional dynamics of CD8+ T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution
              </a>
            </td>
          <td>
            Tzu-Yang Tseng, Ching-Hung Hsieh, Hsuan-Cheng Huang, Yu-Ching Wu, Chiun Hsu, Chia-Lang Hsu, D. Ou, Hsueh‐Fen Juan
          </td>
          <td>2025-12-01</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="Background Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, an immunomodulatory drug (IMiD), demonstrates clinical synergy with CAR-T therapy, yet the underlying mechanisms driving this potentiation remain poorly defined. This study aimed to elucidate how pomalidomide enhances CAR-T cell function and remodels the immune microenvironment to overcome therapeutic limitations. Methods In vitro assays (CCK-8, LDH, qPCR, ELISA, flow cytometry) and bulk RNA-seq assessed pomalidomide’s effects on human CAR-T cells. In vivo efficacy was evaluated in myeloma xenograft models. Single-cell RNA sequencing (scRNA-seq) of PBMCs from a lymphoma patient post-CAR-T/pomalidomide assessed immune microenvironment remodeling. Results Pomalidomide significantly enhanced CAR-T cell proliferation and cytotoxicity in an activation-dependent manner. It upregulated effector molecules (IL-2, IFN-γ) and chemokines (CXCL9-CXCL11), promoted central memory T cells (Tcm), and induced metabolic reprogramming while reducing exhaustion markers. In xenografts, combination therapy induced tumor regression and extended survival vs. CAR-T alone. scRNA-seq revealed pomalidomide-driven remodeling, characterized by increased T/NK cell proportions/activity and reduced myeloid-derived suppressor cell (MDSC) signatures. Conclusions Pomalidomide synergizes with CAR-T by directly enhancing CAR-T function (memory, cytokine/chemokine production, metabolic fitness, and reduced exhaustion) and remodeling the suppressive immune microenvironment (increased cytotoxic effectors, diminished MDSC activity). These findings provide a crucial mechanistic rationale for optimizing pomalidomide-CAR-T combinations in refractory lymphoid malignancies. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04247-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6abcb94332697bc83ab93d4c224183daa93951d7" target='_blank'>
              Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies
              </a>
            </td>
          <td>
            Yi Zhou, Yan Yu, Linzhi Xie, Liwen Wang, Yuhan Yan, Qian Cheng, Jing Liu, Chang Zhang, Xin Li
          </td>
          <td>2025-12-18</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c11565e00df96d730b6130fa5ba4b31516b47635" target='_blank'>
              PI3Kδ promotes T cell effector differentiation and plasticity during chronic infection
              </a>
            </td>
          <td>
            Andrea C. Pichler, J. Cannons, Dominic P. Golec, Julie M. Reilley, Dan Corral, Eduard Ansaldo, Qin Xu, Subrata Paul, Paul Schaughency, Francisco A. Otaizo-Carrasquero, Stacie M. Anderson, Anshu Deewan, Dorian B. McGavern, Pamela L. Schwartzberg
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="ABSTRACT The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dbc5d5398d9317cc8645ea9323e07cb973e30cab" target='_blank'>
              cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
              </a>
            </td>
          <td>
            Meiqi Ren, Zhichao Eric Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong C. Shen, Xiangyu Yao, Zhipeng Yan
          </td>
          <td>2025-11-30</td>
          <td>Cancer Biology & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e088dcd4f395d6c7df482c6c35fcef0137dc41" target='_blank'>
              An epigenetic switch in vascular phenotype augments anti-tumor immunity
              </a>
            </td>
          <td>
            Dae Joong Kim, Mitchell T McGinty, S. Anandh, C. Riedstra, Yuvraj Sethi, Melanie R. Rutkowski, A. C. Dudley
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/275812dc3294ac678dbefad1e9f5e6d112d20c5e" target='_blank'>
              SP140 limits type I interferon–driven pathology, preserving T cell motility and promoting resistance in tuberculosis
              </a>
            </td>
          <td>
            Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Serge Mazères, Yaël Duvergé, Yohan Lorreyte, Emmanuelle Näser, S. Behar, Emma Lefrançais, O. Neyrolles, Denis Hudrisier
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="Epstein-Barr virus (EBV) infects >95% of the adult population with diverse outcomes ranging from benign latency to cancers and autoimmune diseases. Immunological control of EBV infection is known to be an important determinant of EBV infection outcomes. However, species-specific viral tropism and limited infection models have impeded mechanistic insights into early host–immune control of EBV infection. Here, we use ex vivo infection of peripheral blood mononuclear cells (PBMCs), rather than routinely used B cell enriched culture systems, to study immune and viral dynamics during primary EBV infection. We combined bulk RNA sequencing, EBV transcript enrichment, and flow cytometry to characterize cellular responses across Days 1, 7–8, and 14 post-infection. Early infection triggered a monocyte-specific antiviral response marked by changes in the expression of genes associated with lipid metabolism (LIPA, lysosomal acid lipase) and chemotaxis (CCR1 and CCR2). Inhibitors of LIPA increased EBV titers during primary infection, indicating that LIPA is part of an early monocyte-driven antiviral response. At later timepoints post-infection, donor-dependent variability in lymphoblastoid cell line (LCL) outgrowth was associated with divergent immune states. Donors that failed to generate LCLs demonstrated increased frequencies of CD8+ T cells and reduced numbers of regulatory T cells (CD4⁺CD25⁺FOXP3⁺). EBV transcriptomics revealed that LCL-failed donors exhibited elevated early lytic gene expression but did not establish a type III latency program. Our findings suggest that individual variations in immune cell composition and gene expression may account for differences in the immune response to EBV. These findings define temporal immune and viral signatures that predict transformation outcome and highlight intact PBMCs as a tractable model to study EBV pathogenesis in a genetically diverse, human-specific context. AUTHOR SUMMARY Individual variation in response to Epstein-Barr virus (EBV) infection can lead to diverse pathogenic outcomes, ranging from cancers to autoimmune disease. To study this variation, we analyzed immune cell response and viral dynamics during the ex vivo primary EBV infection of peripheral blood mononuclear cells (PBMCs) from donors that either fail or succeed to generate lymphoblastoid cell lines (LCLs). Flow cytometry and RNA-seq revealed a rapid monocyte-specific antiviral response among all donors marked by genes associated with lipid metabolism (LIPA) and chemotaxis (CCR1 and CCR2). LIPA inhibition increased EBV titers during primary infection, demonstrating a functional antiviral role. At later timepoints, donor-specific differences in CD8+ T cells and Treg subsets, along with EBV gene expression, were correlated with successful LCL outgrowth. Treatment with the Treg-depleting antibody RG6292 suppressed viral transformation in donors that otherwise supported LCL outgrowth, confirming a functional role for Tregs in shaping early EBV infection outcomes. Viral transcript enrichment-seq revealed an upregulation of early lytic and failure to sustain latent gene expression correlating with failure to generate LCL. These findings highlight intact PBMCs as a tractable model to study EBV viral-host interaction in a genetically diverse, human-specific context, and that Tregs play a key determining role in viral transformation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8803f87b9598f62e1119244e26857dfd233ed68" target='_blank'>
              EBV INFECTION OUTCOMES DETERMINED BY MONOCYTE AND TREG-DRIVEN IMMUNE DYNAMICS IN AN EX VIVO PBMC MODEL
              </a>
            </td>
          <td>
            Leena Yoon, Lauren N. MacMullen, Leonardo Josué Castro Muñoz, Alina Gu, Jamie Bregman, Mary S. Campion, Avi Srivastava, Rena R. Xian, Richard F Ambinder, A. Kossenkov, Samantha S. Soldan, Paul M. Lieberman
          </td>
          <td>2025-11-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a82efc5b2c9cc4922bf6d2b205d9310648f4f84" target='_blank'>
              Single-cell multiomics reveals epigenetic rewiring of splenic memory B cells in murine malaria reinfection
              </a>
            </td>
          <td>
            Montserrat Coronado, Á. Vincelle-Nieto, Isabel G. Azcárate, S. Pérez-Benavente, A. Puyet, Amalia Díez, José M. Bautista, A. Reyes-Palomares
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Severe fever with thrombocytopenia syndrome virus (SFTSV) infection is associated with poor clinical outcomes and defective humoral immunity yet the immunometabolic mechanisms underlying B cell dysfunction remain incompletely defined. Through integrated single‐cell RNA sequencing and B cell receptor (BCR) repertoire profiling of peripheral B cells from SFTS patients, we dissected the molecular signatures between survivors and fatal cases. Functional validation and metabolic flux analysis were further performed. Seven transcriptionally distinct B cell subsets were identified. Fatal cases exhibited a marked expansion of CXCR3+Ki‐67+CXCR5‐ extrafollicular plasmablasts, coupled with depletion of naïve and memory B cells. These plasmablasts exhibited hyperactivation of interferon‐response genes (IFI27, ISG15), upregulation of inflammatory mediators (S100A8/A9), and contraction of BCR diversity, with skewed usage of λ‐light chains. Pseudotime trajectory analysis and metabolic scoring revealed progressive upregulation of oxidative phosphorylation, glycolysis and endoplasmic reticulum stress during terminal differentiation. In fatal cases, B cells exhibited suppressed antigen presentation capacity and impaired immunoglobulin gene expression, alongside heightened oxidative stress and elevated CD39 levels. Furthermore, analysis of SFTSV‐infected versus uninfected B cells revealed that infected plasmablasts displayed enhanced inflammatory and migratory features, including upregulated CXCR3 and CCR10 expression, suggesting direct viral modulation of B cell function and trafficking. Our study reveals that dysfunctional, metabolically reprogrammed plasmablasts underlie humoral immune failure in fatal SFTS. These findings provide mechanistic insight into B cell‐mediated immunopathogenesis and highlight potential targets for prognostic evaluation and immunomodulatory intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3800a9aa69e7fadce2b5246f5ad88f00ce2eb14b" target='_blank'>
              Dysregulated B Cell Responses in Severe Fever With Thrombocytopenia Syndrome Revealed by Single‐Cell RNA Sequencing
              </a>
            </td>
          <td>
            Hongyan Hou, Siyu Zou, Teding Chang, Yun Wang, Ting Wang, Wei Wei, Rujia Chen, Renren Ouyang, Hui Hu, Shiji Wu, Feng Wang
          </td>
          <td>2025-12-01</td>
          <td>Journal of Medical Virology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/457d4de587553b09db9c04406c900e3b240f5c8f" target='_blank'>
              CD74 regulates antitumor immunity in melanoma by reprogramming dendritic cell immunogenicity and migration
              </a>
            </td>
          <td>
            Eleftheria Maranou, Gayoung Park, Pauline Weinzettl, Jonna Alanko, Otto I. Pulkkinen, Sarah E. Coupland, Marko Salmi, Carlos R. Figueiredo
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a leading cause of global morbidity and mortality. Although gamma-delta (γδ) T cells have increasingly been suggested to contribute to the TB immune response, quantitative and qualitative differences in this immune cell compartment between healthy and TB diseased individuals are not well-characterized. In this study, we used single-cell RNA sequencing to provide a high-resolution characterization of CD4-CD8- γδ T cells in peripheral blood across healthy Mtb-non-sensitized, healthy Mtb-sensitized, and TB disease pre-/post-treatment cohorts. We found upregulation of an activated and cytotoxic gene signature in γδ T cells of TB disease compared to both healthy cohorts. Strikingly, these differences persisted through one year following diagnosis of TB disease (corresponding to six months after completion of anti-TB therapy). We found that these transcriptomic differences were largely mediated by an NK-like cytotoxic Vδ1 and Vδ3 subset that was enriched in TB disease, with a unique Vδ3 TCR gene usage. Our findings suggest long-lasting changes in the CD4-CD8- γδ T cell compartment and highlight Vδ3 cells, a previously underappreciated γδ T cell subset, as potentially important in TB.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bfebb60d4d4f02fb39194b81fd4a071f887608f9" target='_blank'>
              Enrichment of a CD4−CD8− NK-like cytotoxic Vδ1/3 T cell subset in tuberculosis disease
              </a>
            </td>
          <td>
            Kendall Kearns, R. Tippalagama, Ashu Chawla, Jason A. Greenbaum, A. D. de Silva, Wathsala Gunasinghe, Judy Perera, Hansani Gunasekera, Darsha D Senevirathne, Thomas J. Scriba, Julie G. Burel, C. L. Lindestam Arlehamn, Bjoern Peters
          </td>
          <td>2025-11-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fab0829fa668d3f68087f51374ae0be2ba943151" target='_blank'>
              Perturbational single-cell profiling of patient tumors defines lineage- and context-specific programs of innate immune resistance
              </a>
            </td>
          <td>
            C. Perry, A. Frey, Y. Fei, J. Wang, P. Costa, H. N. Amin, S. Ghadermarzi, D. Levine, W. Tong, A. Koda, M. Mackie, M. He, Y. Nie, K. Clulo, F. Ouerghi, J. Wei, T. Cordero Dumit, M. Yaskolko, M. Ding, A. Caldera, O. Kyrysyuk, L. Lum, J. W. Allen, W. Guo, A. Naqash, A. Elliot, A. Vanderwalde, M. Capelletti, T. Adeyelu, S. Barry, M. Hugaboom, A. Bacchiocchi, H. Kluger, M. Bosenberg, A. Iwasaki, D. Braun, J. Clune, D. van Dijk, K. Olino, J. Ishizuka
          </td>
          <td>2025-12-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Tumor-infiltrating lymphocyte (TIL) therapy is FDA-approved for patients with treatment-resistant advanced melanoma, but the TIL subpopulations critical for tumor eradication remains incompletely understood. Using patient-derived TIL-melanoma co-cultures, we identified and characterized a novel subset of CD8+ TIL, capable of class I HLA-independent cancer cell lysis. The lymphotoxin β receptor (LTβR) and interferon (IFN) sensing pathways were nominated as key determinants of TIL-mediated cancer cell killing from a whole-genome, loss-of-function CRISPR screen. Validation studies confirmed that dual LTβR and IFN sensing is necessary and sufficient for cancer cell lysis, and that expanded CD8+ TIL express high lymphotoxin β (LTB) and upregulate lymphotoxin α (LTA) upon coculture with cancer cells. Leveraging paired scRNA-seq and scTCR-seq data, we confirmed that enrichment of LTB+CD8+ T cells is associated with clinical response to TIL, and that LTB+CD8+ TIL are expanded from putative neoantigen-reactive, LTBlo CD8+ T cells in resected tumors. Significance We have uncovered a previously unrecognized mechanism of TIL-mediated tumor eradication, providing mechanistic insights into the role of LTBR/IFN signaling in TIL-mediated cancer cell killing, and potentially offering insights into novel strategies to isolate, enrich, and expand tumoricidal TIL or augment specific TIL functions to enhance tumor control.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96e61290a2db67a69101779de100cc9747e73c2c" target='_blank'>
              Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL
              </a>
            </td>
          <td>
            Hongyan Xie, Aiping Jiang, Aonkon Dey, Joseph W. Dean, Jonathan J. Perera, Neal P. Smith, Alex C. Y. Chen, Seth Anderson, Angelina M Cicerchia, Yi Sun, William A Michaud, Maria Florentin, Jacy Fang, Or-Yam Revach, T. Sharova, Aleigha R Lawless, Katherine H Xu, Yuhui Song, Bidish Kumar Patel, Jonathan D. Stevens, William J. Lane, Derin B. Keskin, Sonia Cohen, Donald P Lawrence, Ryan J. Sullivan, Keith T Flaherty, Genevieve M. Boland, Linda T. Nieman, Moshe Sade-Feldman, N. Hacohen, Debattama R. Sen, Catherine J. Wu, B. Gastman, Rongsu Qi, Hequn Yin, A-C. Villani, R. Manguso, Russel Jenkins
          </td>
          <td>2025-11-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>117</td>
        </tr>

        <tr id="Aging and cerebrovascular pathology drive neuroinflammation in vascular dementia (VaD) but immune mechanisms underlying this interplay remain unresolved. Leveraging multi-modal high-dimensional imaging, flow cytometry, and split pool ligation transcriptomic sequencing in a mouse model of VaD, we constructed a brain immune cell atlas spanning young and aged mice in health and disease. We profiled microglia, T cells, macrophages, neutrophils, and B cells and integrated transcriptomics, cell-cell communication, multiplex imaging, and comparative analysis with human microglia. We found striking depletion of Ccr7+ naïve T cells and expansion of Gzmk+ cytotoxic Cd8+ effector memory T cells in the aging brain. At the same time, microglia shifted toward a pro-inflammatory state with enhanced activity of major histocompatibility class complex I (MHC-I) to T cell receptor and co-stimulation from CD86 to CD28. These shifts suggest enhanced neuroinflammatory polarization within the aged brain and in VaD. These signals were strongest from activated microglia to Gzmk+ Cd8+ TEM cells, indicating that age-related microglial polarization may sustain cytotoxic T cell activation in the aged brain. Our findings suggest pro-inflammatory microglia and Gzmk+ CD8+ TEM cells are central drivers of immune brain aging and highlights a therapeutic potential to disrupt age-related neuroinflammatory cascades in VaD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42ac3a3908e79bc0f916a88d264039358a6730c2" target='_blank'>
              High-Dimensional Single-Cell Analysis Reveals Coordinated Age-Dependent Neuroinflammatory Microglia-T cell Circuits in the Brain
              </a>
            </td>
          <td>
            Md Akkas Ali, Md. Hasanul Banna Siam, Donald Vardaman, Chase Bolding, J. N. Brazell, Ashleigh D. Whatley, Christopher A. Risley, Harrison Tidwell, Syed Nakib Hossain, Juhi Samal, Ashley S. Harms, Mallikarjun Patil, Daniel J. Tyrrell
          </td>
          <td>2025-12-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="ABSTRACT The incorporation of the current immunotherapy, GD2-targeting monoclonal antibodies, into the standard of care has moderately improved clinical outcomes in children with high-risk neuroblastoma (HR-NB); however, overall survival remains low. More than 50% of patients with HR-NB are refractory to or eventually develop resistance to anti-GD2 treatment. HR-NBs are generally known to have a low tumor mutational burden, are immunologically cold and possess an immunosuppressive tumor microenvironment. Understanding the mechanisms of immune evasion may provide novel targets for improving the efficacy of immunotherapies for these immunologically cold HR-NBs. Here, utilizing immunocompetent mouse models of immunologically cold HR-NB, we revealed a novel function of IGF2BP1 in promoting the immune escape of neuroblastoma tumors. We demonstrate that neuroblastoma cell-specific knockdown of IGF2BP1 favorably alters the tumor microenvironment of HR-NBs, turning these “immunologically cold” tumors into an immunogenic type, thereby priming them for anti-GD2 therapy-induced immune responses. Downregulation of IGF2BP1 in NB cells decreased the number of immunosuppressive T-regulatory and dysfunctional/exhausted CD8+ T cells and promoted the accumulation of effector MHCII +  macrophages at the tumor site. Importantly, knockdown of IGF2BP1 along with anti-GD2 immunotherapy induced a synergistic immunogenic effect and achieved a potent antitumor response in an HR-NB mouse model, with increased accumulation of effector CD8+ T cells and CD86+  macrophages but decreased MDSC numbers in the tumor microenvironment. Thus, disrupting NB cancer cell IGF2BP1-mediated immunosuppression is a potential approach for improving the efficacy of anti-GD2 immunotherapy towards HR-NBs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f2673362b04d72c7ef9c09b32302276a86d8cfe" target='_blank'>
              IGF2BP1 fosters an immunosuppressive tumor microenvironment in high-risk neuroblastoma, contributing to their resistance to immunotherapy
              </a>
            </td>
          <td>
            Mayura R Dhamdhere, Chethana Gowda, Yuka Imamura, Hong-Gang Wang, Todd S Schell, V. Spiegelman
          </td>
          <td>2025-12-02</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ab79f630ee108b9ad79cdd23cb73d99a2673e4d" target='_blank'>
              Type 2 diabetes Reprograms Bone Marrow Hematopoiesis and Dysregulates Immune Signaling in Response to Stroke
              </a>
            </td>
          <td>
            Hongxia Zhang, Wanjun Gu, Kailin Yu, Chia-Ling Tu, Wenhan Chang, Jialing Liu
          </td>
          <td>2025-12-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, Na-Young Kim, Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7e50ce208a78ff6653e59e288e486f934aca2d39" target='_blank'>
              Three-Dimensional Epigenome Roadmap of Human B-cell Differentiation Uncovers Mechanisms of Humoral Immunity and Oncogenesis
              </a>
            </td>
          <td>
            Raúl de Haro-Blázquez, Laureano Tomás-Daza, Lucía Fanlo-Escudero, Paula López-Martí, Nicolás Byrne-Álvarez, Llorenç Rovirosa, Blanca Valero-Martínez, Juan Ochoteco, Maria Rigau, Galina Medvedeva, Lucía Álvarez-González, Blanca Urmeneta, Ainoa Planas-Riverola, Jose Carbonell, Teresa Robert-Finestra, A. Alqahtani, Nicholas Brittain, José Falcon-Bermejo, Marta Kulis, J. Martín-Subero, María Dolores Guerrero-Gilabert, Emilio Amilibia, Anna Costa, Sara Pérez, Lisa J. Rusell, Daniel Rico, Alfonso Valencia, B. Javierre
          </td>
          <td>2025-12-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b024d10f1892bbe468173d191392bfbd89e47853" target='_blank'>
              TAp73 mediates anti-tumor immunity through regulation of lipid metabolism in the lung tumor microenvironment
              </a>
            </td>
          <td>
            Hayley D. Ackerman, Vanessa Rubio, Andrew J. Davis, John H. Lockhart, Nicole Hackel, Rachel V. Jimenez, Rosa A. Sierra-Mondragon, Jaden R. Baldwin, Christina L Carr, Michelle Reiser, M. Napoli, Xiaoqing Yu, Chia-Ho Cheng, Paul A. Stewart, S. Acevedo-Acevedo, Rahul Checker, Ioannis Grammatikakis, X. Su, Yaning Wu, Trey Gould, Alexis Bailey, Lary A. Robinson, E. Haura, John M. Koomen, Paulo C. Rodriguez, Elsa R Flores
          </td>
          <td>2025-11-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2+/MHC-I⁻/MHC-II+), we can cure mice with a regimen that includes radiation therapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2) while establishing immunological memory. We interrogated the role of T cells in the antitumor and memory responses following RT+IC. We show a requirement for CD4, but not CD8 T cells, to achieve both the initial and memory responses. Upon IC-induced cell-cell contact, subsets of CD4 T cells, including Foxp3⁺ T regulatory cells, trogocytose GD2 from tumor cells, acquire cytotoxic granules, and kill tumor cells. These results were confirmed using human tumor cell lines. These findings reveal that CD4⁺ T regulatory cells, upon immunologically-induced binding to tumor cells, can trogocytose tumor antigens and directly kill tumor cells, redefining their potential role in antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77253e2042c64402b4c27c711448fdd4c49c02c6" target='_blank'>
              Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing
              </a>
            </td>
          <td>
            AK Erbe, Arika S. Feils, Anqi Gao, Sabrina N. VandenHeuvel, Simon Boyenga, Alina A. Hampton, M. Heck, Jen Zaborek, Dan V. Spiegelman, N. Tsarovsky, A. Hoefges, A. Pieper, Peter M. Carlson, Mildred A. Felder, Ravi B Patel, S. Gillies, Alexa R. Heaton, Zachary S. Morris, Huy Q. Dinh, A. Rakhmilevich, Paul M. Sondel
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9bc787e32b19937cc86d82b167fee2834cae712" target='_blank'>
              T CELLS PROMOTE THE GROWTH OF SMALL-CELL LUNG CARCINOMA VIA AN IL-6/CD74 AXIS
              </a>
            </td>
          <td>
            Maya Baron, Zoé Ginestet, Debadrita Bhattacharya, Myung Chang Lee, Alexandros P. Drainas, Clara L. Poupault, Y. Nishiga, Alec E. Dallas, B. Nabet, Julien Sage
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Cancer immunotherapies, from checkpoint blockade to adoptive cell therapies like tumor-infiltrating lymphocytes (TILs), have revolutionized cancer treatment but are limited by variable efficacy and significant toxicities. A central challenge is identifying ideal T-cell populations that effectively eliminate tumors without causing off-target damage, a distinction not captured by existing biomarkers. We show that co-expression patterns of chemokine receptors (CRs) CXCR3, CCR5, and CXCR6 on CD8+ T cells provide a functional “code” defining subsets with divergent roles in on-target immunity versus off-target inflammation. In mouse and human melanoma, a triple-positive (CXCR3+CCR5+CXCR6+) T-cell subset is essential for tumor control, and its genetic signature correlates with positive clinical response, while a distinct CCR5+CXCR6+ subset drives liver immune-related adverse events (IRAEs). Crucially, this CR code reveals that immunotherapy actively reshapes T-cell trafficking patterns, uncovering profound heterogeneity within conventional populations and distinguishing potent anti-tumor progenitors from cells predisposed to exhaustion or off-target migration. This work establishes CR co-expression as a practical tool, providing a surface marker-based strategy to identify and enrich optimized T cells for adoptive therapies, thereby offering a framework to uncouple efficacy from toxicity. One Sentence Summary Co-expression of CCR5, CXCR6, and CXCR3 provides a functional ’code’ that separates T-cell-mediated anti-tumor efficacy from off-target toxicity, enabling the selection of superior cells for safer and more effective cancer immunotherapies. Graphical Abstract Highlights · CXCR6, CXCR3 and CCR5 co-expression signature stratifies patient survival in human melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 are critical effectors with high proliferative, cytotoxic, and activation profile in human and mice melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 drive anti-tumoral responses during checkpoint blockade in both human and mice">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ffb2ffb5ffbc1f04ce6b70ec760612828941d302" target='_blank'>
              A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma
              </a>
            </td>
          <td>
            Rodney Macedo, David W. Harle, Kevin Hoffer-Hawlik, X. Wang, Thomas McMahon-Skates, Alexandra Matschiner, Kirubel Belay, Yvonne M. Saenger, Benjamin Izar, Elham Azizi, Ran Reshef
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Current therapies for inflammatory bowel disease (IBD) often fail to achieve complete remission and are associated with systemic toxicity owing to their broad immunosuppressive effects. To overcome these limitations, we developed a bioengineered extracellular vesicle (EV) platform that modulates key immune signaling pathways to efficiently restore the T-cell balance in inflamed intestinal tissues. EVs derived from Wharton’s jelly mesenchymal stem cells were engineered to display PD-L1 on their surface and encapsulate miR-27a-3p. Surface PD-L1 engages the PD-1 checkpoint in activated T cells, attenuating T-cell receptor signaling via SHP2-mediated dephosphorylation of ZAP70 and AKT. In parallel, miR-27a-3p suppresses prohibitin 1 (PHB1), a mitochondrial regulator of Th17 cell bioenergetics and inflammatory function, thereby reducing Th17 polarization and increasing the number of FOXP3⁺ regulatory T cells. These dual-targeting EVs preferentially localized to inflamed intestinal tissues via chemokine (CCR2/CXCR4) and PD-1-dependent mechanisms. In humanized mouse models of colitis, these EVs attenuated mucosal inflammation, suppressed effector T-cell responses, and preserved epithelial integrity. In IBD patient-derived colonoid cultures, PD-L1/miR-27a-3p EVs maintained epithelial viability and barrier integrity without inducing cytotoxicity or structural disruption. Transcriptomic and single-cell analyses revealed the downregulation of inflammatory and exhaustion signatures, along with the enrichment of regulatory subsets. Collectively, this study presents a cell-free immunotherapeutic approach that reprograms T cells in inflamed tissues through the PD-1 and mitochondrial signaling pathways while maintaining intestinal epithelial integrity, offering a promising therapeutic strategy for IBD and other T cell-driven inflammatory disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/21a759c51278c1cf53050a54d395a9872336d71e" target='_blank'>
              Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease
              </a>
            </td>
          <td>
            Mi-Kyung Oh, Hyun Sung Park, Dong-Hoon Chae, Aaron Yu, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Byeonghwi Lim, Jun-Mo Kim, Jordan E. Axelrad, Kyung Ku Jang, Jong Pil Im, S. Koh, Byung-Soo Kim, Kyung-Rok Yu
          </td>
          <td>2025-12-25</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Alloreactive T cells mediate graft-versus-leukemia (GvL) reactions and acute graft-versus-host disease (aGvHD) in AML patients following allogeneic hematopoietic stem cell transplantation. To investigate biomarkers that identify alloreactive T cells associated with either beneficial GvL or detrimental aGvHD, we collected graft samples and two post-transplant follow-up blood samples (day 30 and day 100) of ten AML patients undergoing hematopoietic stem cell transplantation and profiled over 777,000 CD45+ leukocytes in total by combinatorial barcoding-based mega-scale single-cell RNA sequencing. Using immune receptor sequences as intrinsic clonal barcodes, we observed that especially CD8+ graft-derived T cells persisted and displayed enhanced proliferation, clonal expansion, and likely alloreactivity. Notably, patient-derived peripheral leukocytes that survived the conditioning, as identified by sex-chromosome-related genes, were primarily CD4+ T helper cells. MDGA1 expression on T cells and NK cells emerged as a novel biomarker potentially associated with aGvHD. Additionally, we observed a significant deficiency of ADGRG1 expression, a marker of alloreactive cytotoxic T cells, by αβ and γδ T cells from relapsed patients. In conclusion, mega-scale single-cell monitoring of graft and hematopoietic immune cell reconstitution allowed us to demonstrate that MDGA1 and ADGRG1 may function as complementary biomarkers expressed by distinct circulating T cells that are associated with divergent outcomes in AML patients, enabling precise risk stratification of alloHSCT outcomes and presenting potential therapeutic targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fe518bb9ca65d3427b9019b19f10b127820644b3" target='_blank'>
              Mega-scale single-cell profiling reveals novel biomarkers associated with acute GvHD after allogeneic hematopoietic stem cell transplantation
              </a>
            </td>
          <td>
            Zheng Song, E. Klyuchnikov, A. Badbaran, Likai Tan, R. Dress, Emilia Czajkowski, Simeon Weßler, R. Massoud, C. Wolschke, Anja Schimrock, Yu Zhang, Cedric Ly, N. Gagelmann, Kristin Rathje, B. Fehse, Stefan Bonn, Sarina Ravens, Nicola Gagliani, Christian Krebs, Ulf Panzer, F. Ayuk, N. Kröger, I. Prinz
          </td>
          <td>2025-12-01</td>
          <td>Biomarker Research</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="Most patients with hepatocellular carcinoma (HCC) develop resistance to immune checkpoint blockade (ICB) or STING agonists despite their immune-stimulating activities. Here, we identify increased intratumoral B-cell infiltration as a mediator of acquired resistance. In HCC models with liver fibrosis in male mice, anti-PD-1 ICB or the STING agonist BMS-986301 increase intratumoral B-cell infiltration, circulating IL-10, and TIM-1+ B-cells, promoting tertiary lymphoid structure formation. B-cell depletion combined with ICB or STING agonism improves survival, and STING agonism inhibits distant metastasis. In addition, co-targeting STING and TIM-1 enhances B-cell differentiation and antigen presentation, reduces intratumoral TIM-1+ B-cells, and increases CD86 and MHC class II expression, thereby augmenting CD8+ T-cell-mediated anti-tumor immunity. These findings reveal that B-cells contribute to ICB and STING therapy resistance in HCC, and that B-cell depletion or TIM-1 blockade can overcome acquired resistance to these immunotherapies. B cell subsets expanding during tumor progression have been associated with impaired anti-tumor responses and resistance to immunotherapy. Here the authors report that STING agonism or anti-PD-1 induce intratumoral B cell infiltration, and that depleting B-cells improves response to immunotherapies in preclinical models of hepatocellular carcinoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3aef0adfea1b3ee9cc082a0682a2dafd6789c8d9" target='_blank'>
              Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Xin Liu, Zelong Liu, Chengzhan Zhu, Tatsuya Kobayashi, Pin-Ji Lei, Yue Shi, Dandan Yuan, Jianguo Wang, Min Li, Aya Matsui, Kassiana Mafra, Tomofumi Ando, Ken Kojo, Rieke Schleinhege, Kento Miyazaki, Peigen Huang, Ming Kuang, Lloyd Bod, Dan G. Duda
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Background Cervical cancer (CC) is a leading cause of cancer-related deaths in women, and understanding the tumor immune microenvironment is crucial for identifying novel biomarkers and therapeutic targets. While T cells have been extensively studied in oncology, the role of B cells in CC remains poorly understood. Methods In this study, we generated and integrated multi-omics data, including single-cell RNA sequencing, single-nucleus RNA sequencing, spatial transcriptomics, bulk RNA sequencing, and multiplex immunofluorescence to investigate the composition and transcriptomic states of B cells in CC. Results Initially, we analyzed plasma cells, classifying them into IgA+ and IgG+ subtypes. We found that the proportion of IgA+ plasma cells was lower in cancer samples, whereas IgG+ plasma cells were higher. IgA+ plasma cells exhibited protein folding and B cell activation characteristics, while IgG+ plasma cells were associated with apoptosis and immune suppression. Subsequently, we focused on two specific plasma cell populations, MANF_PC and HSPA1B_PC. MANF_PC, which were predominantly enriched in normal tissues, were linked to enhanced antibody synthesis and better prognosis, while HSPA1B_PC, primarily found in cancerous tissues, were associated with apoptotic pathways and poor clinical outcomes. Importantly, HSPA1B_PC are associated with tertiary lymphoid structures (TLS), where they show significant spatial colocalization with immunosuppressive T cell subsets, including Tregs and Th17 cells within TLS. Conclusions We identified distinct plasma cell subsets in CC and found that HSPA1B_PC are enriched in tumors, associated with immunosuppressive T cells in TLS. These findings suggest that HSPA1B_PC contribute to an immunosuppressive microenvironment in CC, highlighting their potential as therapeutic targets. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04268-w.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/080e66fe49aff182ded60fe5be8fdc18f68a7609" target='_blank'>
              Multi-omics profiling reveals an immunosuppressive plasma cell subset within tertiary lymphoid structures in cervical cancer
              </a>
            </td>
          <td>
            Qingyu Huang, Fuhao Wang, Xiaohui Li, Wen-Lu Zou, Zhou Huang, Xia Li, Wenhui Yang, T. Lei, Shengqin Yue, Qian Wang, Qi An, Bicheng Zhang, Cong Wang, Chao Liu, Qinyong Hu
          </td>
          <td>2025-12-23</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/71b827598caa3b92c66b1747f1e4d291bdfd16d5" target='_blank'>
              Multi-omics Analysis of Human Blood Cells Reveals Unique Features of Age-associated Type2 CD8 Memory T cells
              </a>
            </td>
          <td>
            Hiroyuki Matsui, Marlene Cervantes, Mir M. Khalid, Alan Tomusiak, Varun B. Dwaraka, Jorge Landgrave-Gomez, Prasanna Vadhana Ashok Kumaar, Qingwen Chen, Jesica Lasky-Su, Jake Stone, Ritesh Tiwari, Ryan Kwok, Shuntaro Ichikawa, Benjamin D. Ambrose, Rebeccah Riley, G. Hormazabal, Ariel Floro, Andreea Cristina Alexandru, Ryan Smith, B. Schilling, Herbert Kasler, Eric Verdin
          </td>
          <td>2025-12-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized the treatment of advanced malignancies such as melanoma. However, a significant proportion of patients fail to respond, owing to mechanisms that remain poorly understood. Here, we developed murine melanoma cell lines (R1 and R2) derived from MO4 tumors and that are resistant to anti-PD−1 therapy. These resistant cells exhibited increased tumor initiation capacity in vivo correlating with enhanced spheroid formation in vitro, and greater invasiveness and metastatic potential in a lung macrometastasis model. Mechanistically, both R1- and R2- derived tumors showed enrichment of a cancer stem cell (CSC)-like population overexpressing Wnt3a, which correlated with reduced infiltration and impaired function of CD8+ tissue-resident memory (TRMs) T cells. This suggested a functional link between Wnt-driven cancer stemness and TRMs dysfunction. Pharmacological inhibition of Wnt/β-catenin signaling in vitro enhanced CD8+ T cell proliferation and expression of functional markers. Notably, Wnt/β-catenin inhibition in vivo reversed anti-PD−1 resistance in resistant tumors, coinciding with reduced OCT4+Wnt3a+ CSC-like cells and restoration of TNFα+CD8+ TRMs. Finally, transcriptomic analysis of publicly available melanoma cohorts showed that enrichment of the Wnt pathway correlates with poor prognosis and ICB resistance, highlighting this pathway as a potential druggable negative regulator of ICB efficacy in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f77e7d52138792d22d71c5dbfbe6f13abb61e07" target='_blank'>
              Wnt3a-expressing cancer stem cells impair CD8+ TRM function, contributing to immunotherapy resistance in Melanoma
              </a>
            </td>
          <td>
            Julian A. Gajón, Ángel Juárez-Flores, Fatima Mendoza-Roldan, J. Hernández-Aceves, Samira Muñoz-Cruz, Armando Pérez-Torres, E. Fuentes-Pananá, L. C. Bonifaz
          </td>
          <td>2025-12-03</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Purpose
Colorectal cancer (CRC) lung metastases exhibit high recurrence rates after resection, underscoring the need for improved therapeutic strategies. This study aimed to characterize the tumor microenvironment (TME) of CRC lung metastases and identify the factors associated with recurrence.


Materials and Methods
Fifteen CRC patients who underwent lung metastasectomy were enrolled. Multiplex immunohistochemistry (IHC), whole exome sequencing, transcriptome profiling, and single-cell RNA sequencing (scRNA-seq) were conducted on matched tumor, adjacent and distant normal lung tissues. Immune cell populations and gene expression profiles were analyzed and correlated with clinical recurrence outcomes.


Results
Exome and transcriptome analyses revealed frequent TP53, KRAS, and APC mutations. Most tumors corresponded to consensus molecular subtypes 2 and 4, characterized by immune-depleted and fibrotic features. Tumors showed downregulation of effector T and NK cell signatures. IHC revealed reduced density and increased distance of CD8+ T cells and macrophages from the epithelial cells. scRNA-seq demonstrated increased regulatory T cells and decreased NK and effector T cells in tumor. Tumor-associated macrophages (TAMs), particularly SPP1 (osteopontin)-expressing subsets, were markedly enriched in tumor and correlated with suppressed effector T cella activity. High SPP1 expression was associated with early recurrence and poor overall survival. Patients with recurrence had higher proportion of PD-1+ CD8+ T cells in adjacent normal tissues.


Conclusion
Immunosuppressive features including enrichment of SPP1+ TAMs and depletion of effector T and NK cells contribute to recurrence after CRC lung metastasectomy. Therapeutic strategies targeting both TAMs and T cells may enhance clinical outcomes in this patient population.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ae972bf762bae15538dd4da3de79b673b4d58b2d" target='_blank'>
              Immunosuppressive Tumor Microenvironment in Colorectal Cancer Lung Metastases: Implications for Recurrence After Metastasectomy.
              </a>
            </td>
          <td>
            Minsuk Kwon, Minkyue Shin, M. An, Y.J. Jeon, T. Hong, Jung Kyong Shin, Sung Hee Lim, Yoonah Park, Y. Cho, Seung-Tae Kim, Y. Choi, Jeeyun Lee
          </td>
          <td>2025-12-17</td>
          <td>Cancer research and treatment</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Background Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of TH1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8+ T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8+ T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f10076dc13711bdee9c69a81615daf0299024df" target='_blank'>
              SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
              </a>
            </td>
          <td>
            Mei Huang, Run Shi, Cong Xu, Yihan Zhang, Xiaoyue Du, S. Wen, Chunbin Wang, F. Jiang, Guoren Zhou, Xin Wang, Bo Shen
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/938f1648314d21b17f5602b7a84c055f9ef0d7b2" target='_blank'>
              Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: Insights from in vitro assays§
              </a>
            </td>
          <td>
            Miriam Kelm, Nourhan Nasr, S. Bendig, Dieter Kabelitz, M. Lustig, H. Trautmann, A. Laqua, Christian Peters, D. Wesch, Heiner Oberg, Ottmar Janssen, T. Valerius, C. Baldus, A. Scheffold, M. Brüggemann, G. Chitadze
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b8cfbe41c4f5eea58d4484e39d30b0c559a09da" target='_blank'>
              Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function
              </a>
            </td>
          <td>
            Armin Gandhi, Kathryn Lande, Yichen Li, Filipe A. Hoffman, Michael LaPorte, Shirong Tan, Garrett Evensen, Benji Portillo, M. Teneche, Rouven Arnold, Adarsh Rajesh, Jessica Proulx, Shanshan Yin, Aaron P. Havas, Charlene Miciano, Qian Yang, Elizabeth Smoot, S. Mamde, Andrew Davis, Kevin Y. Yip, Allen Wang, Bing Ren, April Williams, S. Kaech, Peter D. Adams
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4-CD8-TCRαβ T cells that interact with CXCL16 expressing non-classical monocytes. Leukemia cell intrinsic transcriptional rewiring in these patients is associated with activation of Rap1 signaling. Inhibiting Rap1 signaling results in increased sensitivity to the BCL2/BCL-XL inhibitor navitoclax. Our study provides insights into the immune microenvironment of pediatric hematologic malignancies, forming the basis for identifying potential (immuno) therapeutic targets and risk stratification for treatment. Understanding of the immune microenvironment in pediatric acute T cell lymphoblastic leukemia is limited. By analyzing single-cell transcriptome, surface protein expression and immune repertoire data, the authors here identify non-malignant CD4-CD8- TCRαβ T cells that are present in a subset of patients with Rap1 signaling in leukemia cells and are associated with adverse clinical outcome in patients with low minimal residual disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb527a6740e54a5aab04ff54dc24e5f1755e30d3" target='_blank'>
              Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia
              </a>
            </td>
          <td>
            Caroline R. M. Wiggers, Eugene Y Cho, Merve Ozdemir, Gbolahan Bamgbose, Justin Hegel, Julia Frede, Frederike Warlitz, Tayla B. Heavican-Foral, Ioana Pop, R. Shraim, P. Pölönen, Victoria B. Koch, T. Tran, C. Mullighan, D. Teachey, Jacob R. Bledsoe, Yana Pikman, Marian H. Harris, Andrew E. Place, Lewis B. Silverman, Jens G. Lohr, Birgit Knoechel
          </td>
          <td>2025-11-21</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>108</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96d3861c110e5ae3f35e700cedd4412c7f059c98" target='_blank'>
              T-cell Multiomic Analysis Identifies Subsets and Mechanisms of Interaction with Epithelial Cells in Idiopathic Pulmonary Fibrosis
              </a>
            </td>
          <td>
            A. Serezani, Julia M. R. Bazzano, B. Pascoalino, Ludmilla da Silva, Abigail J. Dietrich, Chase J. Taylor, T. Sherrill, C. Calvi, Paula I. Gonzalez-Ericsson, E. Wilfong, Matthew D Bacchetta, C. Shaver, Lorraine B. Ware, M.L. Salisbury, Luc Van Kaer, N. Banovich, JA Kropski, Timothy S. Blackwell
          </td>
          <td>2025-11-19</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Tumor-infiltrating regulatory T (Treg) cells contribute to immune evasion and are associated with poor prognosis in solid tumors. While CD47 blockade has demonstrated efficacy in hematologic malignancies, its application in solid tumors is hindered by the antigen sink effect and lack of tumor selectivity. Here, we report a rationally designed aptamer-siRNA chimera that selectively targets intratumoral Treg cells by exploiting their co-expression of PD-L1 and CD47 within the tumor microenvironment. The PD-L1 aptamer enables selective binding to PD-L1⁺ Treg cells and simultaneously inhibits PD-L1-mediated immune suppression. Conjugated CD47 siRNA silences CD47 expression, abrogating the “don’t eat me” signal and facilitating phagocytic clearance. Mechanistically, this chimera efficiently depletes tumor-infiltrating Treg cells with negligible impact on peripheral cells, and leads to a pronounced increase in intratumoral CD8⁺ T cell infiltration. Further investigation revealed that the chimera impairs Treg migration by disrupting glycolysis-related signaling pathways, including pERK1/2 and pRac1, and induces metabolic reprogramming characterized by reduced glycolysis, increased oxidative metabolism, and elevated fatty acid oxidation (FAO). In murine hepatocellular carcinoma models, treatment with the chimera significantly inhibited tumor growth, reduced angiogenesis, and prolonged survival. Our findings highlight a dual immune checkpoint-targeting strategy that integrates selective delivery with gene silencing, offering a tumor-specific, non-antibody approach for Treg depletion and a promising avenue for solid tumor immunotherapy. Supplementary Information The online version contains supplementary material available at 10.1186/s43556-025-00392-2.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e08750a58059534a9ab521c1290cb1dabc0d16" target='_blank'>
              Targeting tumor-infiltrating regulatory T cells: combining CD47 and PD-L1 inhibition via a novel aptamer-siRNA chimera
              </a>
            </td>
          <td>
            Yu Zeng, Xiaoli Chen, Wenqiong Huang, Chi Ho Chan, Ziqi Chen, Minchuan Lyu, Yumeng Liu, Meijun Liu, Aiping Lyu, Claudio Mauro, Yuanyuan Yu, Kenneth C P Cheung
          </td>
          <td>2025-12-01</td>
          <td>Molecular Biomedicine</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Fibrotic colorectal cancers (CRC) are largely microsatellite-stable and display desmoplastic stroma with poor immune infiltration. Here we identify thrombospondin-2 (THBS2) as a key regulator of the immune-exclusionary phenotype in fibrotic CRC. THBS2 is highly expressed by matrix cancer-associated fibroblasts at the tumor front. In an orthotopic model using desmoplastic tumor organoids, global or fibroblast-specific Thbs2 deletion disrupts the exclusionary barrier and increases intratumoral CD8 T cells. Mechanistically, THBS2 limits recruitment of CXCR3+ CD8 T cells by restraining dendritic- and macrophage-derived CXCL9/10. Depletion of these myeloid cells or blockade of CXCL9/10-CXCR3 signaling abolishes the enhanced CD8 T-cell influx and antitumor efficacy. Spatial profiling demonstrates that THBS2 loss induces proximity between CD8 T cells and myeloid cells and upregulates chemokines. Despite increased infiltration, CD8 T cells manifest exhaustion, rendering tumors highly susceptible to immune checkpoint blockade. THBS2 thus represents a tractable CAF-restricted target to overcome immune exclusion in fibrotic CRCs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/388320818ae6ea3dc30b0402479bdd593842387a" target='_blank'>
              Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer
              </a>
            </td>
          <td>
            Kosuke Iwane, Y. Nakanishi, Yu Muta, Jiayu Chen, Kento Yasumura, Mayuki Omatsu, Naoki Aoyama, Munehiro Ikeda, Yoko Masui, Liyang Cai, Go Yamakawa, K. Hamada, Kenta Mizukoshi, Munenori Kawai, Kei Iimori, Shinnosuke Nakayama, Nobukazu Agatsuma, Takahiro Utsumi, M. Nagao, T. Maruno, Y. Hiramatsu, N. Kakiuchi, M. Nakagawa, Y. Fukui, Yukina Kusunoki, H. Kasashima, Masakazu Fujimoto, Yoshiro Itatani, T. Kogame, A. Fukuda, Masakazu Yashiro, K. Maeda, K. Kabashima, K. Obama, Seishi Ogawa, Maria T. Diaz-Meco, J. Moscat, Hiroshi Seno
          </td>
          <td>2025-11-23</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>88</td>
        </tr>

        <tr id="Background Osteosarcoma patients with high propensity for metastasis and recurrence generally encounter a poor prognosis. Despite the extensive exploration of immunotherapy, particularly the anti-programmed cell death protein 1 (anti-PD-1) antibody, in clinical trials, the efficacy remains unsatisfactory. A more profound comprehension of the resistance mechanisms and the development of innovative therapeutic strategies is imperative. Methods A screening was performed for drugs capable of upregulating major histocompatibility class I (MHC I) expression among clinically common drugs. The effects of the drug on both T cells and tumor cells, as well as its combination efficacy with anti-PD-1 antibody, were studied in vitro and in vivo osteosarcoma models. The molecular mechanisms underlying these biological processes were explored via RNA sequencing analysis. Results Etoposide was shown to upregulate the MHC I expression in osteosarcoma cells, thereby enhancing the cytotoxicity of CD8+ T cells. Interleukin-33 (IL-33) played a dominant role in etoposide-activated anti-tumor immune response. Etoposide promoted the secretion of IL-33 and augmented the expression of IL-33 binding suppression of tumorigenicity 2 (ST2) receptor, which activated the nuclear factor kappa-B signaling pathway and resulted in MHC I upregulation. Furthermore, etoposide was demonstrated to improve the therapeutic efficacy of anti-PD-1 antibody. Conclusions This study revealed the molecular mechanism underlying etoposide-activated CD8+ T cell anti-tumor immunity. The combination of Etoposide and anti-PD-1 antibody has the potential to benefit patients with advanced osteosarcoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aea14a94e9240ead4d9e63865b48d8450e9c389e" target='_blank'>
              Etoposide activates CD8+ T cell anti-tumor immunity in osteosarcoma through MHC I upregulation via tumor-secreted IL-33 mediated signaling
              </a>
            </td>
          <td>
            Xin He, Hanjun Li, Haoyu Wang, D. Zuo, Haoru Dong, Haoran Mu, Binghui Yang, Yining Tao, Xiyu Yang, Bowen Zhao, Tao Zhang, Yafei Jiang, Zhuoying Wang, Hongsheng Wang, Liu Yang, Yingqi Hua, Zhengdong Cai, Chong Wang, Mengxiong Sun, Jun Gui, Wei Sun
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eda924ce01379c46e7af9cc01dc3f59feafe7bb9" target='_blank'>
              Myeloid cells contribute to bystander CD8 T cell accumulation in metabolic-associated steatohepatitis and are sufficient for fibrosis
              </a>
            </td>
          <td>
            Cynthia Lebeaupin, Katelyn L. Donahue, Stephen M. Christensen, Shoh Asano, Marc H. Wadsworth, Kathryn Bound, Saurav De, James McMahon, Franklin Schlerman, Chang Wang, Xiao Chen, A. M. Barron, Thomas A. Wynn, Kevin M. Hart, Thomas Fabre
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Age is a dominant risk factor for all major breast cancer subtypes. However, the mechanisms by which aging influences tumor development remain unclear. Using a novel mouse model whereby breast cancer is induced in situ in young and old wild-type mice via intraductal delivery of a lentivirus encoding the HER2/neu oncogene, we found that old mice exhibited a higher oncogene-induced tumor burden than young mice. Old tumor cells showed reduced expression of interferon-related genes, particularly the T cell-recruiting chemokines Cxcl9 and Cxcl10, linked to their altered chromatin accessibility. CXCL9/10 expression also declined with age in human HER2+ tumors. Correspondingly, old tumors exhibited fewer T cells within tumor lesions. Targeted interventions showed that decreased expression of Cxcl9/10 is responsible for reduced T cell infiltration and weakened anti-tumor immunity. These results show how aged tumor cells are impaired in their recruitment of immune cells, leading to a defective anti-tumor immune response.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b38011df7fcbd774b6090832583a2578934863ea" target='_blank'>
              Aging alters tumor cell - T cell crosstalk to promote breast cancer progression
              </a>
            </td>
          <td>
            Shanshan Yin, Kay T Yeung, S. Mamde, Kate Lin, Armin Gandhi, Xue Lei, Andrew Davis, Rouven Arnold, Jing Yang, P. Adams
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eaaff9dad9a60083319c3fb56581e38fedd65c55" target='_blank'>
              Senescent host-derived extracellular vesicles potentiate antitumor immunity via bystander T cell activation
              </a>
            </td>
          <td>
            Chenlu Yao, Chenhui Weng, Heng Wang, Bingbing Wu, Rong Sun, Huaxing Dai, Fang Xu, Qingzhen Han, Dong Zheng, Yumin Wu, Chao Wang
          </td>
          <td>2025-12-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Stem-like T cells (TSL) represent a distinct subset of CD4+ and CD8+ T cells characterized by self-renewal, multipotent differentiation, and long-term persistence, and have emerged as pivotal regulators of immune responses in chronic disease contexts. Despite growing interest, the developmental programs, molecular signatures, and clinical relevance of TSL remain incompletely understood, limiting their translational potential. Recent evidence highlights the central role of key transcription factors such as TCF-1 and BCL6, metabolic circuits including the Wnt-β-catenin and STAT3 pathways, and microenvironmental signals in sustaining the identity and function of TSL subsets. In various pathologies—including chronic infections, cancer, autoimmunity, and transplant rejection—TSL cells contribute to both immune persistence and pathogenic activation through their capacity to replenish exhausted effectors or differentiate into inflammatory subtypes. These cells not only shape immune trajectory but also hold promise as dynamic biomarkers and therapeutic targets. Targeted modulation of TSL via cytokine supplementation, immune checkpoint blockade, adoptive transfer, or niche interference is under investigation, with encouraging results in preclinical and early translational studies. This review outlines the molecular regulation and functional diversity of stem-like CD4+ and CD8+ T cells, evaluates their disease-specific roles, and discusses strategies to harness or inhibit these populations for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/957ce990207260aaa43e17d3f30590a154a82c00" target='_blank'>
              Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases
              </a>
            </td>
          <td>
            Wang Zhan, Longyong Lai, Shuan Ran, Yuan Li, Jiulu Zhao, Jie Wu, Chao Guo, Jikai Cui, Jiahong Xia
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Background Colorectal cancer (CRC) progression is shaped by the tumor microenvironment, particularly tumor-associated macrophages (TAMs), which often adopt immunosuppressive functions. CD300e, a myeloid receptor involved in immune regulation, has an uncharacterized role in CRC. Methods Functional studies were conducted in azoxymethane/dextran sodium sulfate and MC38 murine CRC models using CD300e systemic and myeloid-specific CD300e knockout mice, and adoptive transfer experiments assessed macrophage-intrinsic effects. Human studies included analysis of CD300e expression in matched tumor and normal tissue from patients with CRC and in vitro co-culture of patient-derived colon tumor organoids with monocytes to study CD300e induction and TAM polarization. Results In vivo, CD300e deficiency led to reduced tumor burden, enhanced major histocompatibility complex expression on TAMs, and improved T-cell responses. CD300e-deficient macrophages exhibited increased phagocytic activity, antigen presentation, and support for T-cell proliferation and cytotoxicity. Adoptive transfer confirmed that macrophage-intrinsic CD300e expression is sufficient to suppress T-cell function and promote tumor growth. In patients with CRC, CD300e is selectively upregulated in tumor-infiltrating monocytes and macrophages, driving a suppressive phenotype marked by impaired antigen presentation. Tumor-derived signals in vitro induce CD300e expression and promote a protumorigenic macrophage profile. Conclusions Our findings identify CD300e as a critical regulator of macrophage-mediated immune suppression in CRC and a potential target for reprogramming TAMs to enhance immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/16c56c500ab6751223d28c46c0f7327dc521a283" target='_blank'>
              CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming
              </a>
            </td>
          <td>
            Annica Barizza, Stefania Vassallo, L. Masatti, Mattia Laffranchi, Sofia Giacometti, S. Lonardi, Mattia Bugatti, Sara Coletta, C. Della Bella, M. D’Elios, Simone Pizzini, A. Rosato, W. Vermi, Matteo Fassan, G. Spolverato, Silvano Sozzani, E. Calura, R. Sommaggio, Gaia Codolo
          </td>
          <td>2025-07-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Seminoma is the most common solid malignant tumor of the testis in young males, significantly impacting fertility. Approximately 20% of seminomas metastasize, markedly increasing recurrence risk and compromising quality of life. To investigate the poorly understood mechanisms driving seminoma metastasis, we performed a comprehensive analysis by integrating single-cell RNA sequencing, TCGA data mining, and cell biology assays. We identified significant intratumoral heterogeneity. A subset of tumor cells expressing DPPA4 and PSMA7 showed high stemness, enhanced self-renewal, and association with metastasis. Knockdown of these genes reduced sphere formation, tumor migration and proliferation in Tcam-2 and NCCIT cells. Conversely, tumor cells overexpressing PAGE5 and SAT1 exhibited reduced stemness, migratory capacity and proliferation. In the immune microenvironment, we identified IFNG+ T cells, which recruit and activate other antitumor immune cells. These cells secrete IFN-γ, which promotes tumor differentiation, reduces stemness, and mitigates tumor aggressiveness. Based on these findings, we further developed a molecular panel to aid in the identification of seminomas with a higher risk of metastasis. In conclusion, our study identifies unique molecular signatures that facilitate risk stratification based on metastatic potential, providing valuable insights for improving precision medicine.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a200ee992d63f7f5d78cc885c7a3fb857907df52" target='_blank'>
              Single-cell analysis unravels divergent gene signatures shaping seminoma stemness and metastasis
              </a>
            </td>
          <td>
            Zhouliang Bian, Biying Chen, Jiahui Guo, Jiamin Zhang, Guangye Du, Shufang He, Haihua Yuan, Yue Zhou, Bin Jiang, Daliu Min, Dingwei Ye, Hengchuan Su, Yanjie Zhang
          </td>
          <td>2025-11-07</td>
          <td>Cell Death Discovery</td>
          <td>1</td>
          <td>27</td>
        </tr>

        <tr id="Natural killer (NK) cells are an integral component of the tumor microenvironment, and their role in immune checkpoint inhibitors (ICI) therapy has garnered increasing attention. However, comprehensive studies on NK cells across cancers, especially their impact on immunotherapy response, remain limited. We used machine learning algorithms to establish a pan-cancer natural killer cell immunotherapy predictive model (NKCIPM) by combining single-cell RNA sequencing data from 164 samples across 6 cancer types and bulk RNA-seq data from different tumor samples. Tumor immune cell infiltration analysis, drug sensitivity analysis, and cell–cell communication were also further conducted. An upregulation of NK cell proportions post-immunotherapy and the identification of 188 NK cell differentially expressed genes were observed through single-cell RNA sequencing analysis. By integrating bulk RNA-seq data and applying machine learning algorithms, 7 key hub genes were identified, ultimately leading to the construction of NKCIPM, with APOE emerging as the most influential hub gene. Further analysis using the CIBERSORT algorithm revealed that the signature genes within this model were significantly associated with immune cell infiltration and response to ICI. Additionally, therapeutic evaluation of CHEK1 and CHEK2 targets demonstrated potential significance in the communication between B cells, NK cells, and mast cells within the context of ICI therapy. In summary, the NKCIPM model offers a valuable tool for predicting immunotherapy outcomes and informing clinical decision-making, highlighting the potential of NK cell signature genes as therapeutic targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/723208e4a11fcc406d7deb1aa725e99328d097a7" target='_blank'>
              Pan-cancer NK cell-related immunotherapy signatures for predicting PD-1 treatment response
              </a>
            </td>
          <td>
            Shiqi Wu, Hening Li, Pintian Wang, Maolin He
          </td>
          <td>2025-11-21</td>
          <td>Medicine</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background Human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (Mtb) co-infection remains a major cause of mortality in AIDS patients, yet the mechanisms of pathogen interplay and host immune remodeling remain poorly understood. Methods To capture early untreated states, we applied single-cell RNA sequencing (scRNA-seq) to peripheral blood mononuclear cells from healthy controls, and from participants newly diagnosed with HIV mono-infection or HIV-Mtb co-infection, before therapy initiation. Integration guided by a Directed Acyclic Graph (DAG) inferred a pseudo-temporal trajectory from health to HIV infection to co-infection. Results Along this continuum, TNF-α and TGF-β signaling progressively declined in CD8+ T cells and monocytes. Th1 cells emerged as the dominant anti-tuberculosis effectors, whereas Th17 cells exhibited transcriptional exhaustion and ribosomal stress signatures consistent with a non-responsive state. Cell communication analysis revealed fewer overall interactions but increased signaling strength within pathways during co-infection. Notably, we observed a transition in T cell from MHC class II to class I, a shift that was most pronounced in the CD4+ effector memory subset. These rewired interactions featured selective upregulation of inhibitory checkpoint molecules (PGE2–PTGES3–PTGER2/4, PPIA-BSG, PECAM1) and loss of stimulatory signals (CD6-ALCAM, CLEC2B/C/D-KLRB1). Discussion Our study provides a single-cell roadmap of HIV-Mtb co-infection and identifies Th1/Th17 imbalance and MHC-I-biased T-cell signaling reconfiguration as candidate targets for restoring immune homeostasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3079e80670107d8df959c9a9373c58fb84ac742d" target='_blank'>
              Single‐cell transcriptomics reveals pathogen interactions and T cell reprogramming in HIV and Mycobacterium tuberculosis co‐infection
              </a>
            </td>
          <td>
            Zihui Zhao, Suyue Huang, Wei Huang, Wei Song, Li Liu, Jun Chen, Ren-fang Zhang, Yinzhong Shen
          </td>
          <td>2025-11-28</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Melanoma remains a major challenge in oncology because of its aggressive behavior and intricate immune interactions. Advances in immunophenotyping and single-cell atlas technologies have revealed heterogeneous regulatory T cell (Treg) subsets, among which peripheral blood CD39+PD-1+ Tregs have emerged as key mediators of systemic immunosuppression. This review summarizes current evidence on their immunoregulatory functions, emphasizing their role in suppressing anti-tumor immunity and contributing to poor clinical outcomes. By integrating immune atlas data with clinical observations, we outline the mechanisms by which this subset shapes both the tumor microenvironment and systemic immune responses. We further discuss their potential as prognostic biomarkers and therapeutic targets to optimize immunotherapy strategies. In addition, we highlight how this subset interacts with other immunosuppressive pathways, reinforcing resistance to immune checkpoint inhibitors. Despite these advances, challenges remain in fully characterizing this population and translating findings into clinical application. This review provides a comprehensive overview of the significance of CD39+PD-1+ Tregs in melanoma immunopathology and highlights future directions to advance precision immunotherapy and improve patient prognosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc33012596eab785fba7e6d8eba704e87044622b" target='_blank'>
              CD39+PD-1+ regulatory T cells in melanoma: key drivers of systemic immunosuppression and prognostic biomarkers
              </a>
            </td>
          <td>
            Guanlin Qiao, Hongxia He, Xiaobing Wang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/07c7ce9a407bf29f4b537e0cbead424db44e5f61" target='_blank'>
              Targeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL
              </a>
            </td>
          <td>
            J. Bigot, Mathieu Bouttier, Vincent Fregona, Clémence Rouzier, Manon Bayet, Sylvie Hebrard, N. Prade, Stéphanie Lagarde, Christine Didier, Laetitia Largeaud, F. Vergez, A. Quillet-Mary, Loic Ysebaert, C. Broccardo, André Baruchel, Marion Strullu, E. Clappier, Marlène Pasquet, Elodie Lainey, Eric Delabesse, Bastien Gerby
          </td>
          <td>2025-12-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Resistance to immune checkpoint blockade (ICB) remains a major challenge in lung adenocarcinoma (LUAD), with stromal mechanisms underlying CD8⁺ T cell exhaustion still poorly understood. By integrating single-cell, bulk, and spatial transcriptomic datasets using EcoTyper, we identified a distinct immunosuppressive ecotype, EC10, enriched for TGF-β signaling and epithelial–mesenchymal transition. EC10 exhibited spatial co-localization of fibroblasts, malignant epithelial cells, and exhausted CD8+ T cells, and was consistently associated with immune exclusion, poor progression-free survival, and elevated TIDE scores across four ICB-treated LUAD cohorts. Cell–cell communication analyses revealed a dominant TGFB1–SERPINE1 signaling axis originating from fibroblasts, linking stromal remodeling to T cell dysfunction. In contrast, EC12 represented an inflamed, ICB-responsive state enriched in interferon signaling. These findings define EC10 as a spatially organized, fibroblast-driven immunosuppressive ecosystem predictive of ICB resistance, and highlight the therapeutic potential of targeting the TGF-β axis in LUAD. This research identifies a fibroblast-driven immunosuppressive ecosystem in lung adenocarcinoma, linking TGF-β signaling to immune resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130525b051ffbdab87e5edbec0e75b95564de9c8" target='_blank'>
              Fibroblast TGF-β signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance
              </a>
            </td>
          <td>
            Seo-Young Lee, Youngjoo Lee
          </td>
          <td>2025-12-01</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Stem-like progenitors are self-renewing cytotoxic T cells that expand as effector cells during successful checkpoint immunotherapy1,2. Emerging evidence suggests that tumour-draining lymph nodes support the continuous generation of these stem-like cells that replenish tumour sites and are a key source of expanded effector populations3–6, underlining the importance of understanding what factors promote and maintain activated T cells in the stem-like state. Here, using advanced three-dimensional multiplex immunofluorescence imaging, we identify antigen-presentation niches in tumour-draining lymph nodes that support the expansion, maintenance and affinity evolution of TCF-1+PD-1+SLAMF6high stem-like CD8+ T cells. Contrary to the prevailing view that persistent T cell receptor (TCR) signalling drives terminal effector differentiation, prolonged antigen engagement days beyond initial priming sustains the proliferation and self-renewal of these stem-like T cells in vivo. The inhibitory PD-1 pathway has a central role in this process through fine-tuning the TCR signal input that enables the selective expansion of high-affinity TCR stem-like clones as a renewable source of effector cells. PD-1 blockade disrupts this tuning, leading to terminal differentiation or death of the most avid anti-tumour stem-like cells. Our results therefore reveal a relationship between TCR ligand affinity recognition, a key negative-feedback regulatory loop and T cell stemness programming. Furthermore, these findings raise questions about whether anti-PD-1 blockade during cancer immunotherapy provides a short-term anti-tumour effect at the cost of diminishing efficacy due to progressive loss of these critical high-affinity precursors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/70ed431ae2cdbae13fae3bbefc8daf8d1ca1c6fd" target='_blank'>
              Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
              </a>
            </td>
          <td>
            J. Hor, E. Schrom, Abigail Wong-Rolle, Luke Vistain, Wanjing Shang, Qiang Dong, Chen Zhao, Chengcheng Jin, Ronald N. Germain
          </td>
          <td>2025-11-26</td>
          <td>Nature</td>
          <td>1</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e56882b29e98563be8230a7fd202a7abeb1f4acf" target='_blank'>
              Intestinal Stem and Progenitor Cells Exhibit Distinct Adaptive Responses to Inflammatory Stress in IBD
              </a>
            </td>
          <td>
            B. Balasubramanian, Shivam Patel, Louis Gall, N. Hannan, William Dalleywater, Joerg Huelsken, C. Pin, G. Moran, Paloma Ordóñez-Morán
          </td>
          <td>2025-12-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background Tertiary lymphoid structure (TLS) is a neogenized, ectopic lymphoid aggregate found in infected, autoimmune and tumour tissues with an activated adaptive immune response. However, a comprehensive understanding of the pathological role, function, and formation of TLS in allograft rejection remains incomplete. Methods We enrolled two large retrospective cohorts of liver biopsy (LB) after pediatric living donor liver transplantation (LDLT) and developed a deep learning pathomics (DLP) model. Gene expression profiles and corresponding clinical information of 590 cases were enrolled from three transcriptomic databases, including cohort-GSE193135 (n=337), cohort-GSE145780 (n=235), cohort-Renji (n=18). ESTIMATE, CIBERSORT, XCELL and MCP analyses were performed to visualize the immune landscape. Single-cell RNA-sequencing (scRNA-seq) analysis of 11 LBs after LDLT and multiplexed immunohistochemistry (mIHC) were performed to validate the discoveries of bioinformatics analysis. Results We provided evidence that increased TLS in the liver was closely correlated with allograft rejection, fibrosis, and declined liver function. ScRNA-seq and in vitro co-culture analysis revealed that TLS form through the differentiation of atypical memory B (AtM B) cells via the JAK-STAT signalling pathway, stimulated by IFN-γ from exhausted CD8+ T effector memory (TEM) cells. The presence of TLS resulted in IgG accumulation, initiating pathological antibody-dependent cell-mediated phagocytosis (ADCP) of apoptotic hepatocytes by CD68+ macrophages. Preclinically, blocking JAK1/3 or knocking out Lta in mice limited TLS formation and attenuated allograft rejection in mouse orthotopic liver transplantation models, informing novel therapeutics for allograft rejection pathology. Conclusion We proposed an efficient DLP model for predicting allograft rejection, and revealed an unexpected immunological mechanism of TLS in allograft rejection livers and clarified an IFN-γ-JAK-STAT-dependent circuit that could be targeted with drugs and transformed AtM B cells into potent instigators of hepatocellular injury in allograft rejection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/710b5cbdccb6ba31975d4da08744567411216089" target='_blank'>
              Tertiary lymphoid structure drives allograft rejection via IFN-γ-JAK-STAT-dependent atypical memory B cell differentiation
              </a>
            </td>
          <td>
            Lijie Ma, Shiming Gong, Jianchen Fang, Mingxuan Feng, Zhenzhen Zhan, Qiang Xia
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Abstract Soft-tissue sarcomas (STS) are characterized by abundant extracellular matrix (ECM) deposition, yet the functional contribution of specific ECM components remains poorly understood. In this study, we identify periostin (POSTN), a matricellular protein, as a regulator of sarcoma progression and the tumor immune microenvironment. Analysis of human sarcoma datasets revealed that high POSTN expression correlates with poor prognosis and elevated expression of ECM-related and myeloid cell–associated genes. In murine genetic models of sarcoma, tumors expressing high levels of Postn displayed enhanced expression of ECM genes and monocyte-recruiting cytokines. Functional silencing of Postnin vivo reduced tumor growth without altering tumor cell proliferation or intrinsic signaling pathways, suggesting a noncell-autonomous mechanism. Instead, Postn-deficient tumors showed increased infiltration of CD4+ and CD8+ T cells and reduced proportions of immunosuppressive myeloid cells, including tumor-associated macrophages (TAM). Single-cell RNA sequencing revealed that Postn silencing reprograms the myeloid compartment, increasing IFN-responsive and proinflammatory subsets. Mechanistically, recombinant POSTN promoted monocyte migration and maturation into macrophages in vitro, supporting its role as a chemoattractant and differentiation cue. Therapeutic neutralization of POSTN partially recapitulated the immunologic remodeling but was insufficient to reduce tumor burden as monotherapy. Significance: Our findings position POSTN as a key stromal regulator in STS, linking tumor-derived ECM components to immune evasion via myeloid cell recruitment and education. These results open avenues for targeting POSTN as an adjuvant strategy to enhance the efficacy of immunotherapies and overcome the immune-excluded phenotype of sarcoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4fcb661ad1542d712f7aa5599bc104c08fe2694e" target='_blank'>
              Periostin Promotes Sarcoma Growth by Promoting Tumor-Associated Macrophage Migration and Differentiation
              </a>
            </td>
          <td>
            Jinfen Xiao, Kristin Ishaya, E. Ko, Annaliese Fowler, Marina T Broz, Jlenia Guarnerio
          </td>
          <td>2025-11-20</td>
          <td>Cancer Research Communications</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Lifelong immunosuppressive therapy is required to prevent allograft rejection in organ transplantation. Current immunosuppressants effectively suppress adaptive and innate immune responses, but their broad, antigen-non-specific effects often result in severe off-target complications. It remains a significant unmet medical need in transplant medicine. In this study we investigated immunosuppressant effects of four major immunosuppressant classes, including tacrolimus, prednisone, mycophenolate mofetil (MMF), and fingolimod (FTY), on the gut microbiome, metabolic pathways, lymphoid architecture and lymphocyte trafficking after up to 30-day chronic exposure. Despite their distinct mechanisms of action and not designed to target the gut, all immunosuppressive drugs induced profound and time-dependent alterations in both intestine gene expression and gut microbiome composition. Progressive alterations from moderate early, drug-specific changes to a strikingly convergent microbial dysbiosis, marked by significant expansion of pathobionts of Muribaculaceae, occurred across all drug classes. Concurrently, all drugs uniformly induced significant suppression of mucosal immunity including B cell, immunoglobulin, and antigen recognition. Time-dependent changes in lymph node (LN) reorganization and cellular composition were also observed, marked by a progressive shift toward pro-inflammatory phenotypes in gut-draining mesenteric LNs and a gradual loss of tolerogenic architecture in peripheral LNs. Drug-specific metabolic alterations and distinct phases of intestinal transcriptional responses were also characterized. Notably, MMF and FTY demonstrated the most robust immunomodulatory properties, and were able to acutely suppress alloantigen-induced inflammation through mediating regulatory T cell distribution and LN remodeling. Together, our findings show that immunosuppressants elicit complex, time-dependent effects that remodel the gut and exert compartment-specific impacts on lymphoid tissues, differentially affecting gut-draining mesenteric versus peripheral LN. Understanding these relationships offers new opportunities for refining immunosuppressive strategies to reduce treatment-related off-target complications and improve long-term organ transplant outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e9ffe364b9010df902675300b16b741613e61f6" target='_blank'>
              Immunosuppressants rewire the gut microbiome-alloimmune axis through time-dependent and tissue-specific mechanisms
              </a>
            </td>
          <td>
            Long Wu, Allison Kensiski, Samuel J. Gavzy, Yang Song, H. W. Lwin, Michael France, Dejun Kong, Lushen Li, Ram Lakhan, V. Saxena, Wenji Piao, Marina W. Shirkey, Valeria R. Mas, Brendan Lohmar, Yan Shu, Jonathan S. Bromberg, B. Ma
          </td>
          <td>2025-11-26</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="CD8⁺ T lymphocytes are pivotal effectors of adaptive immunity, executing cytotoxic mechanisms essential for pathogen clearance, tumor surveillance and tissue protection. Their activity is shaped by antigenic stimulation, cytokine networks and the metabolic and structural architecture of the tissue microenvironment. Physical exercise has emerged as a potent, non-pharmacological modulator of CD8⁺ T cell biology, capable of influencing recruitment, activation, differentiation and functional persistence. Acute exercise mobilizes effector and memory subsets, enhances trafficking to peripheral tissues and transiently alters activation thresholds, while sustained training remodels subset composition, preserves mitochondrial competence and attenuates immunosenescence. These adaptations are orchestrated through integrated neuroendocrine, vascular and metabolic pathways that recalibrate chemokine gradients, nutrient availability and energetic support. However, the magnitude and direction of these effects are highly context-dependent, varying with host physiology, disease state and microenvironmental constraints. This Review integrates mechanistic and translational evidence across physiological and pathological settings—including cancer, infectious, neurological and metabolic diseases—to clarify when and how exercise can be leveraged to reinforce cytotoxic immunity. We highlight key methodological and biological challenges, and propose biomarker-guided, microenvironment-informed and adaptively titrated exercise interventions as a framework for advancing exercise from an adjunctive measure to a modulatory, precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/697b8e18eede93afa0da0c621d293296cae7424c" target='_blank'>
              Modulating CD8⁺ T cell immunity through exercise: mechanistic insights and implications for precision immunotherapy
              </a>
            </td>
          <td>
            Xinyuan Zhao, Xu Chen, Pei Lin, Yunfan Lin, Weiyao Feng, Meiyan Zou, Nina Li, Li Cui
          </td>
          <td>2026-01-01</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47a86c6d791fa4b2001ba0e3619947d81149d6fc" target='_blank'>
              Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
              </a>
            </td>
          <td>
            Francesco Maura, Ciara L. Freeman, K. Maclachlan, Marta Larrayoz Ilundain, B. Ziccheddu, Erin W. Meermeier, Juan-Jose Garcés, Michael A Durante, Holly Lee, Ross S. Firestone, M. Menges, Kayla Reid, B. Diamond, M. Papadimitriou, A. Silva, P. Sudalagunta, Noémie Leblay, Sungwoo Ahn, Ethan Fuller, Edward Briercheck, Meaghen E. Sharik, Megan T. Du, Phaedra Agius, Doris K. Hansen, Xiaofei Song, Xiaohong Zhao, M. Meads, Jamie K. Teer, T. Jelínek, P. Hagner, Rachid C Baz, Melissa Alsina, A. Ramasubramanian, Eric L. Smith, S. Giralt, S. Mailankody, Leif Bergsagel, Paola Neri, M. Chesi, Jose-Al Martinez-Climent, Frederick L Locke, N. Bahlis, O. Landgren, Issam S. Hamadeh, S. Usmani, K. Shain
          </td>
          <td>2025-12-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="T cells are central components of the adaptive immune system and play key roles in antitumor and antiviral responses. The diverse cell fates of T cells enable them to respond to different durations and strengths of antigen stimulation and various cytokine milieus in a context-dependent manner. During acute infection or vaccination, T cells differentiate into effector cells and later develop into memory cells after antigen clearance, which mediate immune protection against the same antigen. In contrast, during cancer and chronic infection, T cells fail to enter the canonical effector or memory cell differentiation path. Instead, antigen-specific T cells enter a dysfunctional, partially responsive state called exhaustion. Exhausted T cells are heterogeneous. A subset of exhausted T cells exhibits stem cell-like properties. These stem-like T cells sustain immunity through self-renewal and repopulation of terminally differentiated progenies. Stem-like properties are critical for T cell immunity induced by immunotherapy. This review summarizes recent advances in understanding the molecular mechanisms controlling the exhaustion and stemness of T cells and explores the potential of rewiring these circuits to increase the efficiency of T-cell-based immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/01145f359013ec590de5209ce820dcb252b3001d" target='_blank'>
              Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy
              </a>
            </td>
          <td>
            Zeyu Chen, Ziang Zhu, Taidou Hu, Chen Yao, Tuoqi Wu
          </td>
          <td>2025-12-19</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background Stem-like progenitor exhausted CD8+ T cells (TPEX), located within the tumor-draining lymph nodes (TDLNs), are responsible for maintaining tumor-specific responses in cancer. Although cytokines such as interleukin (IL)-15 are known to expand CD8+ T-cell subsets, transforming growth factor (TGF)-β in the TDLN is known to arrest the egress of these TPEX to the tumor microenvironment. We hypothesized that combining IL-15 stimulatory and TGF-β blocking activity would boost antitumor responses mediated by TPEX in the TDLN. Methods We developed a bifunctional TGF-βRII/IL-15 protein complex (HCW9218) and evaluated its antitumor activity in two murine models of melanoma and breast cancer. Peripheral blood, TDLN and tumor-infiltrating CD8+ T cells were characterized by flow cytometry following a single subcutaneous dose (s.c.) of HCW9218. Transcription profiling of CD8+ T cells in both murine models was performed. Synergistic activity of HCW9218 with immune-checkpoint inhibitors (ICIs) was evaluated. Finally, safety and immune profiling in patients with chemo-refractory/relapsed solid tumors was performed in a Phase 1 dose-escalating trial. Results HCW9218 was capable of localizing to the TDLNs and tumors after s.c. administration, neutralized TGF-β, expanded TPEX in TDLNs, increased chemokine-expressing effectors in peripheral circulation and promoted their infiltration into murine tumors. These data were corroborated in RNA sequencing analysis of TDLNs. ICIs significantly enhanced the effects of HCW9218 on TPEX and synergistically improved HCW9218 antitumor efficacy in melanoma and reduced spontaneous lung metastasis in breast cancer models. In a Phase 1 clinical trial, HCW9218 monotherapy was well-tolerated, reduced serum TGF-β levels, promoted and sustained CD8+ T-cell expansion in peripheral blood and CD8+ T-cell infiltration in tumor biopsies. Stable disease was reported for four of six subjects (67%) with advanced ovarian cancer treated with HCW9218. Conclusions Our findings demonstrate that combination therapy targeting immune cells critical for antitumor responses and blocking immune-suppressive environment significantly improves antitumor therapeutic efficacy. These findings provide a strong basis for using HCW9218 to enhance the efficacy of ICIs against solid tumors in the clinical setting.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f82b5cbb01e571f68c6670c836a87ce958c90377" target='_blank'>
              TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors
              </a>
            </td>
          <td>
            Varghese George, Hing C. Wong, M. Felices, M. Rubinstein, Niraj Shrestha, Natalia Valderrama, Hamidreza Farzaneh, Lin Kong, Crystal Gilkes, Alyssa Thompson, Megan Larson, Bai Liu, Xiaoyun Zhu, Gilles M Leclerc, Dongjun Chung, Juan Xie, Jordan E. Krull, Lucas Gomez, Leah Kanakaraj, Ann Bialik, J. Egan, Lijing You, Xianglan Liu, Rachael N. Teodorescu, Ana K Karen Gutierrez, Christian A Echeverri, Reynier Rodriguez, Zheng Wang, J. Xing, Neicy Gonzalez, P. Chaturvedi, Manish R Patel, R. Wangen, Qing Cao, P. Rhode, Jeffrey S Miller, Melissa A Geller
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="Intracerebral hemorrhage (ICH) causes hematoma formation, leading to PHE, which is associated with leukocyte mobilization and increased inflammation at the site of brain injury. However, the fate of accumulated leukocytes within the hematoma and their impact on PHE expansion remain unknown. We performed single-cell immune profiling of hematoma cells from patients with acute ICH and reported a distinct phenotypic transformation of CD8+ T cells within the hematoma during the first 24 h after onset. In addition to enhanced IFN-γ production and migration capacity, these CD8+ T cells displayed remarkable glycolytic signatures. The metabolic fitness and functional reprogramming of hematomal CD8+ T cells are associated with the transcription factor FOXO1. Single-cell profiling of brain-infiltrating CD8+ T cells within the perihematomal tissues of ICH patients and cell culture assays revealed their capacity to activate microglia via the production of IFN-γ. Furthermore, the removal of hematomal CD8+ T cells reduced neuroinflammation, PHE expansion and neurological deficits in ICH mice. Thus, CD8+ T cells undergo metabolic and functional reprogramming within the hematoma during the acute phase of ICH, which contributes to PHE formation and neurological deterioration. FOXO1-driven metabolic reprogramming of hematomal CD8+ T cells drives the expansion of perihematomal edema following intracerebral hemorrhage—mechanisms and clinical implications CD8+ T cells within the hematoma are transformed during the first 24 h after ICH onset. These hematomal CD8+ T cells can possess remarkable glycolytic signatures and enhanced IFN-γ production and migration capacity, which are associated with the transcription factor FOXO1. The infiltration of CD8+ T cells in the brain augments perihematomal edema and neurological deterioration. (Figure created with BioRender). FOXO1-driven metabolic reprogramming of hematomal CD8+ T cells drives the expansion of perihematomal edema following intracerebral hemorrhage—mechanisms and clinical implications CD8+ T cells within the hematoma are transformed during the first 24 h after ICH onset. These hematomal CD8+ T cells can possess remarkable glycolytic signatures and enhanced IFN-γ production and migration capacity, which are associated with the transcription factor FOXO1. The infiltration of CD8+ T cells in the brain augments perihematomal edema and neurological deterioration. (Figure created with BioRender).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/276070da491f835ea64518208e42721a08ff69fe" target='_blank'>
              FOXO1-driven metabolic reprogramming of hematomal CD8+ T cells drives the expansion of perihematomal edema following intracerebral hemorrhage
              </a>
            </td>
          <td>
            Jie Lin, Honglei Ren, Youliang Wang, Hanzhi Yu, Zhili Chen, Xintong Yu, Zhuyu Gao, Yan Zheng, Quanhong Wu, Yizhe Zhang, Qijian Lin, Rui Li, Decai Tian, Zhigang Cai, Qiang Liu, Ying Fu
          </td>
          <td>2025-11-14</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Abstract SLAMF8 is predominantly expressed in macrophages and plays an important role in autoimmune diseases and inflammation. Our previous studies have focused on SLAMF8, however, the potential of SLAMF8 as an immunotherapeutic target and its role in regulating the tumor immune microenvironment remain to be elucidated. This study demonstrated that macrophage-specific SLAMF8 is significantly associated with a poor prognosis for colorectal cancer (CRC). Additionally, M2 macrophage and tumor-associated macrophages (TAMs) models were used to verify that SLAMF8 induces an immunosuppressive phenotype in macrophages and regulates antitumor immunity by inhibiting the activation and function of CD8+ T cells. In vivo, we confirmed that SLAMF8 inhibition promoted remodeling of the immunosuppressive microenvironment and augmented immunotherapy sensitivity in CRC. Mechanistically, we demonstrated that SLAMF8 promotes the polarization of macrophages toward the M2 phenotype via the PI3K/AKT and JAK/STAT3 signaling pathways. In summary, this study confirmed that inhibiting SLAMF8 exerts an antitumor effect by reversing the immunosuppressive tumor microenvironment in CRC, providing new therapeutic targets and strategies for combined immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0eb7d8ffd5d61d0e44a547a2d1181cb708517e0e" target='_blank'>
              Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer
              </a>
            </td>
          <td>
            Xingzhi Han, Xueying Bai, Ning Wang, Yuexin Sun, Jing Hu, Li Li, Zhihao Liu, Yaping Zhang, Zixin Liang, Liuqi Sang, Lu Han, Qun Zhang, Xiaoping Qian
          </td>
          <td>2025-11-10</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Tissue-resident memory T (TRM) cells persist long-term in non-lymphoid tissues and provide rapid local immune protection, yet emerging evidence shows they also act as key drivers of chronic inflammation and relapse in rheumatoid immune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and primary Sjögren’s syndrome (pSS). A systematic search of PubMed, Web of Science, and Google Scholar (through October 2025) identified studies on TRM cell biology, pathogenic roles, and therapeutic modulation in autoimmune diseases. This review summarizes the fundamental features of TRM cells, including their TGF-β and IL-15 dependent development, tissue-specific heterogeneity, and unique metabolic programs. It highlights disease-specific pathogenic mechanisms: promotion of osteoclastogenesis and chronic synovial inflammation via Granulocyte-macrophage colony stimulating factor (GM-CSF) and the IL-23/IL-17 axis in RA; amplification of type I interferon responses and autoantibody production in SLE; potential contribution to fibrosis through TGF-β secretion in SSc; and mediation of glandular injury through cytotoxicity in pSS. Therapeutic strategies targeting TRM cells—such as JAK inhibitors, IL-17/IL-23 blockade, disruption of residency signals, metabolic interventions, and microenvironmental remodeling via nanotechnology—are critically evaluated. Challenges remain in achieving tissue-specific targeting without compromising systemic immune memory. Future directions include spatial transcriptomics, organoid models, and artificial intelligence to support precision medicine. Targeting TRM cells presents a promising novel avenue for achieving long-term remission and potentially even a cure for rheumatoid immune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1201e244b31ebcc016319c4d8203919cb836f463" target='_blank'>
              Tissue-Resident Memory T Cells in Rheumatoid Immune Diseases: Pathogenic Mechanisms and Therapeutic Strategies
              </a>
            </td>
          <td>
            Yu Tian, Jie Zhang, Lianying Wu, Chi Zhang, Fan Zheng, Yang Yang, Guanting Lu, Daoyuan Xie
          </td>
          <td>2025-11-30</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Smoldering multiple myeloma (SMM), which is in principle curable, may develop into life-threatening MM. Intestinal microbiota and gut-born T helper-17 (Th17) lymphocytes may contribute to this development, but the mechanisms are unclear. Here we demonstrate that administering the human commensal Prevotella melaninogenica to transgenic Vk*MYC mice that exhibit SMM-like phenotypes delays the evolution to full-blown MM. Mechanistically, P. melaninogenica increases the production of short-chain fatty acids (SCFA), thereby preventing the skewing of dendritic cells towards a pro-Th17 phenotype and subsequently accumulation of Th17 cells in the bone marrow of treated mice. P. melaninogenica or butyrate synergizes with anti-PD-L1 or anti-TIGIT to suppress myeloma progression by restraining Th17 cell expansion while inducing effector CD8+ T cells. P. melaninogenica also attenuates IL-17-mediated skin lesions that mimic anti-PD-L1-induced adverse events. Our results thus suggest that gut microbiota modulation or SCFAs administration may represent treatment options for patients affected by plasma cell dyscrasias. Smoldering multiple myeloma (SMM) may develop into life- threatening MM, with gut microbiota and Th17 possibly contributing to this progression via unknown mechanisms. Here the authors use a mouse SMM model, VkMYC mice, to show that treatments with butyrate or the commensal, Prevotella melaninogenica, suppress Th17 and cancer progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efb834e770274d48031d910950944fb99e68ddd2" target='_blank'>
              Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
              </a>
            </td>
          <td>
            L. L. Cogrossi, Anna Policastro, Paola Zordan, Matteo Grioni, Anna Tosi, Nathalie Rizzo, Benedetta Mattorre, Marco Lorenzoni, Greta Meregalli, Sofia Sisti, F. Sanvito, A. Palmioli, Cristina Airoldi, Aurora Maurizio, Marta Chesi, Leif Bergsagel, Nicola Clementi, A. Rosato, Matteo Bellone
          </td>
          <td>2025-11-24</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Interferon gamma (IFNγ) priming is a prominent approach to enhance the immune-regulatory capacity of mesenchymal stromal cells (MSCs). Despite its potential, the concentration of IFNγ vary between studies, and how MSCs response to different concentrations of IFNγ is unclear. MSCs were treated with various concentrations of IFNγ (0, 1, 5, 10, 50, and 100 ng/mL) for 48 h. Followed by RNA sequencing (RNA-seq) and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) to profile gene expression and chromatin accessibility, respectively. Integrative analysis was conducted to elucidate the epigenetic regulation of MSCs response to different doses of IFNγ. We found that low dose IFNγ (1 ng/mL) treatment was sufficient to induced significant changes in gene expression and chromatin accessibility. RNA-seq revealed that IFNγ activated genes involved in immune response and inactivated genes related to cell-cycle regulation. ATAC-seq showed that IFNγ reduced global enhancer accessibility of MSCs, possibly by downregulation of the SWI/SNF complex. Moreover, IFNγ selectively opened enhancer regions associated with immune response genes while closing regions linked to proliferation-related genes. Motif enrichment analysis identified binding sites for transcription factors such as IRF and AP-1 family members in open and closed regions, respectively, highlighting selective regulatory mechanisms. This study demonstrates that low dose IFNγ is sufficient to modulate the transcriptional and epigenetic landscape of MSCs by selectively altering enhancer landscape. Our results provide insights into the regulatory mechanisms underlying IFNγ priming and offer a resource for the rational design of strategies to optimize MSC licensing for therapeutic applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af01cd1af8cf4bfaab7e2f30456504cdc937852d" target='_blank'>
              Low dose IFNγ remodels enhancer landscape to potentiate mesenchymal stromal cell activation
              </a>
            </td>
          <td>
            Junxin Lin, Dengfeng Ruan, Qiongying Hu, Xuan Cao, Wenyan Zhou, Siwang Hu
          </td>
          <td>2025-12-01</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Secreted phosphoprotein 1 (SPP1+) macrophages are a recurrent and functionally critical immune cell subset across multiple cancer types. They drive adverse clinical outcomes by promoting immunosuppression, tumor invasion, metastasis, and therapy resistance. Given their prevalence and pivotal role, SPP1+ macrophages have become a major focus in cancer immunology and a promising target for therapeutic development. SPP1+ macrophages have been identified in a wide range of human malignancies through single-cell RNA sequencing and spatial transcriptomics studies. Their differentiation and maintenance are strongly influenced by reciprocal cellular interactions and hypoxic conditions within the tumor microenvironment (TME). Within the tumor microenvironment (TME), SPP1+ macrophages promote tumor progression by interacting with cancer-associated fibroblasts (CAFs) and helping to form a physical barrier that restricts immune cell infiltration into the tumor core. Specifically, they impair the recruitment of CD8+ T cells and promote T cell exhaustion (TEX). In this review, we focus on recent advances in understanding the differentiation of SPP1 macrophages in hypoxic tumor microenvironment and the role of SPP1+ macrophages in immunosuppression and their therapeutic implications in cancer. Targeting this subset of macrophages has emerged as a highly promising therapeutic strategy, with several approaches demonstrating encouraging results in preclinical models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7c7489149a391c5b3e442dad42f10334718f488" target='_blank'>
              SPP1+ macrophages in tumor immunosuppression: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Juanjuan Wang, Ya Wang, Yuqing Liu, Rongcun Yang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related mortality globally, with metastasis and recurrence as the primary determinants of poor prognosis. Despite advances in immunotherapy, intrinsic and acquired resistance to immune checkpoint inhibitors (ICIs) underscores the need to explore alternative immunomodulatory strategies. Emerging evidence highlights the critical yet dual roles of innate and adaptive immune cells within the tumor microenvironment (TME) in either restraining or facilitating metastatic dissemination. Adaptive immunity, dominated by T and B cells, orchestrates context-dependent antitumor responses or immunosuppression, while innate immune dysregulation fosters metastatic niches. We highlight translational opportunities, such as natural killer (NK) cell activation, macrophage reprogramming, and dendritic cell (DC)-based vaccines, alongside prognostic biomarkers like peripheral NK activity and tryptase+ mast cell infiltration. This review summarizes the interplay of immune cell subsets, including T and B lymphocytes, macrophages, DCs, NK cells, and mast cells, in lung cancer progression. By synthesizing preclinical and clinical insights, this review identifies unresolved challenges and proposes targeting innate immunity as a promising avenue to augment current therapies and mitigate metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42946b2788d2e767cb68fa124579a584984286cc" target='_blank'>
              Targeting innate and adaptive immunity to suppress lung cancer metastasis
              </a>
            </td>
          <td>
            Rong Qin
          </td>
          <td>2025-11-27</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Brain metastasis is a major contributor to mortality in patients with lung cancer. The unique microenvironment of the brain plays a critical role in the initiation and progression of brain metastases (BM), yet the molecular mechanisms underlying tumor-microenvironment interactions remain poorly understood. Here, we demonstrate that upregulation of lipocalin-2 (LCN2) in tumor cells promotes brain metastatic progression by orchestrating crosstalk among metastatic tumor cells, astrocytes, and macrophages. Brain metastatic tumor cells secrete LCN2, which binds to SLC22A17 on astrocytes, activating JAK2/STAT3 signaling and inducing astrocyte activation and chemokine secretion, thereby facilitating macrophage recruitment. In turn, macrophages secrete IL-1β, which further upregulates LCN2 expression in tumor cells. Prophylactic administration of the IL-1 receptor antagonist anakinra inhibits BM formation, whereas therapeutic administration alone is ineffective. However, treatment with the STAT3 inhibitor SH4-54, either alone or in combination with anakinra, significantly suppressed tumor growth in the BM. Furthermore, tumor-secreted LCN2 can bind to SLC22A17 on tumor cells, activating JAK2/STAT3 signaling and promoting VEGF-A expression and release, which enhances tumor neovascularization. Inhibition of this axis with SH4-54, bevacizumab, or their combination effectively reduces the tumor burden in BM-bearing mice. These findings underscore the central role of LCN2 in driving brain metastasis and highlight a potential therapeutic strategy for targeting brain metastatic lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29f281e09a6235d0b0b2baf53693c1b005b871ad" target='_blank'>
              Lipocalin-2 drives brain metastatic progression through reciprocal tumor-microenvironment interactions in lung cancer
              </a>
            </td>
          <td>
            Yixiang Zhu, Jian Zhang, Danming He, Hongqing Cai, Yan He, Li Yuan, Si-Shang Li, Yucheng Dong, Zhuang Wei, Zhijie Wang, J. Duan, Xue Zhang, Zixiao Ma, Hua Bai, Jie Wang
          </td>
          <td>2025-12-24</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Background The CpG/α-OX40 in situ vaccine strategy has shown efficacy in immune-hot tumors but remains ineffective in immune-cold tumors possibly due to immunosuppressive microenvironments characterized by myeloid-derived suppressor cells (MDSCs) infiltration and T cell exclusion. This study aims to investigate the antitumor effect of non-α-biased IL-2 combined with CpG/α-OX40 in mice. Methods Using 4T1 breast cancer and CT26 colon cancer models, we evaluated the antitumor effects of combining CpG/α-OX40 with a non-α-biased IL-2 variant via both intratumoral and subcutaneous routes. Tumor growth, lung metastasis, immune profile, and in vitro function analysis were assessed through flow cytometry, transcriptomic analysis, and T cell suppression assays. Results The combination therapy significantly inhibited primary and distant tumor growth and reduced lung metastasis in 4T1 models. Subcutaneous administration induced complete tumor regression in 55% (5/9) of CT26-tumor-bearing mice and conferred durable tumor-specific memory. Mechanistically, the treatment enhanced CD8+ T cell activation, metabolic reprogramming, and IFN-γ production, while suppressing MDSC expansion and immunosuppressive function. Conclusions These findings demonstrate that non-α-biased IL-2 synergizes with CpG/α-OX40 to overcome microenvironmental immunosuppression and achieve systemic antitumor immunity via a subcutaneous route, offering a translatable combinatorial strategy for immune-cold tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d42396ce9a3d36225ebbc84de8f92b7df49fd80" target='_blank'>
              Non-α-biased IL-2 enhances both intratumoral and subcutaneous CpG/α-OX40 therapy, unleashing systemic antitumor immunity in mice
              </a>
            </td>
          <td>
            Kejie Huang, Xiaobo Ding, Xuehuan Wen, Chaoming Huang, Yan Chen, Xujie Zhou, Leying Zhou, Yi He, Zhixiang Bai, Chunhong Zhang, Yi Jin, Jianmin Li, Zhenghua Fei, Wenfeng Li, Chen Chen
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb706d249cfb2775d83ca53d2e8588e8894f0cf6" target='_blank'>
              Dual Transcriptional Drivers of Immune Suppression in SACC: NOTCH1 for Cellular and MYB for Humoral Immunity
              </a>
            </td>
          <td>
            Guoliang Yang, Xudong Wang, Tian Ye, Tingyao Ma, Youmei Chen, Fang Nan, Qian Chen, Lu Kong, Xiao-hong Chen
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Small cell lung cancer (SCLC) is characterized by its highly aggressive phenotype and dismal outcome. Despite the benefit of adding immune checkpoint blockade to standard chemotherapy, tumors acquire the ability to evade immunosurveillance and develop resistance. To investigate these underlying mechanisms, we perform high-dimensional profiling of human and murine SCLC specimens. In matched primary and metastatic human samples, we observe MHC-I loss in metastases, highlighting its role in immune evasion. Correspondingly, silencing MHC-I in SCLC cells drastically reduces immune infiltration and promotes metastasis in mice. Using mass spectrometry and phospho-tyrosine kinase analyses, we identify ERBB2 signaling as a suppressor of MHC-I and driver of immune-modulatory transcripts. Mechanistically, genetic and pharmacologic blockade of ERBB2 induces MHC-I in a STING-dependent manner and prevents immune evasion in autochthonous murine SCLC. Strikingly, combining ERBB2 inhibition with anti-PD-1 elicits profound synergistic responses in preclinical models, suggesting this combination for future clinical trials in SCLC patients. While the emergence of immune checkpoint inhibitors has improved outcomes in patients with small cell lung cancer (SCLC), tumour that develop means of immune evasion become resistant. Here, the authors report that ERBB2 signalling induces loss of MHC Class I expression and subsequently immune evasion in preclinical models of SCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f612388efd2f0a9c1ebc8d3e60e6b396ae989beb" target='_blank'>
              ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer
              </a>
            </td>
          <td>
            L. Meder, C. Orschel, C. Bouchez, R. Gholamipoorfard, C. V. Orschel, David Stahl, Christoph Kreer, Mirjam Koker, Marieke Nill, Ilayda G Kocak, Ka-Won Noh, Xinlei Zhao, Leon Ullrich, B. Häupl, Josefine Jakob, Marie-Lisa Eich, Alexandra Florin, Holger Grüll, J. Wolf, Filippo Beleggia, R. Buettner, T. Oellerich, Florian Klein, J. Brägelmann, H. C. Reinhardt, Nima Abedpour, R. Ullrich
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Lymph nodes, brain, bone, and liver are recognized as the four most common metastatic sites for lung adenocarcinoma (LUAD). Metastasis to these locations exhibits some common features, such as immune suppression, and distinct tumor microenvironment (TME) heterogeneity involving differentiation of immune cells, impacting treatment efficacy and prognosis. Lymph node metastases are characterized by immune suppression with exhausted CD8+ T cells, expanded regulated T cell (Tregs), M2-polarized macrophages, and high programmed death ligand-1 (PD-L1) expression. Brain metastases display an “immune desert” phenotype due to blood–brain barrier constraints, reduced T-cell infiltration, and microglia-mediated immunosuppression. Bone metastases involve osteoclast activation, RANKL/OPG pathway dysregulation, and metabolic reprogramming, while liver metastases show Kupffer cell-driven PD-L1/ programmed death 1(PD-1) axis suppression and elevated Treg infiltration. Key biomarkers across all types of metastases include PD-L1, cytokine profiles, immune cell ratios, and metabolic markers. Therapeutic strategies focus on combination therapies such as immune checkpoint inhibitors (ICIs) with metabolic modulators, localized drug delivery, and biomarker-guided approaches. Challenges in this field encompass spatial heterogeneity, dynamic TME evolution, and clinical translation barriers. Future research directions highlight spatial transcriptomics, microbiome interactions, and organoid models to optimize personalized immunotherapy. This article aims to provide a comprehensive review of regarding TME alterations across these four main metastatic locations of LUAD. It will also discuss relevant TME biomarkers and their clinical significance on therapeutic response and prognosis. We expect this article to serve as a source of evidence and inspiration for the future development of treatment strategies based on LUAD TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8eac0fc7ba7c67303e9257f2a2d91aba7b28ddab" target='_blank'>
              Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis
              </a>
            </td>
          <td>
            Chao Guan, Xiangmin Li, Xiaoshan Zeng, Zhenguang Du, Zhicheng Zhou, Jungang Zhao, Lele Song, Li Yu
          </td>
          <td>2025-12-01</td>
          <td>Therapeutic Advances in Medical Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3b3b7c8b4c7d00c21b220678d75895ad9433bf9" target='_blank'>
              BATF3 controls the homeostatic maintenance and function of innate-like γδ T cells
              </a>
            </td>
          <td>
            P. Papotto, Elena Hernández-García, Ángela Zarco-Cuadrillero, Ana Redondo-Urzainqui, JE. Parkinson, R. Pinheiro, Andrew S. MacDonald, D. Sancho, B. Silva‐Santos, J. Allen, A. Hayday, S. Iborra, Miguel Muñoz-Ruiz
          </td>
          <td>2025-12-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dc6a28b4224c2b2503480a6b2e0edc6bbd8d9c3" target='_blank'>
              Innate antiviral readiness drives the expansion of protective T stem cell memory against influenza
              </a>
            </td>
          <td>
            Ivan Tomic, David J Ahern, J. Tomalka, Alba Escalera, T. Aydillo, Matthew D Pauly, Nadine G Rouphael, S. Lakdawala, Naseem Sadek, E. Clutterbuck, Nisha Singh, P. Aley, Hannah Robinson, S. Marinou, Stephanie Hao, Matthew Fish, Helder Nakaya, Claudia Monaco, Adolfo García-Sastre, Andrew J Pollard, Adriana Tomic
          </td>
          <td>2025-12-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Introduction Tyrosine kinase inhibitors, including lenvatinib approved for advanced non-medullary thyroid cancer (TC), affect the immune system. As tumor-related inflammation contributes to TC pathogenesis, this study assesses the immunomodulatory effects of lenvatinib, focusing on myeloid cells. Methods Peripheral blood was collected from 16 lenvatinib-treated and 15 untreated TC patients (cross-sectional cohort), and from eight patients before and after > 1 month of lenvatinib (longitudinal cohort). Immune profiling included cell subset counts, proteomic analyses, and ex vivo cytokine assays in peripheral blood mononuclear cells (PBMCs) and monocytes. Monocytes from healthy donors were used to evaluate metabolic activity, reactive oxygen species (ROS) production, and phagocytosis. Tumor-intrinsic effects of lenvatinib were studied by proteomics and immunophenotyping of the TPC-1 cell line. Results Lenvatinib increased lymphocytes and reduced neutrophils. In both cohorts, lenvatinib modulated the inflammatory proteome with elevated VEGFA, CCL11, MMP-10, and TRAIL. Monocytes exposed ex vivo to lenvatinib showed reduced production of IL-1β, IL-6, IL-8, and IL-10. In patients treated with lenvatinib, monocytes displayed increased IL-1Ra and TNF, while PBMCs exhibited enhanced IFN-γ production. Monocytes from healthy donors displayed reduced glycolysis and increased ROS after lenvatinib exposure. In TPC-1 cells, lenvatinib altered the secretome and upregulated MHC class I, PD-L1, and CD40. Conclusions Lenvatinib treatment has broad immunomodulatory effects in patients with TC, including shifts in immune cell populations, changes in the proteome, and reprogramming of cytokine responses. Lenvatinib also impacts monocyte metabolism and tumor cell phenotype. These findings provide insight into the multifaceted immunological activities of lenvatinib and highlight opportunities for treatment strategies. Trial registration Not applicable, this is a noninterventional trial. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04241-7.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9eb1875f22268f700734617d50f0b8a114c09849" target='_blank'>
              Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer
              </a>
            </td>
          <td>
            Prashant Changoer, Chunying Peng, P. van Houten, L. van Emst, Janneke E. W. Walraven, P. Ottevanger, Martin Jaeger, R.T. Netea-Maier
          </td>
          <td>2025-12-19</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/789f5732be66cf570b1071d8f7f995f5861cf81a" target='_blank'>
              Targeting C5aR1 Reveals Protective Macrophage Maturation States in Intestinal Injury
              </a>
            </td>
          <td>
            Heather Clark, Ian J. Chai, S. Melemenidis, Dhanya K. Nambiar, Kim K. Ryan, Yanyan Jiang, Kerriann M. Casey, Iryna Zherka, Dominika Majorova, Trent M. Woodruff, Edward G. Graves, Q. Le, Simon JA. Buczacki, A. Giaccia, M. Olcina
          </td>
          <td>2025-11-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Addressing the variability in cancer immunotherapeutic outcomes among patients and the challenge of devising safe strategies to overcome immune evasion in solid tumors are crucial in advancing cancer therapy. This study investigated the anti-tumor effect of millimeter waves (MMWs) alone and in combination with the anti-programmed cell death-ligand 1 (α-PD-L1) antibody in a 4T1 “cold tumor” model. The results show that MMWs not only inhibit tumor growth but also improve tumor metabolism and the immune microenvironment and enhance anti-tumor immune responses by inducing conformational changes of key immune proteins. Further experiments conducted on cellular and animal models demonstrated that the anti-tumor efficacy of MMWs, which plays a pivotal role, was substantially enhanced with the aid of α-PD-L1. This collaboration resulted in a synergistic effect that not only inhibited tumor progression but also promoted a sustained immune response and prevented recurrence. The additional CT26 “cold tumor” model validates the applicability of this strategy across other “cold tumor” types, particularly in reprogramming the immunosuppressed state of “cold tumor”. These findings underscore the unique potential of MMWs as a nonionizing, nonthermal therapeutic tool that complements cancer immunotherapy, offering a novel approach for the precision treatment of solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c5f98cfd2c377f7a7b8d908bf4572978453a827" target='_blank'>
              Reviving Dormant Immunity: Millimeter Waves Reprogram the Immunosuppressive Microenvironment to Potentiate Immunotherapy without Obvious Side Effects
              </a>
            </td>
          <td>
            Zhenqi Jiang, Rui Jing, O. Akakuru, Keyi Li, Xiaoying Tang
          </td>
          <td>2025-11-12</td>
          <td>Cyborg and Bionic Systems</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Prostate cancer remains one of the most prevalent solid tumors in men worldwide and poses a major therapeutic challenge due to its immunologically “cold” tumor microenvironment (TME), which is characterized by low T cell infiltration, limited antigen presentation, and high levels of immunosuppressive factors. While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, it has yielded limited success in solid tumors such as prostate cancer. Macrophage-based CAR (CAR-M) therapies have emerged as promising alternatives, owing to macrophages’ natural tumor-infiltrating capacity, phagocytic activity, and ability to modulate the TME. However, conventional CAR-Ms exhibit limited capacity to prime adaptive immunity due to insufficient co-stimulatory signaling. To address this limitation, we engineered two novel NKG2D-targeted CAR constructs for macrophages: one containing the intracellular Fc receptor common γ chain (FcRγ) alone (CAR-M), and another incorporating both FcRγ and the intracellular domain of the co-stimulatory molecule CD86 (CD86-CAR-M). These constructs were expressed in Raw264.7 macrophages or and evaluated for antigen-specific phagocytosis, tumor cell cytotoxicity, cytokine secretion, and T cell activation in vitro. In vivo efficacy and safety were assessed using both xenograft and syngeneic mouse models of prostate cancer, including combination therapy with anti-PD-L1 checkpoint blockade. Both CAR-M and CD86-CAR-M exhibited robust, antigen-specific phagocytosis and cytotoxicity against NKG2D ligand-expressing prostate cancer cells in vitro. CD86-CAR-Ms demonstrated enhanced M1 polarization, higher expression of CD86 and superior activation of cytotoxic T lymphocytes, accompanied by increased secretion of IFN-γ and TNF-α. This interaction triggers the phosphorylation of ERK, a central mediator of M1 macrophage polarization and inflammatory responses. In vivo, CD86-CAR-Ms achieved greater tumor suppression and survival benefit than CAR-Ms in immunocompetent models and significantly enhanced the efficacy of anti-PD-L1 antibody therapy without systemic toxicity. The improved anti-tumor effect was associated with increased T cell, NK cell infiltration and macrophages MHC-II expression, indicating TME reprogramming from cold to hot one. This study presents the first demonstration of CD86-enhanced CAR-macrophages targeting NKG2D ligands in prostate cancer. By integrating innate and adaptive immune activation, CD86-CAR-Ms represent a novel and potent strategy for overcoming immunosuppression and improving the therapeutic efficacy of immune checkpoint inhibitors in solid tumors. Supplementary Information The online version contains supplementary material available at 10.1186/s12964-025-02548-7.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a92502fd070af58b4a67230d880201dd22ee2fc7" target='_blank'>
              CD86 costimulation enhances the antitumor activity of NKG2D CAR-Macrophages and synergizes with Anti-PD-L1 therapy to suppress prostate cancer progression
              </a>
            </td>
          <td>
            Abdulrahman Ibrahim, Zihao Liang, Wan Liu, Xiaofei Di, Lawan Rabiu, Rong Li, Pengchao Zhang, M. A. Saliu, Maoxuan Liu, Guizhong Zhang, Xiaochun Wan, Dehong Yan
          </td>
          <td>2025-11-25</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Staphylococcal enterotoxins (SE) crosslink the MHC‐II on antigen‐presenting cells (APC) with the T‐cell receptor, inducing a polyclonal T‐cell response. Although APCs are the initial targets of SE and are critical in shaping subsequent T‐cell activation, the effects of SE on APC function remain poorly understood. This study investigates the immunomodulatory effects of staphylococcal enterotoxin A (SEA) on monocytes and their differentiation into monocyte‐derived dendritic cells (moDC) or macrophages (MDM). Transcriptomic analyses of human monocytes via RNA sequencing revealed SEA‐induced enrichment of gene pathways associated with inflammation, infection, and dermatitis, effects that were amplified in the presence of T cells. Phenotypic and functional characterization showed that SEA‐primed monocytes differentiated into MDM with an altered polarization, deviating from classical M1/M2 pathways. SEA‐primed MDM exhibited downregulation of key markers, including HLA‐DR, CD80, CD86, and PD‐L1. Functional assays demonstrated that SEA‐primed MDM pushed hyperinflammatory T‐cell responses, with significantly enhanced proliferation and IFN‐γ secretion. In contrast, following SEA‐priming, moDC retained robust antigen‐presenting capabilities and displayed enhanced expression of molecules involved in T‐cell interactions. These findings provide mechanistic insights into SEA‐mediated immune modulation, illustrating how SEA reprograms MDM functions and amplifies proinflammatory T‐cell responses. This advances our understanding of superantigen‐driven immune interactions, offering a foundation for developing therapeutic strategies to mitigate superantigen‐mediated immune conditions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31b8b3bf0438451c3b982c5f615c660d9c3ce361" target='_blank'>
              Staphylococcal Enterotoxin A Shapes Monocyte Transcription and Macrophage Polarization: Implications for Immune Responses in Infection and Inflammation
              </a>
            </td>
          <td>
            C. Arasa, Khaleda Rahman Qazi, David Brodin, Manuel Mata Forsberg, E. Sverremark-Ekström
          </td>
          <td>2025-12-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>31</td>
        </tr>

        <tr id="Human epidermal growth factor receptor 2 (HER2) -positive breast cancer exhibits aggressive clinical progression and unfavorable outcomes. While HER2-directed agents and immune checkpoint inhibitors have transformed clinical management, persistent challenges include suboptimal response rates and acquired resistance. These limitations underscore the critical need for alternative therapeutic approaches. Our investigation, leveraging single-cell transcriptomic data derived from both healthy and neoplastic breast tissues, sought to elucidate the specific cellular subsets and regulatory pathways that contribute to the aggressive characteristics of HER2 + breast cancer. Subsequent validation of these findings was achieved through the incorporation of bulk transcriptomic datasets from various breast cancer cohorts, alongside spatial transcriptomics data pertaining to HER2 + breast malignancies, and comprehensive multiplex immunohistochemistry examinations. We identified a marked elevation of SPP1 + macrophages, displaying an M2-like immune-suppressive phenotype, within the tumor microenvironment. These particular macrophage populations were deeply implicated in modulating T cell activities and consistently correlated with adverse patient outcomes. At a mechanistic level, we ascertained that SPP1 + macrophages bolster the immune-suppressive capacity of Tregs via engagement of the CD86-CTLA4 axis, thereby facilitating the advancement of the tumor. Furthermore, the strong association between SPP1 + macrophages and both unfavorable prognosis and advanced disease stages was corroborated in an independent, in-house HER2 + breast cancer patient group. Our work uncovered the pro-tumorigenic capabilities and underlying molecular mechanisms of SPP1 + macrophages in HER2 + breast cancer, suggesting these cells represent a promising new therapeutic target. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-025-29530-0.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/360fa2e94ffa34ef9dfde744e04829860bffbcf7" target='_blank'>
              SPP1 + macrophage and Treg interaction mediates immunosuppression and adverse survival in HER2 + breast cancer
              </a>
            </td>
          <td>
            Hao Gao, K. Shen, Luhong Chen, Chao Huang, Jie Ji, Xiaochao Zhu
          </td>
          <td>2025-11-26</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="ABSTRACT Systemic lupus erythematosus (SLE), characterized by immune dysregulation, urgently requires improved diagnostic tools and mechanistic insights. The role of interferon regulatory factor-1 (IRF-1) remains unclear. We integrated single-cell transcriptomes (scRNA-seq; GSE254176), 6 bulk transcriptomic datasets (1079 SLE patients, 137 controls, GSE72326 and GSE61635 were merged as training datasets, including 256 SLE patients and 50 controls), and clinical samples (70 SLE patients and 58 controls). IRF-1 dynamics in T-cell subsets were analyzed via clustering and pseudotemporal trajectory. Diagnostic genes were identified by intersecting single-cell-derived IRF-1–associated markers with SLE differential genes, followed by feature selection. Six machine learning models were trained and validated in four independent cohorts. scRNA-seq revealed significant downregulation of IRF-1 in T-cell subsets (central memory CD8⁺, Th17) during active SLE, with compensatory overexpression in remission—validated clinically. Cross-analysis identified four IRF-1–correlated diagnostic genes: CCR7, CD274, KLRB1, and NRCAM, that are enriched in MAPK signaling and immune receptor activity. Generalized linear model (GLM) and partial least squares (PLS) models achieved superior diagnostic accuracy across validation cohorts. Immune analysis revealed decreased numbers of resting CD4⁺ memory T cells and Tregs (P < 0.01), alongside expanded proinflammatory cells (M1/M2 macrophages, neutrophils; P < 0.01). IRF-1 regulates T-cell differentiation and contributes to SLE immune imbalance. The IRF-1–associated gene–based machine learning model provides a robust, noninvasive diagnostic tool.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fee8fbcb2e712ec10437e9cabca33ae9f067a525" target='_blank'>
              The role of IRF-1 in mediating T-cell immune imbalance in systemic lupus erythematosus and the construction of a diagnostic model
              </a>
            </td>
          <td>
            Zichen Huang, Cheng Zhao, Fang Qin, Leting Zheng
          </td>
          <td>2025-11-19</td>
          <td>Autoimmunity</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Within the tumor microenvironment (TME) of solid malignancies, tumor-infiltrating antibodies, have been identified as significant modulators of tumor progression and immune response. Tumor-infiltrating antibodies predominantly secreted by plasma cells but also including a small proportion of cancer-derived antibodies. This review aims to elucidate the multifaceted roles of tumor-infiltrating antibodies in the immunology of solid tumors, focusing on their dualistic nature within the TME. This review outlines the mechanisms of B cell activation, antibody class switching, plasma cell differentiation and antibody production, with a focus on their contributions to tumor immunity in solid cancers. Additionally, we discuss the emerging potential of tumor-infiltrating antibodies as both therapeutic targets and diagnostic biomarkers, offering insights that may inform future strategies in cancer treatment. Collectively, antibody functions are shaped by their isotypes: IgG is often associated with improved prognosis in various solid tumors. IgG1 and IgG3 generally mediate anti-tumor responses via antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), while IgG4 may impair immune effector functions and associate with immune tolerance. IgM, as an early humoral responder, enhances tumor surveillance through complement dependent cytoxicity (CDC), phagocytosis, and apoptosis induction. IgA predominantly promotes tumor progression through immune suppression. IgE exhibits context-dependent pro- and anti-tumor activities, though current evidence is limited, whereas the function of IgD remains largely unknown. Additionally, tumor-derived IgG promotes tumor growth, metastasis, and immune evasion. These findings may open new avenues of research to develop targeted therapies that modulate tumor-infiltrating antibodies, potentially improving the efficacy and safety profiles of current immunotherapeutic approaches. Overall, this review focuses on tumor-infiltrating antibodies in solid tumors and does not encompass hematological malignancies, aiming to provide a more precise understanding of antibody-mediated regulation within the solid tumor microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8616bf287135d120e92e4c09a4ba7ac972e65717" target='_blank'>
              Unraveling the dual roles of tumor-infiltrating antibodies in solid tumors: friend or foe in the tumor microenvironment?
              </a>
            </td>
          <td>
            Lingrui Miao, Run Zhou, Longfei Zhang, Linlu Feng, Yiao Wang, Pan Song, Dong Lv, Tai-Min Shen
          </td>
          <td>2025-11-21</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Pancreatic ductal adenocarcinoma (PAAD) metastasis is driven by complex tumor–microenvironment interactions. Here, we integrated single-cell and bulk transcriptomic analyses of 104,855 cells from 10 patients to delineate the cellular and molecular landscape of primary versus metastatic PAAD. We identified metastasis-associated epithelial (LMO7⁺, TOP2A⁺, PIGR⁺), fibroblast (IGKC⁺, RGS5⁺), and M2-like macrophage (APOE⁺, CD14⁺, FOLR2⁺, SPP1⁺) subpopulations, validated via bulk deconvolution. Functional analyses revealed upregulated Wnt signaling, epithelial–mesenchymal transition, and angiogenesis in metastatic epithelial and fibroblast compartments. Intercellular communication analysis highlighted SPP1-mediated macrophage–epithelial/fibroblast crosstalk involving key receptor–ligand pairs, contributing to immune suppression and metastatic niche formation. Integrating gene expression and cell proportions, we developed a prognostic model with high predictive accuracy (C-index > 0.85), stratifying patients into risk groups with distinct immune landscapes. Furthermore, PTK6 was identified as a driver of PAAD proliferation, migration, and invasion. Collectively, our study elucidates TME-driven mechanisms of PAAD metastasis, identifies prognostic and therapeutic targets, and provides a framework for precision intervention. Supplementary Information The online version contains supplementary material available at 10.1007/s10238-025-01974-8.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/759c03413ef4b1106fa2a25c75713885026e6884" target='_blank'>
              Single-cell transcriptomic analysis reveals key cell types and pathogenic genes associated with metastasis in pancreatic adenocarcinoma
              </a>
            </td>
          <td>
            Shijun Shen, Zhiqiang Li, Hong Yang, Xinwei Zhang, Gang Chen, Chengzhou Pa
          </td>
          <td>2025-11-29</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Oral squamous cell carcinoma (OSCC) presents a persistent clinical challenge, with high recurrence rates and limited improvements in survival despite therapeutic advances. Tumor-draining lymph nodes (TDLNs) are key immunological sites where anti-tumor responses are orchestrated, yet the prognostic relevance of B cell phenotypes in TDLNs remains underexplored. TDLNs from 49 OSCC patients treated at Karolinska University Hospital were prospectively analyzed. Single-cell suspensions were examined using multicolor flow cytometry to characterize B cell subsets (naïve, memory, plasma cells) and expression of immunoregulatory markers (CD11c, CD24, CXCR5, CD73, HLA-DR, PD-L1). B cell profiles were correlated with clinical outcomes, including disease-free survival (DFS) and overall survival (OS). Disease-free patients exhibited a distinct B cell profile marked by a higher proportion of naïve B cells, strong CXCR5 and CD11c expression, and increased plasma cell differentiation. Recurrence was associated with elevated CD24, CD73, and HLA-DR expression, markers linked to immunoregulatory or dysfunctional B cell states. Interestingly, high PD-L1 expression on memory B cells correlated with improved prognosis, suggesting a context-dependent immune function. In line with these observations, multivariate analysis confirmed HLA-DR expression, together with nodal status, as independent prognostic factors for survival in OSCC. B cell phenotypes in OSCC TDLNs are strongly associated with patient outcomes. A microenvironment enriched in naïve and functionally active B cells supports durable tumor control, whereas regulatory/exhausted phenotypes are linked to recurrence. These findings position B cell markers as promising prognostic indicators and therapeutic targets in OSCC, warranting validation in larger cohorts and functional studies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e53fc077cfc1be5ffeb3e5533cd2213e7b74ff1" target='_blank'>
              B Cell dysfunction in tumor-draining lymph nodes predicts relapse in oral squamous cell carcinoma
              </a>
            </td>
          <td>
            Vilma Liljeström, Pedro Farrajota Neves da Silva, Rusana Bark, A. Elliot, L. Marklund, G. Margolin, S. Kumlien Georén, L. Cardell, Krzysztof Piersiala
          </td>
          <td>2025-11-12</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Acute ischemic stroke triggers immunosuppression, yet existing therapies struggle to balance neuroprotection with poststroke immunosuppression. We demonstrated that bone marrow mesenchymal stem cells (BM-MSC) reverse stroke-induced thymic atrophy by promoting T-cell differentiation and restoring peripheral T-cell populations. Bulk RNA sequencing of BM-MSC-treated thymuses revealed enhanced proliferative signatures. Mechanistically, BM-MSC secrete migrasomes (organelles derived from migrating cells) that traverse the blood‒thymus barrier. Single-cell RNA sequencing analysis demonstrated that migrasome-mediated proliferation occurred specifically in medullary thymic epithelial cell I (mTECI) subpopulations. Proteomic profiling via liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) identified Pin1—a cell cycle regulator—as the predominant cargo in BM-MSC-derived migrasomes. In vivo and in vitro studies confirmed migrasome-mediated thymic epithelial proliferation, T-cell niche reconstruction, and immune homeostasis restoration. Migrasome monotherapy improved neurological deficits and survival rates in stroke model mice, demonstrating dual neuroprotective-immunomodulatory efficacy. This work addresses the clinical dilemma between neuroprotection and immunosuppression alleviation, establishing migrasomes as a cell-free therapeutic strategy for poststroke immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e21a53a77f8bdc47edb44b216f414ef301654933" target='_blank'>
              BM-MSC-derived migrasomes reverse stroke-induced thymic atrophy and immunosuppression via Pin1 delivery to thymic epithelial cells
              </a>
            </td>
          <td>
            Haotong Yi, M. Hu, Liling Yuan, Xiaotao Su, Shilin Wu, Tiemei Li, Shisi Wang, Xinmei Kang, Yuxin Liu, Zhiruo Liu, Qin Qin, Weihua Yu, Yifan Li, Wei Qiu, W. Cai, Zhengqi Lu
          </td>
          <td>2025-11-15</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Abstract Dendritic cells (DCs) are central players in the immune system, serving as a bridge between innate and adaptive immunity. Their unique abilities to capture, process, migrate, and present tumor-associated antigens to T cells make them essential actors in initiating and regulating anti-tumor immune responses. This review provides an overview of the phenotypic heterogeneity and functional diversity of DC in cancer immunity, with an emphasis on their interactions with other immune cells within the tumor microenvironment, highlighting their collaborative efforts in driving effective antitumor immunity. Additionally, we examined the impact of tumor-derived signals and immunosuppressive mechanisms on DC functions and their implications for DC-based cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4023e2a8e275a8c6ec2887c09a43912804a69b60" target='_blank'>
              Dendritic cells: the central partner for cancer immunity
              </a>
            </td>
          <td>
            Léo Laoubi, Elisa Gobbini, Pierre Duplouye, Margaux Hubert, Christophe Caux, N. Bendriss-Vermare, J. Valladeau-Guilemond, Aurélien Voissière
          </td>
          <td>2025-11-14</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="B lymphocytes are the core of the pathogenesis of various autoimmune diseases, playing an irreplaceable role in the disease process as plasma cell precursors that produce autoantibodies, potent antigen-presenting cells, and key regulators of immune responses through cytokines. Therefore, therapies targeting B cells have become an important cornerstone for treating such diseases, and exploring their related mechanisms and optimizing treatment plans has significant clinical significance. This article focuses on B-cell targeted monoclonal antibodies (mAbs), systematically explaining their mechanisms of action and drug resistance issues. Regarding drug resistance, the article analyzed its multifactorial mechanisms, including target-related changes (such as CD20 mutations or downregulation), host factors (such as Fc γ R polymorphism), and the influence of tumor microenvironment and compensatory survival pathways. This article underscores the transformative impact of advanced techniques like single-cell multi-omics and CRISPR screens in biological inquiry and elucidates approaches to overcome resistance, including developing next-generation antibodies (bispecifics, ADCs), rational combo therapies, and personalized medicine. This article systematically reviews the mechanism of action and drug resistance issues of B-cell targeted monoclonal antibodies, which not only deepens the understanding of related biological processes but also provides theoretical references for optimizing treatment plans and avoiding drug resistance in clinical practice, helping to promote the precise and efficient development of autoimmune disease treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d9eba684af32d578d9b476278dcfb6dcfe73cb21" target='_blank'>
              Mechanisms of Action and Resistance of B Cell-Targeting Monoclonal Antibodies in Autoimmune Diseases
              </a>
            </td>
          <td>
            Jiacheng Liang
          </td>
          <td>2025-12-28</td>
          <td>Academic Journal of Science and Technology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3443903af73c8ea2603fc42506194395d5951dde" target='_blank'>
              Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
              </a>
            </td>
          <td>
            Chien-Huan Weng, Anais Assouvie, Lauren Dong, JC Beltra, S. Budhu, L. Mangarin, Yacine Marouf, Lucia Morgado-Palacin, Cailian Liu, Sébastien Monette, Jonathan F. Khan, Isabell Schulze, Dmitry Zamarin, Linda Hamadene, Fadi Samaan, Daniel Hirschhorn, S. Pourpe, David Schröder, R. Zappasodi, Pamela M. Holland, N. Anandasabapathy, E. Wherry, J. Wolchok, T. Merghoub
          </td>
          <td>2025-11-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>171</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/58ad21f0ac78d5c82537932a36fb92c178b210c8" target='_blank'>
              Microenvironment-specific modulation of macrophage function and tumour progression by ADAMTS1 through Syndecan-4 shedding
              </a>
            </td>
          <td>
            Silvia Redondo-García, R. Caracuel-Peramos, F. J. Rodríguez-Baena, Salvador Muñoz-Mira, Ana García-Muñoz, R. López-Domínguez, María del Carmen Plaza-Calonge, Belén López-Millán, P. Carmona-Sáez, J. C. Rodríguez-Manzaneque
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dfa1103b42fb7aad2cf0d81519ef11fa1c555b5" target='_blank'>
              Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
              </a>
            </td>
          <td>
            Josephine G. M. Strijker, Ronja E. van Berkum, Elisavet Kalaitsidou, Arjan Boltjes, Naima Hiddink Verberne, Mirjam A. Damen, F. van den Ham, Liselotte E. Baaij, John Anderson, Jan J. Molenaar, Wei Wu, J. Wienke
          </td>
          <td>2025-12-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Significance T cell recognition of cancer cells for their elimination is mediated by an immunological synapse that supports the coordinated activation of cytolytic T cells to efficiently kill tumor cells. Traditional tumor-targeting T cell engager proteins synthetically activate T cells via a strong affinity T cell receptor agonism “signal 1,” which may lead to T cell dysfunction and curtail sustained antitumor T cell activity. We have engineered trispecific antibodies that directly supply both signal 1 and “signal 2” through simultaneous attenuated affinity CD3 and CD2 interactions that induce T cell costimulation and result in increased tumor killing while avoiding superagonism. These features highlight the potential of his trispecific platform to address unmet patient needs in both solid and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0f6543b55222ae93cb54b3611b676d100d6baf68" target='_blank'>
              EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors
              </a>
            </td>
          <td>
            Oksana A Sergeeva, Guixian Jin, Mohosin Sarkar, Jennifer Zeiger, Sonali Dhindwal, Shu Shien Chin, Abudukadier Abulizi, Zengzu Lai, Colleen Brown, William DeMaria, Donal Ryan, Xingyue An, H. Karp, Evelyn Teran, Changqing Yuan, Danielle Klaskin, Tracy A Reeve, Guoying Karen Yu, Eric M Tam, S. Kaech, Martin Preyer, Louis Matis, Jay S. Fine, Stella Martomo, Jeremy S Myers
          </td>
          <td>2025-11-18</td>
          <td>Proceedings of the National Academy of Sciences of the United States of America</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are central constituents of the tumor microenvironment (TME), recruited from circulating monocytes through chemotactic signals, and they execute complex, multifaceted functions throughout tumor progression. Functionally heterogeneous, TAMs are broadly classified into distinct subtypes that display a dynamic duality, capable of shifting between tumor-suppressive and tumor-promoting states, though the pro-tumorigenic functions tend to dominate across multiple cancer types. The polarization of TAMs is modulated by diverse cytokines and signaling networks within the TME. Key pro-tumor mechanisms include activating proliferative signaling pathways, enhancing invasive and metastatic potential, establishing an immunosuppressive TME through immune cell interactions, and conferring therapy resistance. The spatial heterogeneity of TAMs further underscores the predictive relevance. Translational research increasingly focuses on TAM-targeting strategies such as inhibiting recruitment, depleting subsets, or reprogramming function. Emerging approaches, including nanomedicine-based targeting, macrophage-mediated therapies, and novel drug formulations, highlight the importance of combining conventional treatments with immune checkpoint inhibitors (ICIs). Such combinations help overcome therapeutic resistance and improve clinical outcomes. This review systematically summarizes recent advances in TAM biology and plasticity, biomarkers from single-cell and spatial analyses for distinguishing TAM subsets, and their prognostic relevance in immunotherapy. It also discusses TAM-targeting strategies and their synergistic potential with existing therapies. Together, these insights lay the foundation for next-generation cancer treatments that precisely target TAMs to overcome therapy resistance and improve patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/364fbf1a7e99dd37bbe5b81db733d5ee958dbfae" target='_blank'>
              Tumor-associated macrophages in cancer: from mechanisms to application
              </a>
            </td>
          <td>
            Wan Tang, Xin Wang, Bing Han, Shuheng Jiang, Hongshi Cao
          </td>
          <td>2025-12-01</td>
          <td>Molecular Biomedicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Head and neck squamous cell carcinoma (HNSCC) remains a prevalent epithelial malignancy. Immune-checkpoint inhibitors have reshaped first-line therapy for recurrent/metastatic disease; yet durable benefit is confined to a subset, reflecting myeloid-centric mechanisms—SPP1+ TAM barriers, cDC1/IL-12 insufficiency, and CXCL8–CXCR1/2–driven neutrophil trafficking—distinct from, and complementary to, classical lymphoid exhaustion. In this review we summarize advances from single-cell RNA and ATAC profiling and spatial transcriptomics that resolve macrophage, dendritic-cell and neutrophil programs, and appraise translational opportunities spanning myeloid reprogramming, innate–adaptive combinations and spatial biomarkers. We also discuss enduring challenges—including HPV-status heterogeneity, limited assay standardization and a scarcity of predictive metrics—that temper implementation. By integrating myeloid-informed readouts (e.g., SPP1–TAM burden, cDC1 competency, serum IL-8) with PD-1–based regimens, EGFR-directed antibodies and myeloid checkpoints (CD47–SIRPα, PI3Kγ, CXCR1/2), emerging strategies aim to restore antigen presentation, improve lymphocyte trafficking and remodel tumor–stroma interfaces. Our synthesis provides an appraisal of the evolving landscape of myeloid-informed precision immuno-oncology in HNSCC and outlines pragmatic standards and avenues for clinical translation. We hope these insights will assist researchers and clinicians as they endeavor to implement more effective, individualized regimens.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1e1e89f3eb622744a2cb356a1f52faae72322d69" target='_blank'>
              Myeloid-driven immunosuppression in head and neck cancer: single-cell ATAC/RNA and spatial transcriptomic perspectives
              </a>
            </td>
          <td>
            Rui Luo, Jianzheng Yang, Zimeng Cao, Bing Li
          </td>
          <td>2025-12-18</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, causing significant morbidity and disability. Inflammation-induced activation of myeloid cells is involved in disease pathogenesis and contributes to joint destruction. Due to the significant plasticity of myeloid lineage, peripheral blood (PBL) monocytes have the potential to differentiate into a variety of mature cells, including macrophages, osteoclasts, and dendritic cells (DCs), depending on the environmental cues and activated signaling pathways. Therefore, we aimed to determine how the Notch pathway affects differentiation of human PBL monocyte progenitor under inflammatory conditions. We first determined the frequency of monocyte subsets and identified a common trilineage monocyte progenitor (TMP), expressing the phenotype CD45+CD15−CD3−CD19−CD56−CD11b+CD14+, in the PBL of healthy controls and RA patients. To assess the effect of Notch-pathway activation on TMP differentiation, we then coated culture plates with the immobilized Notch ligands Jagged 1 (JAG1) and Delta-like ligand 1 (DLL1). Macrophages, osteoclasts, and DCs were differentiated from TMPs of control subjects by the appropriate cytokines (M-CSF, M-CSF/RANKL, or GM-CSF/IL4, respectively), whereas the addition of bacterial lipopolysaccharides mimicked an inflammatory environment. We observed that the TMP population is expanded in RA PBL and expresses Notch receptors, implicating its susceptibility to Notch regulation. Our results further suggest that in the context of inflammation, Notch signaling, especially via DLL1, polarizes TMP differentiation in favor of the pro-inflammatory and antigen-presenting capacity of DCs and macrophages, while suppressing phagocytosis and matrix degradation by macrophages and osteoclasts. Specifically, these Notch effects are seen as higher IL1B expression and enhanced T lymphocyte stimulation by DCs, higher HLA-DR expression and suppressed phagocytosis by macrophages, as well as lower CTSK expression and suppressed TRAP activity by osteoclasts. In conclusion, we demonstrated that the Notch-axis effectively regulates the commitment of common TMP into myeloid cell subtypes. Therefore, modulation of Notch signaling may be an important complementary approach to treating RA pathogenesis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92f927dbc6965bfcc1c442423a8950332fff8e2c" target='_blank'>
              Effects of Notch signaling on the lineage commitment of human peripheral blood monocyte trilineage progenitor under inflammatory conditions
              </a>
            </td>
          <td>
            Sara Aničić, Maša Filipović, Ivo Krešić, Ozana Jakšić, Marta Radošević, D. Flegar, Pavao Planinić, M. Ikić Matijašević, Z. Jajić, T. Kelava, N. Kovačić, A. Šućur, D. Grčević
          </td>
          <td>2025-11-10</td>
          <td>Cell Death Discovery</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="The tumor microenvironment (TME) orchestrates tumor growth, immune evasion, and therapeutic response in head and neck squamous cell carcinoma (HNSCC). Current immune checkpoint inhibitors (ICIs) target the programmed death receptor-1/programmed death-ligand 1 (PD-1/PD-L1) axis and improve survival in recurrent, metastatic, and locally advanced HNSCC. Tumor cells produced exosomes directly suppress cytotoxic T-lymphocytes activity by modulating immune checkpoint pathways and disrupting T-cell receptor signaling. Cancer-associated fibroblast-derived exosomes (CAF-Exos) function indirectly by conditioning immune escape and tumor growth. Together, these exosomal populations cooperate to create an immunosuppressive niche that hinders the efficacy of immunotherapies. CAF-Exos induce TME changes that exclude CD8+ T-cells, promote regulatory T-cells (Tregs), and upregulate PD-L1 expression in tumor cells. The bidirectional transfer of microRNAs (miRNAs) between tumor cells and CAFs enhances epithelial–mesenchymal transition (EMT), suppresses cytotoxic lymphocytes, and undermines ICI efficacy. This review article summarizes recent publications about plasma-derived exosomes from HNSCC patients. These exosomes carry tumor and immune checkpoint markers, reflect tumor burden and treatment response, and strongly modulate immune cells by suppressing T- and B-cell activity and promoting immunosuppressive macrophages. We encourage functional and biomechanistic future studies in the field of HNSCC that examine how CAF subtypes exosomes achieve an immunoresistant TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/045447a931fd77543654643276c8475e775846e3" target='_blank'>
              Cancer-Associated Fibroblasts-Derived Exosomes as Mediators of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma
              </a>
            </td>
          <td>
            Julia Federspiel, J. Dudas, B. Hofauer, B. Wollenberg, T. Steinbichler
          </td>
          <td>2025-12-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Despite effective viral suppression, a subpopulation of people living with HIV (PLWH) receiving combination antiretroviral therapy (ART) experience a suboptimal immunological response, failing to restore CD4+ T‐cell counts to levels deemed indicative of good immune recovery. Innate immune cell dysregulation, particularly in mucosal‐associated invariant T (MAIT) and natural killer (NK) cells, is increasingly recognized as a key contributor to immune reconstitution. However, the dynamic changes, interactive crosstalk, and potential roles of these immune cells in immune reconstitution remain poorly understood. A total of 89 participants were enrolled, including 29 healthy controls and 60 HIV‐infected individuals, who were classified as immune responders (IRs, CD4 ≥ 500 cells/µL; n = 34) and suboptimal immunological responders (SIRs, CD4 < 500 cells/µL; n = 26) on the basis of immune recovery status. Longitudinal flow cytometric analysis was performed to assess the phenotypic changes in MAIT and NK cell subsets in peripheral blood mononuclear cells (PBMCs) before treatment (T0) and after 4 years of ART (T4). Correlation analysis was conducted to explore their associations with CD4+ T‐cell recovery. After 4 years of ART, both IRs and SIRs exhibited persistent depletion of total MAIT and invariant natural killer T (iNKT) cells, whereas pretreatment‐diminished CD56bright and CD56dim NK cell subsets increased significantly. MAIT cells also underwent phenotypic remodeling in both groups, with decreased CD4−CD8+ and increased CD4−CD8− subsets. Notably, these cell subset proportions and quantitative changes correlated significantly with CD4+ T‐cell counts in IRs but not SIRs. In IRs, CD4+ T‐cell recovery positively correlated with baseline CD4−CD8− MAIT and CD56bright NK cell numbers, but negatively with baseline CD4−CD8+ MAIT cell numbers. Correlation networks revealed distinct MAIT–NK interactions across ART stages. LASSO models integrating MAIT and NK subsets achieved high predictive accuracy, highlighting the dynamic role of CD4−CD8+ MAIT cells in immune reconstitution. Our study highlights the dynamic correlations between and within MAIT and NK cell subset proportions in PLWH, revealing that phenotypic remodeling rather than absolute cell counts plays a key role in immune reconstitution. CD4−CD8+ MAIT cells show time‐dependent predictive shifts, reflecting functional adaptation. These findings identify MAIT and NK subset dynamics as potential biomarkers and therapeutic targets for enhancing immune recovery of PLWH during ART.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8a98d3cfcae4bc3d9e7d0f462e62d60ace1750c6" target='_blank'>
              Subset Remodeling of MAIT and NK Cells Correlates With Immune Reconstitution in People Living With HIV Following Four Years of Antiretroviral Therapy
              </a>
            </td>
          <td>
            Zhuoya Deng, Xin Zhang, Aiwei Zhu, Xiao-dong Yang, Qiuyue Zhang, Hongxia Yan, Hao Wu, Tong Zhang, Christiane Moog, Bin Su
          </td>
          <td>2025-11-29</td>
          <td>Journal of Medical Virology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood (PB) and bone marrow (BM) monocytes was performed from healthy donors (HDs) and MM patients to generate a comprehensive single-cell transcriptional map. Although PB and BM monocytes displayed comparable cellular compositions, MM monocytes exhibited marked transcriptional alterations, most prominently within the type I interferon (IFN) signaling pathway. Trajectory analyses revealed IFN-driven disruptions in monocyte differentiation and developmental trajectories in both PB and BM compartments. Functional co-culture assays demonstrated that activation of the type I IFN pathway enhanced MM cell proliferation, suggesting that IFN-mediated monocyte reprogramming facilitates tumor progression. In an independent validation cohort, longitudinal sampling before and after induction therapy confirmed that anti-myeloma treatment alleviated the excessive IFN response of BM monocytes. Collectively, these findings uncover a mechanistic link between aberrant IFN activation and monocyte dysregulation in MM, providing new insights into immune dysfunction and highlighting the IFN pathway as a potential therapeutic target to restore anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c95b600545a3e90a13c96978be5b8e9b2126411" target='_blank'>
              Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
              </a>
            </td>
          <td>
            Jian Cui, Jingwei Wang, Xiaoyun Li, Lina Wang, X. Mao, Rui Lyv, Wenqiang Yan, Jingyu Xu, Jieqiong Zhou, C. Du, S. Deng, Mu Hao, Yan Xu, S. Yi, D. Zou, Tao Cheng, Xin Gao, Lugui Qiu, Gang An
          </td>
          <td>2025-11-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive therapeutic strategy. Tumor Treating Fields (TTFields), an FDA-approved, electric-field–based therapy, has recently been suggested to modulate immune responses in addition to its established anti-mitotic activity. Here, we investigated the direct effects of TTFields on macrophage activation and function. Murine bone marrow–derived macrophages (BMDMs) were polarized toward a pro-inflammatory M1-like phenotype or an anti-inflammatory M2-like phenotype and exposed to TTFields. TTFields rapidly activated guanine nucleotide exchange factor-H1 (GEF-H1), and downstream nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1, via c-Jun N-terminal kinase [JNK]) signaling. Functionally, TTFields reprogrammed M2-like macrophages by increasing major histocompatibility complex class II (MHC-II) and cluster of differentiation 80 (CD80); reducing arginase-1 (Arg1); and elevating secretion of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin-6 (IL-6), IL-1β, and IL-12 subunit p70 (IL-12p70). In interferon gamma (IFN-γ)-primed macrophages, TTFields provided a secondary signal, driving myeloid differentiation primary response 88 (MyD88)-dependent expression of inducible nitric oxide synthase (iNOS). In vivo, TTFields reduced tumor burden in an orthotopic murine lung cancer model and increased iNOS expression in both M1-like and a subset of M2-like TAMs. These findings demonstrate that TTFields directly reprogram macrophages toward a pro-inflammatory phenotype, suggesting a novel immunomodulatory mechanism that may enhance anti-tumor immunity in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db7963f819719f5d174aa6e308c691c9523b680d" target='_blank'>
              Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)
              </a>
            </td>
          <td>
            T. Kan, Y. Barsheshet, Tharwat Haj Khalil, B. Brant, T. Voloshin, K. Ben-Meir, Simona Zisman Rosen, M. Giladi, U. Weinberg, Y. Palti
          </td>
          <td>2025-12-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Glioblastoma (GBM) is characterized by fast progression, infiltrative growth pattern, and a high relapse rate. A defining feature of GBM is the existence of spatially and functionally distinct cellular niches, where malignant cells engage in paracrine crosstalk with cell types comprising the tumor microenvironment. Here, we identify pericytes as the most active paracrine signaling hub within the tumor parenchyma. Their depletion through genetic engineering results in accelerated tumor progression and shortened survival. Mechanistic studies reveal that pericyte deficiency remodels the endothelium and impacts the immune cell landscape, exacerbating tumor cell invasion and immune suppression. Specifically, the pericyte-deprived endothelium recruits perivascular, tumor-associated macrophages polarized towards an immune-suppressive phenotype. The recruited macrophages express Hepatocyte Growth Factor, which reinforces activation of its receptor tyrosine kinase MET on GBM cells harboring a pronounced mesenchymal subtype driven by the key phenotypic regulator Fosl1. Indeed, orthotopic implantation of MET-expressing GBM cells corroborates their superior tumor-initiating and invasive capabilities. Thus, pericytes represent critical modulators of GBM development by orchestrating a tumor-suppressive microenvironment, highlighting the importance of their preservation in therapy. Improved understanding of the tumor ecosystem in glioblastoma is critical for developing new treatment strategies for the disease. Here, the authors identify pericytes as an active paracrine signaling hub within the tumor parenchyma that orchestrates a tumor-suppressive microenvironment, suggesting pericyte preservation as a key feature of future therapeutic regimens for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c09a05790107e087a632df06714ceec3176e20b4" target='_blank'>
              Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma
              </a>
            </td>
          <td>
            S. Braun, P. Bolivar, C. Oudenaarden, J. Sjölund, M. Bocci, K. Harbst, Mehrnaz Safaee Talkhoncheh, B. Phung, E. Cordero, R. Rosberg, E. Johansson, G. Jönsson, A. Pietras, Kristian Pietras
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML) is primarily driven by leukemic stem cells (LSCs), the main cause of relapse and therapy resistance. Here, we discover that LSCs are predominantly small and mechanically soft. These mechanical properties enable their selective isolation using microfluidic chips. Single-cell RNA-sequencing of primary human AML bone marrow identifies enrichment of LSCs within the FSClow ALDH1A1+ subpopulation, which exhibits long-term stemness in functional assays. Notably, inhibiting ALDH1A1 in these cells promotes F-actin polymerization and increases cellular stiffness, reducing their stemness while enhancing their susceptibility to natural killer (NK) cell-mediated cytotoxicity. In AML patient-derived xenograft models, the combination of ALDH1A1 inhibition with NK cell therapy markedly suppresses leukemia progression. These findings suggest that targeting the mechanical properties of LSC offers a promising strategy to overcome AML treatment resistance, providing insights into stem cell mechanobiology and paving the way for combining targeted therapies with immunotherapy to improve clinical outcomes. Leukemic stem cells (LSCs) drive relapse and therapy resistance in acute myeloid leukemia (AML). Here, the authors show that increasing the stiffness of LSCs reduces their stemness and enhances their susceptibility to natural killer cell-mediated immunotherapy in AML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bd4d9af75a4b85e67dee8555546e74be5696efd1" target='_blank'>
              Targeting leukemic stem cell biomechanics suppresses stemness and enhances NK cell-mediated immunotherapy
              </a>
            </td>
          <td>
            Mingming Zhu, Haoxiang Yang, Kailong Qiu, Beibei Huang, Tingting Liang, Yan Wang, Huan Li, Mingming Wu, Xinru Liu, Na Zhao, Xian Song, Xuxu Zhao, Mengqing Gao, Yue Zhao, Xiangting He, Rui Zhao, Lili Qian, Qinhua Liu, Changcheng Zheng, Xiaoyu Zhu, Hongyuan Jiang, Fang Ni
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Sepsis is a systemic inflammatory response syndrome induced by infection, characterized by high morbidity and mortality, and responsible for over 11 million deaths worldwide annually. Recent studies have demonstrated that immune dysfunction represents a core element in the pathophysiology of sepsis, in which cluster of differentiation 8–positive (CD8+) T cells, as key executors of cellular immunity, play a critical role in immune dysregulation. This review systematically elaborates on the quantitative changes, functional status, and molecular regulatory mechanisms of CD8+ T cells in sepsis, including abnormalities in metabolic reprogramming, cell death pathways, transcriptional regulation, and intercellular communication. Additionally, it explores potential therapeutic strategies targeting CD8+ T cells, such as immune checkpoint modulation, cell death intervention, and metabolic regulation, and offers an outlook on future research directions, aiming to provide novel insights for immunotherapy in sepsis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/99e991f9e6f9946dff0ca3eb21a47f7eaa4959b8" target='_blank'>
              The Role and Research Progress of CD8+ T Cells in Sepsis
              </a>
            </td>
          <td>
            Xianwen Wang, Qihang Huang, Zhihong Zuo, Zhanwen Wang, Lina Zhang, Zhaoxin Qian
          </td>
          <td>2025-11-27</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Cancer remains one of the most severe global health burdens, and its high mortality is closely linked to the ability of tumor cells to evade immune surveillance. While immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapies have significantly advanced the field of oncology, their efficacy is often limited by complex immune escape mechanisms. This study reviews the main molecular and cellular pathways of tumor immune evasion, including the PD-1/PD-L1 signaling axis, tumor-associated macrophages (TAMs), and other immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Clinical progress and limitations of single agent immunotherapies are summarized, encompassing primary and acquired resistance as well as unpredictable immune related adverse events. Emerging evidence supports combination immunotherapy approaches such as pairing ICIs with antiangiogenic agents or TAM targeted strategies, which have demonstrated synergistic efficacy across preclinical models and clinical trials. This review aims to elucidate the mechanisms of tumor immune evasion and assess current and emerging therapeutic approaches to guide more precise and effective clinical applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e65f7d8b41ca82473df3e2561ea0efa0fce7ec82" target='_blank'>
              Tumor Immune Evasion Pathways and Intervention Strategies
              </a>
            </td>
          <td>
            Che Su
          </td>
          <td>2025-12-28</td>
          <td>Academic Journal of Science and Technology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b5194bae9c69021f828aa05080f63974bfecb81" target='_blank'>
              Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene Therapy
              </a>
            </td>
          <td>
            Brandon L. McClellan, Jorge A. Peña Agudelo, Anzar A. Mujeeb, Ali A. Dabaja, Ziwen Zhu, Sadhakshi Raghuram, M. Varela, Claire E. Tronrud, Kaushik Banerjee, Abraham Wei, Cecilia Calatroni, Lucia H. Zhang, Lissa Cruz Romero, Paul Oh, Mahmoud S. Alghamri, Andrew Robbins, Matthew D Perricone, Ying Wang, Brian Shay, Peter Sajjakulnukit, C. Lyssiotis, Joshua D. Welch, A. Schwendeman, Pedro R. Lowenstein, Maria G. Castro
          </td>
          <td>2025-11-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="Background and aims Atherosclerosis is a chronic immunometabolic disease driven by lipid accumulation and immune cell infiltration. Macrophages and T cells play key roles throughout plaque development. Galectin-1 (Gal-1), a glycan-binding protein, modulates immune functions in these cells and has been reported to attenuate atherosclerosis, though its mechanisms remain incompletely understood. Here, we investigated the effects of Gal-1 on macrophages and T cells during plaque formation. Methods Effects of Gal-1 on atherosclerosis, macrophages and T cells during lesion formation were studied in Apoe−/− mice treated with recombinant Gal-1. Complementary mouse peritoneal foam cell and in vitro macrophage and T cell cultures experiments were performed to study T cell differentiation, macrophage function, polarization end energy metabolism. The impact of Gal-1 on human macrophages was further evaluated in endarterectomy specimens. Results Gal-1 treatment reduced lesion size and increased circulating IL-10 levels, inversely correlating with plaque burden. Unexpectedly, IL-10 neutralization also mitigated atherosclerosis, indicating that its action is at least partially IL-10–independent. In plaques, Gal-1 promoted anti-inflammatory macrophage phenotypes, mirrored by a quiescent metabolic and anti-inflammatory profile in foamy macrophages ex vivo. The use of the Gal-1E71Q variant revealed that these effects were only partly dependent on glycan binding. Beyond IL-10, Gal-1 reshaped cytokine profiles by increasing IL-17, IL-22, and IL-23, consistent with a macrophage-driven regulatory Th17 response, alongside higher frequencies of IL-10–producing and regulatory T cells. Conclusion Gal-1 protects against atherosclerosis associated with reprogramming macrophages and tuning T cell immunity through glycan-dependent and –independent pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2bb689064d23f64e92df5e88983aeac0866276a1" target='_blank'>
              Galectin-1 induces macrophage immunometabolic reprogramming, modulates T cell immunity and attenuates atherosclerotic plaque formation
              </a>
            </td>
          <td>
            Ya Li, J. Leberzammer, X. Blanchet, R. Duan, M. Lacy, V. Triantafyllidou, Veit Eckardt, Eva Briem, A. S. Jung, R. Su, Joel Guerra, Y. Jansen, Michael Hristov, W. Enard, J. Bernhagen, C. Weber, D. Atzler, Alexander Bartelt, Yvonne Doring, D. Santovito, Herbert Kaltner, Anna-Kristin Ludwig, P. von Hundelshausen
          </td>
          <td>2025-11-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Cancer stem cells (CSCs) represent a small subset of tumor cells populations characterized by their ability to self-renew and differentiate. These cells are often considered resistant to chemotherapy, radiotherapy, and immunotherapy, playing a crucial role in driving tumor progression and metastasis. To evade immune attacks, CSCs utilize various genetic and epigenetic strategies that diminish immune recognition, enhance tolerance to immune-induced cytotoxicity, and foster the development of a protective immunosuppressive microenvironment. This microenvironment is shaped by a group of key immunosuppressive cells, particularly myeloid-derived suppressor cells (MDSCs), which not only directly inhibit effector T cells and natural killer (NK) cells, facilitating the immune escape of CSCs, but also significantly contribute to the maintenance of tumor cell stemness and promote their metastasis. Conversely, the developmental signals of MDSCs are also regulated by CSCs. This complex interplay between MDSCs and CSCs adds layers of complexity to the cancer-immune cycle and the associated tumor treatment strategies. Therefore, understanding the detrimental interdependence between MDSCs and CSCs to effectively impede tumor progression has become heated topic in tumor immunology. In this review, we provide a timely summary of the latest studies on the reported characteristics of CSCs and MDSCs, discuss their interconnection during tumor progression, and evaluate various immunotherapeutic strategies targeting these cell populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f6883e12fe0f725487279c796b8b972017bb7c9" target='_blank'>
              Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy
              </a>
            </td>
          <td>
            Bo Wang, Xiaoguo Zhao, Shuxin Han, Yuekang Xu, Jinyao Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7eec5092ca04ca50d54f7a273e3e46cdc98efcc8" target='_blank'>
              Aging increases ovarian cancer growth, metastasis, and immunosuppression that can be alleviated by inhibiting hedgehog signaling
              </a>
            </td>
          <td>
            Asha Kumari, M. H. Elbahoty, Resha Rajkarnikar, Khushi Sureja, M. Monavarian, L. Quintero, K.C. Fuh, Daniel J. Tyrrell, L. Shevde, Camilla Margoli, Karthikeyan Mythreye
          </td>
          <td>2025-12-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="The induction of immune responses in tissues and mucosa has emerged as one of the most promising strategies for the development of more effective vaccines and immunotherapies. In this context, CD8+ resident memory T cells (CD8+ TRM) have arisen as key players in local immune surveillance, acting persistently within non-lymphoid tissues. These cells represent a new and promising frontier in local immune responses and as potential clinical tools. CD8+ TRM are being extensively investigated as therapeutic targets against viral infections and cancer, although their clinical applications have yet to be fully established. Understanding the molecular signals that regulate their generation, differentiation, maintenance, and activation is crucial for the precise targeting of their immune functions. This review explores the main mechanisms involved in the formation and maintenance of CD8+ TRM, from the strength of MHC: TCR interactions to the coordinated role of cytokines, chemokines, and transcription factors in tissue retention and the expression of markers such as CD69, CD103, and CD49a. By integrating this knowledge, we discuss strategies to manipulate these pathways with the goal of developing more effective vaccines and personalized therapies based on resident memory T cells. We also examine how these molecular signals and pathways, either independently or in combination, can be explored both in the fight against viral infections and cancer, and in identifying CD8+ TRM predictive biomarkers for response to anticancer immunotherapies across various tumor types.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7a54040a23911cb44878186479043eac242cce4" target='_blank'>
              Keeping it local: how CD8 TRMs regulate viral and cancer immunity
              </a>
            </td>
          <td>
            Luiz Rodrigues Junior, Cristina Bonorino, Alisson F. Haubert, Marvin Paulo Lins, Gabriel Pozo Pereira, Pedro R. Torres Romao, Barry T. Rouse
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Abstract Immune-mediated glomerulonephritis (IMGN) is a major cause of kidney failure worldwide, yet the precise roles of T cells in its pathogenesis remain poorly understood. However, existing studies lack a comprehensive understanding of the characteristics and functional roles of IMGN T cells in the human context. Addressing this gap is crucial for advancing targeted therapies. By integrating single-cell RNA sequencing (sc-RNA-seq) data from three primary IMGN types—IgA nephropathy (IgAN), lupus nephritis (LN), and membranous nephropathy (MN)—we identified T cell subtype alterations at single-cell resolution. Utilizing advanced sc-RNA-seq computational pipelines, we constructed gene co-expression networks (GCNs), inferred T-cell differentiation trajectories, and assessed metabolic and intercellular signaling features. IMGN kidneys presented expanded T-cell compartments, with significant enrichment of cytotoxic natural killer T (NKT) cells and GZMK⁺ effector memory T (GZMK⁺ Tem) cells. Notably, LTB⁺ memory T cells (LTB⁺ Tm) were selectively elevated in IgAN and LN patients. A coexpression module centered on RGS1 was significantly correlated with 24-h proteinuria (p < 0.001). Metabolic profiling revealed subtype-specific disruptions in the glutathione (GSH) and 3-phospho-D-glyceroyl phosphate (3PD) pathways. Interaction analysis highlighted endothelial cells, mesangial cells, and fibroblasts as key mediators of pathogenic T-cell activation via defined ligand‒receptor pairs. This study provides the first comprehensive single-cell atlas of human IMGN T cells, revealing disease-specific T-cell states, metabolic signatures, and activation mechanisms. Our findings offer new insights into human renal immunopathology and identify promising therapeutic targets for IMGN.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/355e0f6ab7752fce8d41720415bcb57b5ac71157" target='_blank'>
              Single-cell transcriptomic analysis reveals T cell heterogeneity and metabolic reprogramming in human immune-mediated glomerulonephritis
              </a>
            </td>
          <td>
            Jianbo Qing, Yiting Zhao, W. Cheungpasitporn, Jing Miao, C. Thongprayoon, Henglan Wu, Junnan Wu
          </td>
          <td>2025-11-16</td>
          <td>Autoimmunity</td>
          <td>0</td>
          <td>52</td>
        </tr>

        <tr id="Intestinal stem cells (ISCs) promote tissue repair after genotoxic or immune-mediated injury. However, ISCs are particularly sensitive to various stressors and primary targets of overwhelming immune responses, such as interferon γ (IFNγ)-mediated killing. In mouse models of radiation therapy-induced gut damage and in biopsies from patients who underwent allogeneic hematopoietic stem cell transplantation, we observed IFNγ expression by intestinal Treg cells. Treg cells leverage combined IFNγ and interleukin 10 (IL-10) stimulation of ISCs to nurture the growth of intestinal organoids through the activation of the mTORC1 and Myc pathways. Similarly, Treg cells or the combined addition of recombinant IFNγ and IL-10 promoted the regeneration of organoids after irradiation, and both cytokines were essential for ensuring epithelial regeneration following acute intestinal tissue injury in vivo. The exposure of organoids to growth factor-free culture conditions revealed distinct EGF-like properties of IFNγ and Wnt-like properties of IL-10. While IFNγ rapidly induced epithelial proliferation, it depleted the pool of ISCs in vitro. Only the combination of IFNγ and IL-10 led to epithelial proliferation and organoid growth while simultaneously ensuring ISC maintenance over time. Our results reveal a context-dependent role of inflammatory signaling in ISCs, through which Treg cells promote epithelial repair following therapy-induced injury.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d94b1c2ecbf09b8eb96b76cf6ccb45e0eb507208" target='_blank'>
              Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
              </a>
            </td>
          <td>
            J.C. Fischer, Sascha Göttert, Maximilian Giller, Paul Heinrich, Kaiji Fan, Omer Khalid, C. Walther, Maria Drießlein, S. Nefzger, Gabriel Eisenkolb, V. R. Timnik, S. Jarosch, Lena Klostermeier, T. Engleitner, Nicholas Strieder, C. Gebhard, Sarah Diederich, Nicole A. Schmid, Laura Lansink Rotgerink, Laura Joachim, Sakhila Ghimire, E. Vonbrunn, M. Büttner-Herold, Marianne Remke, Katja Steiger, R. Öllinger, R. Rad, Daniel Wolff, Markus Feuerer, Petra Hoffmann, Matthias Edinger, Michael Rehli, Markus Tschurtschenthaler, O. Kepp, Guido Kroemer, Erik Thiele Orberg, Stephanie E. Combs, Wolfgang Herr, Florian Bassermann, Dirk H. Busch, Ernst Holler, S. Heidegger, H. Poeck
          </td>
          <td>2025-11-26</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>123</td>
        </tr>

        <tr id="Stem-like CD8⁺ exhausted T cells (Tex) sustain antitumor immunity, whereas TGFβ signaling acts as a major immunosuppressive pathway. In patients with colorectal liver metastases, we observe that elevated TβRI expression in peri-metastatic hepatocytes correlates with poor prognosis. We therefore investigate whether disrupting hepatocytic TGFβ signaling can reinvigorate stem-like CD8⁺ Tex cells to restrict liver metastasis. In support of this hypothesis, mice with hepatocyte-specific TβRI depletion exhibit reduced liver metastatic burden across multiple tumor models. Mechanistically, hepatocytic TβRI blockade suppresses Galectin-9 secretion, which reshapes the transcriptional program of intra-tumoral CD8⁺ T cells. This reprogramming promotes a phenotypic transition from terminal exhaustion toward stem-like and effector states, yielding T cell subsets with enhanced metastasis-control capacity. Importantly, this axis functions independently of macrophages and CD4⁺ T cells. Furthermore, therapeutic delivery of Galunisertib using choline-modified lipid nanoparticles synergizes with αPD-1, fostering the conversion of exhausted CD8⁺ T cells into responsive Ly108⁺CX3CR1⁺ subsets and suppressing liver metastases. Collectively, our results identify hepatocyte TGFβ signaling as a targetable checkpoint against liver metastases. How TGF-β regulates liver metastasis remains further investigation. The authors here find that TβRI blockade in hepatocytes decreases liver metastatic progression via revitalizing stem-like CD8⁺ Tex subsets, and an LNP encapsulated with the TβRI inhibitor Galunisertib synergizes with αPD-1 to ameliorate liver metastasis">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8539be173ace8a0b4d35310e7d3ebf922993bf40" target='_blank'>
              Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8+ Tex subsets
              </a>
            </td>
          <td>
            Hao Wang, Yan Zhou, Yuanyu Tu, Junxiong You, Baogui Gao, Kun Yuan, S. Zhong, Changjie Huang, Q. Han, Yuntao Dai, Ye Ma, Qingyuan Zhang, Xinyi Yan, Junjiang Wang, Xiaorui Wang, Liang Zhao, Xuegang Sun
          </td>
          <td>2025-11-27</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Purpose Conventional type 1 dendritic cells (cDC1s) mastermind anti-cancer immunity and play a pivotal role in determining the efficacy of cancer immunotherapies. In this study, we sought to decipher the dynamic changes in the tumor immune landscape during intrahepatic cholangiocarcinoma (iCCA) development and harness the therapeutic potential of targeting cDC1s for cancer therapy. Methods We constructed spontaneous murine iCCAs via hydrodynamic tail vein injection (HDTVi) of plasmids encoding AKT/YAP. To characterize tumor-infiltrating immune cell populations throughout iCCA carcinogenesis and progression, we performed time-of-flight mass cytometry (CyTOF). To expand and activate cDC1s, we combined Flt3L with poly I:C (FL-pIC) therapy and assessed its therapeutic efficacy in both AKT/YAP-induced iCCAs and a subcutaneous tumor injection model. Flow cytometric analyses were used to evaluate intra-tumoral infiltration levels of cDCs and CD8+ T cells. Results CyTOF analysis revealed the progressive formation of an immunosuppressive tumor microenvironment as iCCA advances. Crucially, infiltration of cDC1s dramatically decreases in advanced iCCAs compared to early-stage tumors. Combined FL-pIC therapy preferentially expanded CD103+ cDC1s, powerfully inhibiting tumorigenesis in AKT/YAP-driven murine iCCAs and sensitizing these tumors to anti-PD-1 therapy. Moreover, FL-pIC therapy markedly suppressed the growth of established mIC-23 subcutaneous tumors. Conclusions Our findings demonstrate that recruiting and activating intra-tumoral cDC1s is feasible and essential for driving anti-tumor CD8+ T cell immune responses and enhancing anti-PD-1 therapeutic effectiveness in iCCA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0302218b55971d224461dce8f8bbf85290ab2de1" target='_blank'>
              Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinoma
              </a>
            </td>
          <td>
            Dong-ni Pei, Yang Song, Yingxia Zhou, Bo Shu, Shao-wei Huang, Fa-zhao Li, Wei-dong Dai, Bao-Ye Sun
          </td>
          <td>2025-12-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Human T-lymphotropic virus type 1 (HTLV-1) infection is associated with a spectrum of clinical outcomes, ranging from lifelong asymptomatic carriage to severe conditions such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL). Although antibody responses are known to shape immune regulation, the functional relevance of IgG idiotype repertoires in HTLV-1 pathogenesis remains poorly understood. This study investigated the immunomodulatory effects of IgG from individuals with distinct HTLV-1 clinical outcomes. IgG was purified from pooled serum samples of asymptomatic carriers (ACs), HAM/TSP, and ATLL patients and used to stimulate peripheral blood mononuclear cells (PBMCs) from healthy donors. Cytokine production in CD4+, CD8+, and γδ T cells was assessed by flow cytometry. Additionally, proteome-wide IgG reactivity was evaluated using a human protein microarray encompassing over 21,000 proteins, and bioinformatic analyses were conducted to identify protein–protein interaction networks and tissue-specific autoreactivity. HAM/TSP-derived IgG selectively enhanced IFN-γ production in all T-cell subsets and suppressed IL-4 in CD4+ T cells. ATLL-derived IgG induced IL-9 and IL-13 production in CD4+ T cells, and both HAM/TSP and ATLL IgG elevated IL-13 levels in CD8+ T cells. Microarray data revealed distinct autoreactive IgG profiles across clinical groups, targeting immune-related proteins, apoptotic regulators, and proteins expressed in T cells, monocytes, and non-immune tissues such as brain and testis. Notably, no functional or structural clustering was observed in protein–protein interaction networks, suggesting these reactivities reflect complex, idiotype-specific immune alterations rather than compensatory responses. The present findings suggest that HTLV-1 infection may be associated with the development of distinct IgG repertoires that potentially modulate cytokine responses and exhibit broad reactivity toward human proteins. Such patterns could contribute to immune dysregulation and may partially explain the divergent clinical trajectories observed in HAM/TSP and ATLL. Further investigations are warranted to validate these observations at the individual level and to clarify their mechanistic relevance in disease progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b8aecb632668431c7ccb5800cfb0abb0219813d" target='_blank'>
              IgG Idiotype Diversity Shapes Cytokine Profiles and Autoantibody Targets in HTLV-1 Clinical Outcomes
              </a>
            </td>
          <td>
            Isabela Siuffi Bergamasco, N. Machado, Lais Alves do Nascimento, Beatriz Oliveira Fagundes, F. da Ressureição Sgnotto, J. Casseb, S. Sanabani, L. H. da Silva Nali, Denis Miyashiro, José Antonio Sanches, Jefferson Russo Victor
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Psychosocial stress impacts immune system and brain function, yet mechanisms linking peripheral immune dysregulation to major depressive disorder remain unclear. Here, we demonstrate that a specific subset of T cells, the stem cell-like memory CD8+ T (TSCM) cells, is elevated in patients and stress-susceptible mice. CD8+ TSCM cells from patients display unique transcriptional programs and correlated with depression severity. Adoptive transfer of stress-derived CD8⁺ TSCM cells induced depressive-like behavior and neuroinflammation in recipients, without brain migration. Employing a whole-body immunolabeling technology, we discover CD8+ TSCM cells migrated to intestine via the interaction of pro-platelet basic protein and C-X-C motif chemokine receptor 2. CD8+ TSCM cells decrease the abundance of tyrosine-metabolizing bacteria to reducing homovanillic acid production, triggered neuroinflammation and depressive symptoms. Thus, our findings uncover a complex interplay between CD8+ TSCM cells and gut microbial metabolism, shedding light on potential mechanisms underlying depression and suggesting avenues for therapeutic intervention. Major depressive disorder has been linked to peripheral immune dysfunction. Here, the authors identify elevated stem cell-like memory CD8⁺ T cells in patients and in a murine stress model show migration to the intestine via PPBP-CXCR2 and suggest gut CD8 cells modulate tyrosine metabolizing bacteria and homovanillic acid potentiating neuroinflammation and depressive phenotype.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35b60060166ee9a2ca47646aac614361b170bc9e" target='_blank'>
              Migration of CD8 + TSCM cells into intestine via PPBP–CXCR2 axis increases host stress susceptibility by inhibiting gut microbiome-derived homovanillic acid
              </a>
            </td>
          <td>
            Yuan Zhang, Minzi Ju, Suzhen Chen, Wendi Yang, Yang Cai, Xiaoyu Yu, Gang Chen, Zhongxia Shen, Ying Bai, Hui Ren, Yinghui Li, Ling Shen, Junxu Li, Peng Shi, Yonggui Yuan, Bing Han, Honghong Yao
          </td>
          <td>2025-11-19</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Sterol-O acyltransferase 1 (SOAT1) functions by converting cholesterol and acyl-CoA into cholesterol ester and CoA-SH. SOAT1 inhibition suppresses tumor growth. A recent study has shown that inhibiting cholesterol esterification in T cells using genetic manipulation or drug treatment of SOAT1 boosted the cytotoxicity of CD8+ T cells. To better understand the role of SOAT1 in the tumor immune microenvironment of ovarian cancer (OC) and to optimize combined immunotherapy strategies, we examined the effect of SOAT1 manipulation and drug inhibition in OC cells on CD8+ T cell-mediated immune response in vitro. Correlation analysis results obtained using GEPIA2 showed that SOAT1 expression was positively correlated with cytotoxic CD8+ T cell (CTL) infiltration levels and effector CD8+ T cell signature in OC. Additionally, the survival plot from the GSE26712 dataset indicated that CTLs provided clinical benefit in OC patients with high SOAT1 expression but not in those with low expression. The study findings also revealed that SOAT1 knockdown or avasimibe (SOAT1 inhibitor) treatment in OC cells resulted in the downregulation of IFN-γ secretion by CD8+ T cells in vitro. Interestingly, IL-6 and IL-8, two immunosuppressive cytokines known to promote CD8+ T cell dysfunction, were upregulated in SOAT1-silenced and avasimibe-treated OC cells. In conclusion, the present study suggested that SOAT1 inhibition in OC cells could impair the cytotoxic capability of CD8+ T cells in vitro, probably through the increased secretion of IL-6 and IL-8 in OC cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4b967ac9fb4546620b3567252b034af72a5ca75" target='_blank'>
              SOAT1 in ovarian cancer cells regulates immune response mediated by CD8+ T cells
              </a>
            </td>
          <td>
            Jiangnan He, M. K. Siu, Runying Long, Lingshan Hung, Ruiqian Zhang, Mingo M H Yung, Haonan Lu, H. Ngan, K. K. Chan
          </td>
          <td>2025-11-19</td>
          <td>Journal of Ovarian Research</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="Dysregulated lung immunity drives excessive inflammation, leading to diseases like acute respiratory distress syndrome (ARDS) and pulmonary fibrosis that have high morbidity and mortality. Immunomodulation can attenuate inflammation and improve outcomes, however off-target effects from systemic delivery lead to adverse events that limit clinical translation. Herein, we develop a modular cell-based microcapsule platform that can be administered via the airway for localized, durable, and tunable delivery of various immunomodulatory proteins to the lungs. With this system, we demonstrate therapeutic efficacy of localized delivery of two proteins, interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1Ra), in a lipopolysaccharide-induced rodent model of ARDS. Single-cell RNA sequencing revealed that IL-10-secreting capsules reprogram the lung immune landscape in ARDS by altering myeloid cell composition, suppressing pro-inflammatory gene expression, and promoting the resolution of inflammation. In a bleomycin pulmonary fibrosis model, the platform enables durable and sustained delivery of IL-10 to alleviate hypoxemia and rescue lung architecture. Safety and biocompatibility were further confirmed in a large animal model, highlighting the clinical potential of the platform for the treatment of inflammatory lung diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/338ec599bc7f0d26b98590a54b2f280994f96d83" target='_blank'>
              Airway Delivery of Encapsulated Cytokine-Secreting Cells for Local Immunomodulation in Inflammatory Lung Diseases
              </a>
            </td>
          <td>
            O. Veiseh, S. Aghlara-Fotovat, Kailyn Nunez, Miguel Mendez-Sosa, Michael Guinn, Saad Malik, Saliha Pathan, Jacob Cabler, Maheshwari Ramineni, Suridh Chakravarty, Julia Goldman, Michael Diehl, R. Ghanta
          </td>
          <td>2025-11-27</td>
          <td>Research Square</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Introduction We have recently shown that the DNA hypomethylating agent decitabine (DAC) rescues lung allografts from acute rejection. This involves a mechanism that is dependent on host CD4+ FoxP3+ T cells for maximal benefit. DAC treatment also reduces host T-cell IFN-γ production. We therefore hypothesized that DAC may also reduce host macrophage activation. Our objective was to determine if an effect on macrophages contributes to the beneficial effects of DAC in transplantation. Methods In murine orthotopic lung transplant, hosts were treated on post-op day 3-8 with Clodronate (n = 5), DAC (n = 9), or DMSO (n = 11). Results Partial macrophage depletion (clodronate) improves allograft gross and histologic integrity. DAC-mediated allograft rescue was associated with reduced host macrophage recruitment into allograft airways, reduced activation of recruited macrophages, and regeneration of donor resident alveolar macrophages. Discussion These findings suggest that infiltrating host macrophages promote allograft rejection. They also suggest that donor alveolar health is indicative and/or promoting of allograft tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1c63160c7629dcafa8b9f8bf95ff593b261fc72b" target='_blank'>
              The role of macrophages in the mitigation by decitabine of acute allograft rejection
              </a>
            </td>
          <td>
            W. Daccarett-Bojanini, Manuel Sollmann, Kristine Yarnoff, Nicola M. Heller, J. Dodd-o
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Transplantation</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Monocyte exhaustion is a dysfunctional state characterized by prolonged pathogenic inflammation and immune suppression, commonly observed in chronic infections and sepsis. However, the mechanisms underlying the generation and propagation of exhausted monocytes remain poorly understood. In this study, we investigate the impacts of exhausted monocytes on neighboring naïve monocytes, endothelial cells, and T cell function. Using an in vitro co-culture system, we demonstrate that exhausted monocytes induced by prolonged LPS stimulation propagate the exhaustion phenotype to neighboring naïve monocytes. Meanwhile these exhausted monocytes can promote endothelial apoptosis, upregulate adhesion molecules ICAM-1 and VCAM-1, and enhance monocyte transmigration, contributing to endothelial dysfunction. Pharmacological inhibition of CD38, a key marker of monocyte exhaustion, significantly mitigates these effects, highlighting its critical role in monocyte-driven endothelial alterations. Furthermore, we show that exhausted monocytes suppress T cell proliferation and activation, a process reversed by CD38 inhibition. We also identify mTOR signaling as a key regulator of monocyte exhaustion and its propagation, with mTOR inhibition partially restoring monocyte functionality by downregulating exhaustion markers and STAT1/STAT3/S6K signaling. Collectively, our findings highlight the CD38-mTOR axis as a central driver of monocyte exhaustion and its pathological consequences, offering potential therapeutic targets for reversing immune dysfunction in inflammatory diseases. The inhibition of CD38 can alleviate monocyte exhaustion through suppressing the sustained mTORC1-STAT1 activation. Upon LPS stimulation, TLR4 signaling is activated through the TRAM-TRIF adaptor complex, leading to the phosphorylation of Src. This activation promotes mTORC1 signaling, characterized by the recruitment of Raptor and the activation of S6K. mTORC1 activation subsequently drives STAT1/3 signaling, which further induces CD38 expression and forms a sustained positive feedback loop. Elevated CD38 levels contribute to monocyte exhaustion by depleting NAD⁺, a key metabolic cofactor. NAD⁺ depletion negatively impacts mTORC2 signaling, leading to impaired Akt phosphorylation, resulting in diminished expression of PGC1α/β, CREB and CD86, both of which are associated with exhausted monocyte immune suppression. The CD38 inhibitor 78c disrupts this exhaustion pathway, offering a potential therapeutic strategy to mitigate monocyte dysfunction during monocyte exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/339d48c34c821d9297b2f89fa7a33fe439da7b15" target='_blank'>
              Propagation of monocyte exhaustion memory and underlying mechanisms
              </a>
            </td>
          <td>
            Jing Wang, Blake A. Caldwell, Yajun Wu, Babak Razani, Liwu Li
          </td>
          <td>2025-12-01</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="The tumor microenvironment (TME) is a complex ecosystem where interactions between tumor cells, immune cells, and microbes notably influence cancer progression and response to therapy. Tumor-associated macrophages (TAMs), which are crucial components of the TME, exhibit remarkable plasticity, adapting their functions in response to signals from both the tumor and its microbiota. Microbes—including bacteria, viruses, fungi, and their metabolites—modulate multiple aspects of TAM biology, from polarization and metabolism to immune modulation, thereby influencing tumor progression and immune evasion. This review focuses on the mechanisms through which microbes shape TAM responses, particularly in the context of cancer immunotherapy. Emerging therapeutic strategies leverage these microbe–TAM interactions using engineered microbes, oncolytic viruses, and microbial nanomaterials to reprogram TAMs and enhance antitumor immunity. Although formidable challenges remain, including spatial and temporal heterogeneity, mechanistic complexity, and safety concerns, these innovative approaches hold the potential to revolutionize cancer treatment. By targeting the microbe–TAM axis, this therapeutic strategy offers a promising avenue for overcoming resistance and improving the effectiveness of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8d35035aaaac9820113403b52fedea9b4aaf5d8f" target='_blank'>
              Targeting Microbe-Mediated Macrophage Education: A Novel Paradigm in Cancer Immunotherapy
              </a>
            </td>
          <td>
            Rongwei Xu, Xinyuan Zhao, Xu Chen, Huixi Zhou, Li Cui
          </td>
          <td>2025-11-18</td>
          <td>Biomaterials Research</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="The tumor microenvironment (TME) constitutes a highly complex and dynamic ecosystem wherein diverse leukocyte subsets engage in intricate cross-talk that ultimately dictates the balance between tumor progression and suppression. This review provides a comprehensive analysis of the dualistic functions of key immune cell populations-including natural killer (NK) cells, effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)-within this milieu. Particular emphasis is placed on the Nigerian context, where unique genetic backgrounds, such as the high prevalence of sickle cell trait, and environmental factors, including endemic infections, significantly shape immune phenotypes and cancer pathogenesis. We explore how cutting-edge single-cell technologies are revolutionizing our understanding of the spatial architecture, functional plasticity, and cellular heterogeneity of these leukocytes in patient cohorts, revealing mechanisms of both immune surveillance and tumor-promoting immunosuppression. The paradoxical roles of these cells elucidate the variable clinical outcomes observed with immunotherapies and underscore the critical need for precision medicine strategies that are tailored to individual immune landscapes. Finally, we discuss emerging therapeutic modalities aimed at selectively depleting pro-tumor subsets like Tregs or MDSCs while activating anti-tumor effectors such as NK cells, which hold substantial promise for reshaping the TME and improving oncology outcomes both in Nigeria and across the globe.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85d4138591bf3dda987df758be78f378fdcee1f4" target='_blank'>
              Leukocyte Subset Dynamics in the Tumor Microenvironment: Dual Roles, Single-Cell Insights, and Implications for Cancer Immunotherapy in Nigeria
              </a>
            </td>
          <td>
            Okluchi Hartumu
          </td>
          <td>2025-11-25</td>
          <td>Hematological Disorders in the Single-Cell Era</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Auranofin, an FDA-approved antirheumatic drug and thioredoxin reductase 1 (TXNRD1) inhibitor, has demonstrated anti-tumoral properties, but its immunological effects are not well characterized. Here, we report that auranofin unexpectedly promotes regulatory T cell (Treg) expansion. In a B16F10 melanoma model, auranofin treatment increased lung tumor coverage, IL-10 serum levels, and FOXP3+CD44+CD4+ T cell frequencies. It also altered the proportion of antigen-presenting cells (APCs), increasing B cells and reducing dendritic cells. To test whether Treg expansion occurs independently of tumor antigens, we stimulated T cells ex vivo in lymph node cultures from naïve mice using anti-CD3/CD28, with or without auranofin. Auranofin increased Treg frequency in these cultures, as well as in treated human PBMCs. Similar effects were observed with the TXNRD1 inhibitor TRi-1, suggesting a ROS-dependent mechanism. Using mice with conditional expression of neutrophil cytosolic factor 1 (NCF1), we found that both TXNRD1 inhibition and APC-specific NCF1-NOX2-ROS expression enhanced tumor burden and Treg expansion. Alternatively, sorted T cells from mice harboring conditional TXNRD1 knockouts showed reduced FOXP3 and GITR expression in the naïve state and reduced tumor burden when challenged with B16F10. These data suggest TXNRD1 inhibitors likely drive Treg expansion by elevating ROS levels in APCs during T cell priming and less by intrinsic Treg TXNRD1 blockade. Our findings reveal a paradoxical immunosuppressive effect of TXNRD1 inhibitors that may contribute to their limited efficacy in immunocompetent cancer models. This work provides mechanistic insight and underscores the need to consider Treg-mediated immune suppression when designing TXNRD1-targeted therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d550032d5846026566798063a07794f79e6dddf8" target='_blank'>
              Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice
              </a>
            </td>
          <td>
            Michael Y. Bonner, Tamas Vancsik, Ana Oliveira-Coelho, Pierre Sabatier, C. Beusch, Kejsi Zeqiraj, Carolin Svensson, Roman A. Zubarev, Elias S. J. Arnér, Rikard Holmdahl
          </td>
          <td>2025-11-01</td>
          <td>Antioxidants</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="This research elucidates a novel strategy wherein CD8⁺ T cells overcome tumor immune evasion by initiating ferroptosis and establishing a self-sustaining positive feedback loop. Unlike traditional cytolytic pathways employed by CD8⁺ T cells (e.g., Fas-L/Fas and perforin/ granzyme mechanisms), the interferon-gamma (IFN- γ)-facilitated ferroptosis pathway unveils a distinct immunoregulatory role. Ferroptosis is an iron-dependent, non-apoptotic form of cell death driven by excessive lipid peroxidation, loss of mitochondrial membrane integrity, and eventual plasma membrane disruption. Crucially, beyond direct tumor cell killing, the process leads to emission of damage-associated molecular patterns (DAMPs), which potently stimulate dendritic cell maturation and enhance antigen-specific T cell responses. This establishes a cyclic “immune activation--ferroptosis- -immune reactivation” cascade, effectively alleviating immunosuppression within the tumor microenvironment (TME). Our comprehensive analysis demonstrates that CD8⁺ T cell-secreted IFN-γ downregulates SLC7A11, limiting cystine uptake and impairing glutathione (GSH) biosynthesis, thereby inactivating GPX4. Concurrently, IFN-γ upregulates ACSL4, promoting esterification of polyunsaturated fatty acids (PUFAs) into phospholipids and increasing susceptibility to lipid peroxidation. Together, these synergistic changes induce robust ferroptosis. This mechanism offers a transformative therapeutic perspective for tackling resistance to immune checkpoint inhibitors, with considerable theoretical and clinical implications for next-generation cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc592830024c2ef74ca04dbb64f75f144610d41c" target='_blank'>
              CD8⁺ T Cell-Induced Ferr optosis via a Positive Feedback Mechanism to Overcome Immune Resistance
              </a>
            </td>
          <td>
            Jiaqi Mou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Rationale: Natural killer (NK) cells are emerging as a promising source of immunomodulatory secretomes with regenerative potential. However, heterogeneity in primary NK cell populations limits the reproducibility of NK-derived cell-free therapies. To address this, we developed directly reprogrammed NK (drNK) cells with a stable CD56brightCD16bright phenotype and investigated the therapeutic potential of their conditioned medium (drNK-CM) in wound healing, focusing on underlying molecular mechanisms such as chemokine signaling and angiogenesis. Methods: drNK cells were generated by transcription factor-mediated reprogramming (OCT4, SOX2, KLF4, MYC) and characterized via flow cytometry and RNA-seq. The secretome profile of drNK-CM was evaluated using proteomic analysis. Human epidermal keratinocytes (HEKs), dermal fibroblasts (HDFs), and endothelial cells (HUVECs) were treated with drNK-CM to assess proliferation, migration, and extracellular matrix (ECM) remodeling. Chemokine receptor involvement was evaluated using CCR1, CCR3, and CCR5 antagonists. In vivo efficacy was tested in mouse excisional wound models, with histological and immunofluorescence evaluation of angiogenesis, re-epithelialization, and collagen deposition. Results: drNK-CM significantly promoted proliferation and migration of HEKs, HDFs, and HUVECs, accompanied by enhanced expression of Type I/III collagen, VEGF, and MMPs. Transcriptomic profiling revealed that drNKs uniquely upregulated genes associated with ECM remodeling, chemokine signaling (CCL3/4/5), and angiogenesis. Notably, CCR5 inhibition by maraviroc abrogated drNK-CM-induced cell migration and delayed wound closure in vivo, highlighting the central role of the CCL3/4/5-CCR5 axis. Furthermore, drNK-CM activated AKT and ERK pathways and promoted anti-inflammatory macrophage polarization. In vivo application of drNK-CM accelerated wound closure, improved neovascularization, and supported organized tissue regeneration compared to controls. Conclusion: This study demonstrates that drNK-CM enhances wound healing through coordinated actions on epithelial, stromal, and endothelial compartments. The reparative effects are primarily mediated via the CCL3/4/5-CCR5 signaling axis and pro-angiogenic cascades. Given their consistent phenotype and reproducible secretome, drNKs represent a scalable and safe source for cell-free regenerative therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/826d3cc4689581b7361aa10ac63e8a73cda8a212" target='_blank'>
              Cell-free secretome of CD56brightCD16bright directly reprogrammed NK cells enhances wound healing via CCL3/4/5-CCR5 signaling
              </a>
            </td>
          <td>
            Jae Yun Kim, Han-Seop Kim, Binna Seol, Ji Eun Choi, Ji-Young lee, Yee Sook Cho
          </td>
          <td>2026-01-01</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Circular RNAs (circRNAs) have recently emerged as critical regulators of tumor–immune interactions. Owing to their covalently closed structure, remarkable stability, and tissue-specific expression, circRNAs not only serve as molecular sponges and protein regulators but also play multifaceted roles in shaping the tumor immune microenvironment. Accumulating evidence indicates that circRNAs drive immune suppression by stabilizing PD-L1 through post-translational modifications and RNA-binding protein interactions, transmitting suppressive signals via exosomes to T cells and myeloid-derived suppressor cells, reprogramming glucose and lipid metabolism to deprive effector lymphocytes, and reinforcing cancer stemness and therapy resistance. In striking contrast, a subset of circRNAs has been shown to sensitize tumors to immunotherapy by activating innate immune pathways such as RIG-I/MAVS and STING, inducing immunogenic cell death, and overcoming resistance to endocrine therapy or ferroptosis inducers, thereby enhancing the efficacy of immune checkpoint blockade. Beyond their mechanistic functions, circRNAs also hold promise as stable and accessible biomarkers for prognosis, patient stratification, and therapeutic monitoring, particularly when enriched in circulating exosomes. Advances in antisense oligonucleotides, RNA interference, and nanomedicine provide new opportunities to therapeutically target oncogenic circRNAs or deliver engineered pro-immunogenic circRNAs. While significant challenges remain in detection accuracy, functional annotation, delivery specificity, and clinical validation, circRNAs represent a new frontier in immuno-oncology. Harnessing their dual roles may unlock innovative biomarker platforms and next-generation RNA-based therapeutics, ultimately improving the efficacy of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4d997c9720e9890b039f09060198c82b2dba63d" target='_blank'>
              From immune suppression to immunotherapy sensitization: the dual roles of circRNAs in cancer progression
              </a>
            </td>
          <td>
            Quan Dai, Xiaoli Yuan, Hang Dong, Haiyi Xue
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Many inflammatory stimuli can induce progenitor cells in the bone marrow to produce increased numbers of myeloid cells as part of the process of emergency myelopoiesis. These events are associated with trained immunity and have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many cytokines support emergency myelopoiesis, less is known about the mechanisms that temper these events. When mice that lack the cytokine IL-27 were infected with Toxoplasma gondii, there was enhanced generation of monocyte progenitors and increased numbers of inflammatory monocytes. In the bone marrow of infected mice, there was increased production of IL-27 that localized with HSPCs, and a survey of cytokine receptor expression highlighted that HSPCs were uniquely poised to respond to IL-27. Furthermore, the use of in vitro differentiation assays and mixed bone marrow chimeras revealed that HSPCs from IL-27-deficient mice are predisposed toward the monocyte lineage. Additional studies highlighted that after infection, loss of the IL-27R resulted in reduced HSPC fitness that manifested as reduced proliferative responses and a decreased ability to reconstitute the hematopoietic system. Thus, the ability of IL-27 to act on HSPC provides a regulatory brake on differentiation to limit monocyte induction and preserve HSPC stemness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4296e880a374b1ca1dccbcbdeb368a411cccee06" target='_blank'>
              IL-27 limits HSPC differentiation during infection and protects from stem cell exhaustion
              </a>
            </td>
          <td>
            D. Aldridge, Zachary Lanzar, Anthony T Phan, David A. Christian, Ryan D. Pardy, Booki Min, Ross M. Kedl, Christopher A. Hunter
          </td>
          <td>2025-12-15</td>
          <td>eLife</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="The tumor immune microenvironment plays a critical role in tumor progression and responses to immunotherapy. Nevertheless, its cellular complexity and heterogeneity remain incompletely understood. In this study, we employed high-resolution single-cell RNA sequencing on CD45+ immune cells isolated from ten syngeneic murine tumor models, representing seven distinct cancer types under treatment-naïve conditions, thereby enabling a comprehensive profiling of tumor-infiltrating immune cells. We identified seven principal immune cell populations and provided an in-depth characterization of T cells, NK/innate lymphoid cells, dendritic cells, monocytes/macrophages, and neutrophils. Cross-species analyses further delineated conserved immune cell states and transcriptomic features within the T cell and monocyte/macrophage compartments that are shared across syngeneic models and human tumors. To investigate the functional relevance of the predominant monocyte/macrophage compartment and the notable presence of neutrophils in syngeneic tumors, we evaluated responses to anti-PD-1 therapy across various models and analyzed the enrichment of monocyte/macrophage subsets in tumors that responded to treatment. Furthermore, we conducted neutrophil depletion experiments using anti-Ly6G antibodies, administered both as monotherapy and in combination with PD-1 blockade. Remarkably, an interferon-stimulated gene-high (ISGhigh) monocyte subset was significantly enriched in models responsive to anti-PD-1 therapy. Neutrophil depletion resulted in variable antitumor effects across models but failed to enhance the efficacy of PD-1 blockade. In summary, our single-cell profiling offered a detailed atlas of the immune microenvironment across multiple syngeneic mouse tumor models, thereby enabling rational model selection for immuno-oncology studies. We uncovered an ISGhigh monocyte subset enriched in anti-PD-1 responsive models, and showed the context-dependent effects of neutrophil depletion on tumor immunity and immunotherapy, underscoring the heterogeneity and functional divergence of immune cell sublineages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f925e5b4fe351a72672a38a0505d78e0be84e52" target='_blank'>
              Single-cell atlas of the tumor immune microenvironment across syngeneic murine models
              </a>
            </td>
          <td>
            Jia Wang, Bin Jiang, Minjuan Deng, Han Yan, Peilin Zhang, Wei Jin, Zhirong Shen
          </td>
          <td>2025-11-14</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Abstract Objective Examine the role of T cells in shaping and sustaining humoral immunity to SARS‐CoV‐2 and identify immune factors associated with durable antibody responses. Methods Unvaccinated adults (n = 67) with SARS‐CoV‐2 infection (Wuhan) of any severity were followed longitudinally for up to 14 months. Anti‐Spike (S) binding and neutralising antibodies were measured. Bulk T cell IFNγ and IL‐2 responses were assessed by Fluorospot to multiple viral proteins. S‐specific T‐cell subsets and functions were analysed in detail by flow cytometry in a subset of participants (n = 14), combining activation‐induced markers (AIMs) and cytokines. Correlations between S‐specific T‐cell subsets, their polyfunctionality and antibody levels over time were defined. Results Over 14 months post infection, anti‐S IgG and neutralising antibodies declined significantly but remained detectable in > 85% of participants. Bulk T‐cell IFNγ and IL‐2 responses persisted without significant reduction. However, S‐specific CD4 T cells declined over time. A large proportion of these were peripheral helper T cells (Tph; CXCR5−PD‐1+), which were the main producers of IL‐21 and showed marked polyfunctionality during early convalescence, in contrast to circulating follicular helper T cells (cTfh). The early presence of polyfunctional, IL‐21‐producing Tph strongly correlated with S‐specific IgG and neutralising antibodies early post‐infection and predicted neutralising antibody maintenance a year later. Older age correlated with higher Tph and antibody levels. Conclusion Early S‐specific T‐cell responses—particularly polyfunctional, IL‐21‐producing Tph cells—play a key role in sustaining durable antibody levels post‐infection, offering insights for future vaccine strategies and understanding long‐term immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/63995037b8ae83290f6bb5ffec2deaef5580d4b2" target='_blank'>
              Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID‐19
              </a>
            </td>
          <td>
            Katie Tungatt, Gabriela Martins Costa Gomes, Nicole L. Fewings, Aija Stubis, C. Doyle, V. Merheb, A. Aggarwal, K. Byth, Harry Robertson, S. Dervish, Susan Maddocks, Janette Taylor, R. Bull, M. Martinello, F. Brilot, S. Turville, Anthony L. Cunningham, K. Sandgren
          </td>
          <td>2025-01-01</td>
          <td>Clinical & Translational Immunology</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="ABSTRACT Macrophages are innate immune cells that extensively infiltrate and play a key role in the tumor microenvironment (TME). Tumor cell–secreted factors recruit monocytes into the TME, where they differentiate into tumor‐associated macrophages (TAMs), which can polarize into distinct phenotypes: M1 and M2. M1 TAMs promote antitumor immunity through cytokine secretion and antigen presentation, whereas M2 TAMs support tumor progression by facilitating angiogenesis, invasion, and immune escape. Despite these dual roles, the specific mechanisms governing macrophage plasticity and polarization remain insufficiently understood. This review comprehensively summarizes the origin, polarization, and functional diversity of macrophages in the TME, with emphasis on pathways that regulate TAM‐mediated immune responses. Furthermore, this article examines current TAM‐targeted therapeutic strategies, including recruitment inhibition, phenotypic reprogramming, and the development of chimeric antigen receptor macrophages (CAR‐Ms), as well as macrophage‐based drug delivery and exosome therapy. By integrating recent advances in cell engineering and immunometabolism, this review highlights the translational potential of TAM‐targeted therapies and their value in reshaping the immunosuppressive TME to enhance cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7215a076e2ef0687c2a7e70ce9deca69722be237" target='_blank'>
              The Role of Macrophages in Cancer: From Basic Research to Clinical Applications
              </a>
            </td>
          <td>
            Zhimei Liu, Yan Li, Jingchao Cao, Yefeng Qiu, Kun Yu, Shoulong Deng
          </td>
          <td>2025-12-19</td>
          <td>MedComm</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Infected skin tumors are challenging to treat and frequently result in tumor progression, relapses, and post-surgical complications. Moreover, bacterial infections significantly contribute to tumor therapy resistance as they release tumor microenvironment (TME)-modulating molecules. Immune or cancer cells can recognize these pathogen-associated molecular patterns (PAMPs), initiating signaling and pro- or antitumoral response. Hence, understanding PAMPs in tumor therapy may improve the understanding and efficacy of cancer treatment. Cold gas plasma treatment has shown promise in treating infected, ulcerative head and neck cancers. Here, we elucidated gas plasma-induced bacterial PAMP release and their combination with direct gas plasma exposure in skin cancer cells in vitro. Evaluating metabolic activity and viability of tumor cells revealed a significantly stronger growth-inhibitory effect of the combinatory treatment, suggesting a relevant contribution of bacterial molecules to tumor toxicity. A synergistic effect was found regarding the oxidative damage marker γH2AX that was elevated in response to the combination treatment. Cancer cells subjected to gas plasma and provoked PAMPs exhibited an altered phenotype that displayed a strikingly different chemokine and cytokine profile. Mass spectrometry analysis showed improved bacterial cell lysis by gas plasma treatment, increasing intracellular protein release of all three tested bacterial strains.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/293a30a89e7025c1bd7e6b159297e4ac34cc91f2" target='_blank'>
              Gas plasma-induced bacterial PAMP release promotes skin cancer cell death
              </a>
            </td>
          <td>
            Julia Berner, Malin Sieben, Eric Freund, P. Schulan, L. Miebach, S. Bekeschus
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="There are multiple reports of elevated inflammation in patients with major depression. It is, however, unclear whether these reported perturbations in immune functions in depression affect the general functionality of the peripheral immune system. Here, using single-cell RNAsequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) extracted from blood samples collected prior to a flu vaccination administration/immunization (at baseline), we found downregulated T cell and B-cell-associated gene expression repertoire coupled with a selectively upregulated plasmablast, CD14 classical monocytes, and natural killer (NK) proliferating cell-associated gene expression in 9 depressed patients (6 females) compared to 5 healthy controls (5 females), as well as in association with depression ratings. Our cell type proportion analysis revealed shifts in immune cell populations, specifically reduced numbers of CD4+ T and CD8+ T proliferating cells, plasmablasts, and NK cells in individuals with depression compared with controls. In contrast, we found increased numbers of CD14 classical and CD16 monocytes as well as doublet cells in depressed individuals compared with controls. Although our baseline and flu vaccine challenge did not show marked differences in peripheral immune markers measured by a multiplex cytokine assay, our results suggest impaired innate and adaptive immune responses at the transcriptomic and cellular population levels in depressed patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2cf073f7c3882ea32b466937ec788669b0a8b86" target='_blank'>
              Immune System Alterations in Depression across Baseline and Flu Vaccine Challenge
              </a>
            </td>
          <td>
            D. Arasappan, Alyssa Marron, Sina Sanei, Mbemba Jabbi
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20f65e1524ffb4190a28bef066a656c7fa921b4e" target='_blank'>
              B-cell Follicles in the Secondary Lymphatic Tissues Act as a Critical Microanatomical Niche for Sustained Viral Replication, Virus-host Interaction and Damage During Chronic SIV Infection of Rhesus Macaques
              </a>
            </td>
          <td>
            Yilun Cheng, Miaoyun Zhao, Jackson Chen, Subhra Mandal, Mark G. Lewis, Qingsheng Li
          </td>
          <td>2025-11-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Gastric cancer (GC) remains a major global health burden with persistently high mortality despite therapeutic advances. Accumulating evidence highlights the pivotal role of tumor-associated macrophages (TAMs) in orchestrating gastric tumor progression through immune suppression, angiogenesis, extracellular matrix remodeling, and metastasis. Within the tumor microenvironment (TME), TAMs exhibit functional plasticity, often polarizing toward an M2-like phenotype that promotes immunosuppression and tumorigenicity. These cells actively participate in immune evasion via immune checkpoint expression and cytokine-mediated T cell inhibition, while also facilitating lymphovascular invasion and chemoresistance through exosome-mediated crosstalk. The density and phenotype of TAMs have been associated with prognosis and therapeutic response in GC. Recent studies have proposed TAMs as promising targets for therapy, with strategies focusing on depleting M2 subsets, reprogramming toward M1 phenotypes, and blocking TAM-driven oncogenic signaling. Targeted interventions, including MENK, paclitaxel, and NF-κB inhibitors, have shown potential in preclinical models. This review comprehensively discusses the mechanistic roles of TAMs in GC and evaluates emerging TAM-targeted therapeutic strategies that may enhance the efficacy of immunotherapy and improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/913bc3f4af4f9d7fed06d178714e6cfa582ea213" target='_blank'>
              Tumor associated macrophages in gastric cancer dual roles in immune evasion and clinical implications for targeted therapy
              </a>
            </td>
          <td>
            Chang Wang, Xu Fan, Xiaomeng Sun, Yi Xu, Yanna Sun, Jidong Liu
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) harbors a dynamic tumor microenvironment (TME) in which macrophages are highly abundant and plastic. Under physiological conditions, macrophages switch between inflammatory and resolution/tissue-repair programs to maintain homeostasis; however, during hepatocarcinogenesis these programs are reprogrammed into tumor-associated macrophage (TAM) states that foster immune suppression, angiogenesis, and tumor progression. Purpose: To summarize macrophage heterogeneity and polarization mechanisms in HCC, and to highlight omics-informed therapeutic opportunities for targeting TAMs and improving precision immunotherapy. Research Design: This review summarizes physiological macrophage polarization and the mechanistic basis of macrophage reprogramming in the hepatocellular carcinoma immune microenvironment, integrating evidence from recent advances in single-cell sequencing, multi-omics, and spatial transcriptomics, with a focus on macrophage subset diversity, key regulatory pathways governing polarization and function, and emerging macrophage-targeted interventions and biomarkers. Results: Recent single-cell and spatial multi-omics studies reveal substantial TAM heterogeneity and plasticity in HCC. Macrophage-targeted strategies—including TAM depletion, phenotypic reprogramming, and exosome-mediated drug delivery—show encouraging preclinical efficacy. Macrophage-associated prognostic models and biomarkers may support individualized immunotherapeutic approaches. Conclusions: Macrophage polarization in HCC represents a dynamic continuum that is essential for homeostasis but is co-opted by tumors to drive immunosuppression and tissue remodeling. Advances in single-cell and spatial multi-omics are redefining TAM subsets and actionable pathways, enabling more rational macrophage-targeted therapies. However, challenges remain in standardizing TAM definitions, identifying robust predictive biomarkers, minimizing off-target effects, and optimizing combinations with immunotherapy. Integrating longitudinal multi-omics with AI-based modeling may help predict macrophage state transitions, guide patient-specific regimens, and advance precision medicine in HCC. Plain language summary Hepatocellular carcinoma is a highly aggressive cancer. Studies have found that immune cells within tumors—particularly macrophages—play a crucial role in cancer development and therapeutic response. Macrophages have two main “personalities”: the M1 type, which can kill cancer cells, and the M2 type, which supports cancer growth. They shift between these states in response to signals from the tumor microenvironment. Both liver-resident Kupffer cells and infiltrating macrophages are involved in this process. Various molecules, such as cytokines, enzymes, and exosomes, influence their polarization. This polarized state of macrophages, in turn, affects key tumor processes such as stemness, proliferation, metastasis, and angiogenesis. In recent years, scientists have been exploring drugs that specifically target macrophage polarization to suppress liver cancer, offering new directions for future therapy. Graphical Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b9c3d3369daa7c8bd747ff210bf91cca4945570" target='_blank'>
              Macrophage Polarization in the Tumor Microenvironment of Hepatocellular Carcinoma: From Mechanistic Insights to Translational Therapies
              </a>
            </td>
          <td>
            Xiaoqing Fu, Mingquan Pang, Zhixin Wang, Haijiu Wang
          </td>
          <td>2025-11-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Therapy-induced senescence (TIS) generates an immunogenic state in cancer cells by altering how they present antigens, produce cytokines, and organize their surfaceome. TIS can be exploited for therapeutic purposes using “immunosenolytic” strategies, including adoptive cellular therapies such as chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells. A frequently overlooked barrier may limit the success of these living drugs: mitochondrial apoptotic priming in the target TIS cancer cells. Contrary to the prevailing dogma, recent assessments of mitochondrial apoptotic signaling via BH3 profiling (a functional assay measuring proximity to the mitochondrial apoptotic threshold and identifying BCL-2 family dependencies) have revealed that TIS cancer cells are globally less primed for apoptosis than their proliferating precursors. TIS cancer cells exhibit a conserved, druggable dependence on specific members of the BCL-2 family for survival. Interestingly, the pre-existing priming and anti-apoptotic addictions of parental, non-senescent cells, are retained upon induction of senescence. This suggests an “inherited” mitochondrial memory that may predict the (immuno)senolytic responsiveness of TIS cancer cells. BH3 profiling could help to personalize CAR-based immunosenolytic therapy according to apoptotic readiness across pre- and post-TIS states. This companion diagnostic could inform the rational use of BH3 mimetics in combination with CARs and guide the engineering of precision immunosenolytic interventions such as “armored” CAR-T/NK cells neutralizing specific anti-apoptotic dependencies at the effector-target interface. This perspective reframes mitochondria as predictive checkpoints that can be monitored and targeted to enable TIS cancer cells to respond precisely and durably to adoptive CAR-T/NK immunotherapy within “one-two punch” senogenic-immunosenolytic designs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d448509a34a438cbd0714844d26b75b81a37d50" target='_blank'>
              Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy
              </a>
            </td>
          <td>
            Javier A. Menendez, Ruth Lupu, B. Martín-Castillo, Josep Sardanyés, Tomás Alarcón, S. Verdura, E. Cuyás
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is an aggressive malignancy that is often refractory to chemotherapy and immune checkpoint inhibitors. This therapeutic resistance is driven in part by the persistence of cancer stem-like cells (CSCs) and the development of an immune-cold tumor microenvironment. However, the upstream regulators that coordinate these malignant features remain poorly defined. In this study, we identified dysadherin as a novel upstream activator of YAP that promotes both CSC plasticity and immune evasion through the FAK/YAP/TEAD2 signaling axis. Using single-cell transcriptomic analysis, in vitro assays, and multiple in vivo models including a humanized immune mouse system, we showed that dysadherin enhances the expression of pluripotency genes, such as OCT4 and upregulates PD-L1. These changes support stem-like tumor behavior and contribute to T-cell exclusion, fostering an immunosuppressive niche. Notably, genetic knockdown or peptide-based pharmacologic inhibition of dysadherin effectively restored antitumor immune activation, suppressed metastasis and improved therapeutic responsiveness. Our findings reveal a mechanistic link between dysadherin-mediated cell adhesion signaling and the transcriptional regulation of both stemness and immune escape. Collectively, these findings establish the dysadherin/YAP axis as a key driver of HCC progression and resistance, and highlight it as a compelling therapeutic target that could overcome treatment failure in advanced liver cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29884335d480102826ec8b793e157ba0b7881a1e" target='_blank'>
              Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer
              </a>
            </td>
          <td>
            T. Jang, So-El Jeon, H. Yun, Choong-Jae Lee, , Sang Hoon Lee, Dajun Lee, Seungwon Lee, Jungmin Choi, , Jeong-Seok Nam
          </td>
          <td>2025-12-29</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8+ T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/863d3f6179309aee5c3016baab1955820d8c1527" target='_blank'>
              The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma
              </a>
            </td>
          <td>
            Soyoung Kim, IkJoon Han, Suin Lee, Sujin Park, Jae-Won Jeon, Hyunsu Bae
          </td>
          <td>2025-11-25</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) is a multifunctional scavenger receptor expressed on tumor-associated macrophages (TAMs). In a recent study published in the Journal for ImmunoTherapy of Cancer, Yu et al reported that CLEVER-1+ TAMs accumulate in advanced gastric cancer (GC), associate with poor prognosis, and contribute to resistance to chemoimmunotherapy. CLEVER-1 blockade using bexmarilimab reprogrammed TAMs toward a pro-inflammatory phenotype by suppressing peroxisome proliferator-activated receptor gamma (PPARγ)-driven lipid metabolism and enhancing antigen presentation and inflammatory cytokine secretion. CLEVER-1 blockade also synergized with anti-programmed cell death protein 1 (PD-1) therapy in ex vivo GC models, particularly in tumors enriched with CLEVER-1+ TAM. These findings identify CLEVER-1+ TAMs as both biomarker and functional mediator of anti-PD-1 therapy resistance, providing a rationale for combining bexmarilimab with immune checkpoint blockade in GC. In this commentary, we discuss the mechanistic significance, translational potential, and clinical prospects of CLEVER-1 blockade to overcome immunotherapy resistance in GC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f7f73a277d949dbe8513657f917fab43d315e09" target='_blank'>
              CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer
              </a>
            </td>
          <td>
            Xiaonan Xiang, Fei Wang, Yanbin Shen, Sheng Dai
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Lipocalin-2 (Lcn2) is a sensitive early marker for acute kidney injury, delayed graft function and acute rejection of kidney transplants. We previously showed the renoprotective effect of recombinant Lcn2:Siderophore: Fe3+ (rLcn2) in a mouse kidney transplantation (KTx) model. Here, we investigate the molecular and cellular mechanisms underlying these effects. Methods Male C57BL/6 mice (10–12 weeks) received BALB/c kidney allografts, with or without rLcn2 treatment (250 µg, s.c.). To examine the immunomodulatory function of rLcn2, immune cells from graft, spleen, lymph nodes and blood were analyzed by flow cytometry at post-operative days (pod) 3 and 7. Syngeneic C57BL/6 grafts were used to investigate the impact of rLcn2 on alloimmune-independent tissue injury and inflammation through multiplex signaling assays, functional readouts, cytokine profiling and histopathological analyses. Results rLcn2 treatment markedly reduced frequencies of distinct T cell subsets, including effector memory T cells and their cytotoxic (Tc) and helper (Th) subsets across grafts, lymphoid tissues and blood by pod-7 following allogeneic KTx. In graft infiltrating CD8+ T cells, rLcn2 decreased degranulation capacity and diminished expression of interferon-γ and perforin. rLcn2 also lowered the proportion of NKG2D+ CD8+ T cells, an activating Tc subset, in spleen and blood. In contrast, its impact on innate immune cells was modest and selective, influencing only neutrophils, macrophages in lymph nodes and intermediate mature NK cells in spleen and blood. No significant effect of rLcn2 treatment was observed on alloimmune-independent tissue injury or inflammation in syngeneic kidney grafts. Conclusion rLcn2 selectively modulates T-cell activity after KTx without affecting alloimmune-independent injury pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ed180d49cdbfb39ec89a170f0fe6750f292b2bde" target='_blank'>
              Lipocalin-2 modulates recipients alloimmune responses to the murine kidney transplants
              </a>
            </td>
          <td>
            A. M. Pfefferkorn, R. Fritsche-Guenther, Angelika Kusch, Hubert G. Schwelberger, Shiqian Liu, R. Klopfleisch, Yuhuan Li, R. Catar, Shaokun Liu, Felix Aigner, Johann Pratschke, I. M. Sauer, Muhammad-Imtiaz Ashraf
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="The progression of endometrial cancer (EC) is significantly affected by the inflammatory microenvironment (IME), which is essential for facilitating immune evasion and developing resistance to therapeutic interventions. Components that promote immune suppression, such as regulatory T cells (Tregs), macrophages associated with tumors (TAMs), cytokines like interleukin-10 (IL-10) and transforming growth factors-beta (TGF-β), are crucial in establishing a favorable microenvironment for tumor growth. TAMs with a M2-like phenotype promote angiogenesis and inhibit antitumor immunity through the secretion pro-tumorigenic factor. Further, metabolic shifts in the extracellular matrix and structural modifications of the extracellular matrix (ECM) inhibit the infiltration of cytotoxic T lymphocytes (CTLs), thereby strengthening mechanisms of immune evasion. Inflammatory signaling pathways, such as interleukin-6/janus kinase/signal transducer and activator of transcription 3 (IL-6/JAK/STAT3) and NF-κB/tumor necrosis factor-alpha (TNF-α/NF-κB), also stimulate the expression immune checkpoint molecules, such as programmed cell death protein 1 (PD-1). Novel interventions aimed at modulating immune checkpoints, inhibiting TGF-β signaling, and altering metabolic circuits are under investigation and offer potential to counteract immune suppression and enhance therapeutic success. Nevertheless, significant obstacles remain, including intratumoral heterogeneity, fluctuating immune dynamics, and the absence of dependable biomarkers. Advancements in single-cell analysis and spatial transcriptomics are anticipated to unveil actionable molecular patterns and support the development of individualized strategies to interrupt immune evasion and therapeutic resistance in EC. These advances offer promise for personalized immunotherapy approaches that could significantly improve outcomes in endometrial cancer patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/08650738c72d5687a0479b11b8c3deb3610cc229" target='_blank'>
              Inflammation-driven mechanisms in endometrial cancer: pathways from inflammatory microenvironment remodeling to immune escape
              </a>
            </td>
          <td>
            Zhaoping Tan, Binyue Sheng, Lu Chen, Hong Dong, Yaqin Deng, Yunyun Li, Cong Liu, Han Wang, Zi Yang, Ting Xie, Yanming Huang
          </td>
          <td>2025-11-26</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Long COVID has emerged as a major global health concern, yet the long-term trajectory of immune recovery and its contribution to persistent symptoms remain to be elucidated. Here, we conducted a three-year longitudinal follow-up of the 47 COVID-19 patients and applied single-cell RNA sequencing (scRNA-seq) and multiplex cytokine profiling to comprehensively characterize the peripheral immune landscape during convalescence. We observed persistent immune dysregulation up to three years post-infection, characterized by chronic inflammation and impaired restoration of naïve CD4⁺ T cells, naïve CD8⁺ T cells, and SLC4A10⁺ MAIT cells—features reminiscent of immunosenescence. Notably, Th17 cells, rather than monocytes, emerged as key drivers of chronic inflammation beyond one year. We identified two distinct Th17 subsets: RORC⁺ Th17 cells and LTB⁺ Th17 cells. While RORC⁺ Th17 cells were negatively correlated with inflammatory cytokine levels, LTB⁺ Th17 cells showed proinflammatory features and were positively associated with long COVID symptoms. Sustained elevation of S100A8 and IL-16 in follow-up patients may contribute to the persistent presence of LTB⁺ Th17 cells. Together, our study provides an in-depth longitudinal map of immune remodeling in COVID-19 convalescents, revealing key cellular and molecular drivers of sustained inflammation up to three years post-infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f682ef5df5972e318b0093c3cf2459508e92d089" target='_blank'>
              T cell-driven sustained inflammation and immune dysregulation mimicking immunosenescence for up to three years post-COVID-19
              </a>
            </td>
          <td>
            Tian Zheng, Ru Gao, Yiwei Liu, Ye-ming Wang, Chao Wu, Li Guo, Lan Chen, Xinming Wang, Yan Xiao, J. Zhong, Rongling Zhang, Ying Wang, Xianwen Ren, Bin Cao, Lili Ren, Jianwei Wang
          </td>
          <td>2025-11-20</td>
          <td>Immunity & Inflammation</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Liver metastasis continues to be a leading cause of cancer-related mortality, particularly in colorectal, pancreatic, and breast cancer. The successful establishment of metastatic lesions depends critically on the liver metastatic tumor microenvironment, where reciprocal cellular interactions between disseminated tumor cells and both parenchymal hepatocytes and non-parenchymal cells facilitate tumor cell colonization and outgrowth. Hepatic macrophages that encompass both tissue-resident Kupffer cells (KCs) and monocyte-derived macrophages (Mo-Macs) have emerged as pivotal regulators of liver metastatic progression. This review summarizes recent progress from the following perspectives: (I) Primary tumors recruit macrophages via secretion of cytokines and exosomes, or induce phenotypic alterations in resident KCs and recruited Mo-Macs, thereby establishing a premetastatic niche; (II) Once the premetastatic niche is formed, hepatic macrophages directly interact with tumor cells to mediate their capture, colonization, and subsequent outgrowth; (III) Furthermore, hepatic macrophages regulate phenotypic changes in T cells, NK cells, hepatocytes, and hepatic stellate cells (HSCs) through cytokine/exosome secretion or direct cell-cell interactions, which induce T cell exhaustion, impairment of NK cell cytotoxicity, and activation of HSCs leading to fibrotic microenvironment formation. Additionally, we review advances in macrophage-targeted therapeutic strategies against liver metastasis. By delineating the pivotal roles of hepatic macrophages in metastatic progression and analyzing current clinical limitations of targeting macrophages for liver metastasis therapies, this review provides foundational insights for understanding macrophage biology and developing effective therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad28500548fcc71d426ab070d872289195a208d5" target='_blank'>
              The hepatic macrophage: a key regulator of liver metastatic tumor microenvironment through cell crosstalk
              </a>
            </td>
          <td>
            Weihua Wang, Ziying Yi, Zeyu Yang, Yinde Huang, Hongdan Chen, Yao Li, Lianghong Jing, Supeng Yin, Fan Zhang
          </td>
          <td>2025-11-21</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Introduction Biallelic mutations in MAP3K14, encoding NF-κB-inducing kinase (NIK), disrupt non-canonical NF-κB signaling and lead to a rare inborn error of immunity marked by impaired lymphoid organ development, defective lymphocyte maturation, and susceptibility to recurrent infections. Hematopoietic stem cell transplantation (HSCT) has been considered a curative approach, yet its long-term efficacy remains unclear. Method We report long-term outcomes of two patients with genetically confirmed NIK deficiency who underwent HSCT. Results Both patients achieved full donor chimerism and early T-cell reconstitution with normalized CD3+, CD4+, and CD8+ counts and naïve T-cell subsets. However, memory T-cell differentiation remained impaired, with persistently reduced central memory T cells and circulating T follicular helper cells. Immune dysregulation emerged years after HSCT, with one patient developing seropositive arthritis and the other exhibiting autoimmune hepatitis. Thymic dysfunction was suspected as an underlying contributor to impaired central tolerance in this pathology. Similarly, B-cell reconstitution was incomplete, characterized by persistent hypogammaglobulinemia and a marked deficiency in class-switched memory B cells, despite donor-derived chimerism. Lymphoscintigraphy confirmed absence of lymph nodes. Both patients suffered from recurrent, severe infections and ultimately died of infection-related complications. Our findings indicate that HSCT alone is insufficient to fully correct the immune disorder in MAP3K14 deficiency, likely due to non-hematopoietic defects in lymph node stromal structures and thymic central tolerance. Discussion These results highlight the importance of long-term immunologic monitoring, including assessments for immune dysregulation and anti-cytokine autoantibodies. Future therapies should consider adjunct strategies such as thymic regeneration or targeted immune modulation to address the underlying architectural defects in this disorder.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d60db8c16895ac0f2003023393d492760901cc6" target='_blank'>
              Long-term outcome of bone marrow transplantation in NIK deficiency: non-redundant role of non-canonical NF-κB signaling in thymic reconstitution and secondary lymphoid organ development
              </a>
            </td>
          <td>
            S. Köstel Bal, Şule Haskoloğlu, Bernhard Ransmayr, Selin Sevinç, Candan İslamoğlu, Kubra Baskin, Nazlı Deveci, Berna Savaş, S. Fitoz, A. Küpesiz, T. Kendirli, K. Boztug, F. Doğu, Kamile Aydan Ikincioğullari
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Immunity during cancer progression involves critical responses that may be harnessed to augment anti-tumor cytotoxicity. A potent arm of immunity in cancer involves cytotoxic T cells (a key CD8+ T-lymphocyte subset): Anti-tumor responses by such cells optimally involve sensitization and acquired responses to tumor antigens by antigen presenting cells. Many tumor microenvironment (TME) biophysical and functional limitations in carcinomas limit robust achievement of this ideal cellular-immunologic pathway. This is especially challenging in lung carcinoma, on which we focus mechanistically and with an eye to therapeutic translation. Localization of tumor-sensitized and activated CD8+ T cells to tumor “nests” with efficient tumor cytolysis involves many challenging steps. Amplifying and sustaining such responses is also a unique challenge. The variety of homeostatic and immunosuppressive obstacles often becomes overwhelming. Measuring the state of this response during lung cancer progression is also challenging, making it difficult to mount (and/or predict) T-cytotoxic responses in the heterogeneous and dynamic carcinoma antigen landscape. We investigate these challenges herein, while examining strategies to boost T-cytotoxic immunity in lung cancer through novel and emerging immunotherapeutic approaches. Beyond current immune checkpoint blockade approaches that are relatively non-specific with respect to antigen recognition by the T-cell receptor, we highlight ongoing and translational vaccines, cell-therapies, antigen-presenting cell boosting approaches, T-cell therapies, and biophysical considerations with an eye to overcome key barriers of this powerful arm of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d405cc42ae9819222b3a3a0b50f4e0cc2451158" target='_blank'>
              The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma
              </a>
            </td>
          <td>
            Aditya Dash, Afsheen Banisadr, Donivian Al Dikka, Scott C. Johns, Mark M. Fuster
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Natural killer (NK) cells, essential components of the innate immune system, undergo subtype changes with aging that diminish their cytotoxic and tumor surveillance functions. Recent reports indicate that small extracellular vesicles (sEVs) derived from stem cells could ameliorate age-related diseases, while their effects on NK cell senescence remain unexplored. We administered induced pluripotent stem cell(iPSC) derived sEVs via tail vein injection for 6 months to naturally aged mouse models. Then we detected a senescent phenotype of splenic NK cells based on a series recognized markers in aged mice. To further investigate the impact of iPSC-sEVs mediated rejuvenation on NK cell function in vivo, purified splenic NK cells from iPSC-sEVs or vehicle-treated mice were co-injected subcutaneously with B16 tumor cells to establish co-inoculation models. In vitro, we used D-gal induced NK92 aged model and conducted transcriptome analysis on the cells. Furthermore, NK92 cells overexpressing CISH were used to explore the mechanism by which iPSC-sEVs improve NK92 cells senescence. Further we conducted a mass spectrometry analysis of the substances in iPSC-sEVs and performed bioinformatics analysis. iPSC-sEVs treatment partially reversed these immunosenescence phenotypes in aged mice models. In splenic NK and B16 tumor cells co-inoculation models, iPSC-sEVs-NK cells exhibited significantly enhanced cytotoxicity against tumor cells and the ability to recruit T cells. Mechanistic studies suggest that iPSC-sEVs inhibit the upregulation of CISH in senescent NK cells, subsequently activating p-STAT3, which is involved in regulating NK cell senescence and cytotoxicity. Overexpression of CISH significantly suppresses STAT3 phosphorylation and accelerates NK92 cell senescence. Proteomic analysis indicates that iPSC-sEVs modulate the CISH-STAT3 signaling pathway by delivering RNA binding proteins. In summary, our study shows that iPSC-sEVs effectively rejuvenate senescent NK cells by partially suppressing CISH expression and promoting STAT3 phosphorylation. As a cell-free therapeutic agent, iPSC-sEVs represent a promising strategy for treating cancer in the elderly and other inflammatory senescence-related diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/546c497d038dc4383f097b0866c7d9185149dc54" target='_blank'>
              iPSCs derived sEVs ameliorate NK cell senescence by targeting CISH-STAT3
              </a>
            </td>
          <td>
            Yu Chen, Rongrong Cao, Zhengsheng Chen, Juntao Zhang, Yajing Ren, Xin Niu, Ji Yuan, Lei Luo, Shuxiang Yu, Yang Wang, Qing Li
          </td>
          <td>2025-11-12</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Beta-arrestin 1 (ARRB1) is a multifunctional adaptor protein that regulates diverse signaling pathways beyond its canonical role in G-protein-coupled receptor desensitization. While ARRB1 has been implicated in cancer progression, its role in modulating host immunity against multiple myeloma (MM) remains unexplored. Here, we demonstrate that host ARRB1 deficiency significantly enhances anti-myeloma immunity and prolongs survival in a syngeneic murine MM model. Using Vk*MYC myeloma cells transplanted into wild-type and ARRB1 knockout mice, we show that ARRB1 deficiency in the host microenvironment promotes robust T cell infiltration and activation while reducing immunosuppressive myeloid populations. Notably, ARRB1 knockout mice exhibited markedly decreased programmed cell death protein-1 (PD-1) expression on both T cells and myeloid-derived suppressor cells, indicating reduced immune exhaustion. Furthermore, ARRB1 deficiency conferred protection against myeloma-induced bone disease, suggesting a dual role in immune regulation and bone homeostasis. These findings establish ARRB1 as a critical negative regulator of host anti-myeloma immunity and identify it as a potential therapeutic target for enhancing immunotherapy efficacy in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3458263c03dcd78fb680e514ef2ef3a2d506e7e" target='_blank'>
              Beta-Arrestin 1 Deficiency Enhances Host Anti-Myeloma Immunity Through T Cell Activation and Checkpoint Modulation
              </a>
            </td>
          <td>
            Jian Wu, Xiaobei Wang, Shaima Jabbar, Niyant Ganesh, Emily Chu, V. T. Math, Lindsay Rein, Yubin Kang
          </td>
          <td>2025-11-27</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Melanoma is a highly aggressive and metastatic malignant tumor originating from melanocytes, with globally rising incidence rates that pose significant challenges to patient prognosis. Traditional therapies for advanced melanoma have limited efficacy. In recent years, the emergence of immune checkpoint inhibitors (ICIs) has significantly altered this landscape by reactivating the body’s antitumor immune response through blocking interactions between immune checkpoint proteins and their ligands, demonstrating remarkable therapeutic outcomes. However, some patients do not respond to ICIs or develop resistance, indicating that treatment responses involve complex interactions between tumors, immune cells, and the tumor microenvironment. This review comprehensively summarizes the mechanisms of ICIs, delves into the roles of various immune cells (including T cells, NK cells, macrophages, T helper cells, dendritic cells, and B cells) and the tumor microenvironment (TME), and explores their impact on ICI efficacy. It further distinguishes the application of ICBs across different disease stages (primary, adjuvant, neoadjuvant, and metastatic) and highlights the role of skin-specific immune cells (e.g., TRM, Langerhans cells) and microenvironmental components (e.g., skin microbiome). This review focuses on the mechanisms of ICIs in melanoma therapy, exploring the interactions between immune cells and the skin microenvironment in melanoma development and their impact on ICI efficacy. It aims to provide new insights and theoretical foundations for optimizing immunotherapy strategies in melanoma treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cbf6c59b49787682671d847581a4045389cf2335" target='_blank'>
              Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment
              </a>
            </td>
          <td>
            Yiwen Liang, Yan Zheng, Yuyan Zeng, Chengjing Hu, Yuqi Si, Xiqian Fan, Qihua Chen
          </td>
          <td>2025-11-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0895fbd19269fbdc4298e324e79791c8a18caebd" target='_blank'>
              CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.
              </a>
            </td>
          <td>
            J. Boldison, P. Leete, E. Robinson, Wendy Powell, Joanne Davies, Conor McMullan, Sophie L Walker, Noel G. Morgan, S. Hanna, F. S. Wong
          </td>
          <td>2025-11-22</td>
          <td>Diabetologia</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Plasmacytes, the effector arm of humoral immunity, produce sufficient amounts of specific antibodies to provide protection against infection or disease. The durability of this humoral protection depends on the generation of long-lived plasmacytes (LLPC), a specialized population that is capable of secreting antibody over long periods of times - years to decades. Here we investigate the role of constitutively active germinal centers (GCs) in generating the plasmacytes resident in bone marrow, a site critical for vaccine-induced LLPC to provide meaningful protection to infection and resistance to morbidity. In unimmunized B6.S1pr2-Cre mice, we show that a short period of conditional labeling marks 85% of gut-associated GC B cells and their progeny. Frequencies of labeled GC B cells fall over time, but frequencies of labeled bone marrow PC increase to approximately one-third of all bone marrow PC by 70-80 days after pulse labeling. Labeled, GC derived bone marrow PC express the identical isotypic distribution of the unlabeled PC in bone marrow. We conclude that the progeny of gut-associated GC B cells are responsible for most, and perhaps all, bone marrow PC and that under homeostatic conditions, serum antibody reflects exposure to gut antigens. Bone marrow occupancy by these gut-derived PC raises the possibility of competition with more transient, vaccine-induced humoral responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cbb121bf0ac8dd95134fd53dc1a8a140a008ead3" target='_blank'>
              On the carrying capacity of the bone marrow survival niche in mice
              </a>
            </td>
          <td>
            Keisuke Tonouchi, Chen-Hao Yeh, D. Cain, E. Moseman, B. Haynes, K. Wagh, K. Wiehe, Tomohiro Kurosaki, G. Kelsoe, Julie Tellier, J. Weill
          </td>
          <td>2025-11-20</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>80</td>
        </tr>

        <tr id="The discovery of the PD-1 receptor and its ligand PD-L1 revolutionized our understanding of immune regulation and, together with that of CTLA-4, allowed the development of immune checkpoint blockade, now a cornerstone of cancer therapy. Early models emphasized a simplistic view in which PD-L1 expression by tumor cells directly inhibited cytotoxic T lymphocytes through PD-1 engagement. However, recent findings reveal that this pathway is far more complex, involving multilayered regulation of PD-L1 expression, extensive post-translational modifications, and a broad spectrum of interacting partners. In addition to tumor cells, multiple immune and stromal populations, including dendritic cells, macrophages, T cells, and endothelial cells, express PD-L1 and critically shape anti-tumor immunity and therapeutic responses. Moreover, PD-L1 exerts intrinsic, non-immune functions within tumor cells, including regulation of proliferation, apoptosis resistance, and metabolic adaptation. PD-1 itself, long viewed as a T-cell-restricted inhibitory receptor, is now recognized as functionally relevant on additional cell types such as natural killer cells, myeloid cells, and even tumor cells, further diversifying its role in immune regulation and tumor biology. Together, these insights challenge the classical dogma and call for a refined view of the PD-1/PD-L1 axis that accounts for its cellular heterogeneity, molecular complexity, and bidirectional signalling. Incorporating this knowledge into clinical practice will be essential to improve patient stratification, overcome therapeutic resistance, and design innovative combination strategies to fully exploit the potential of immune checkpoint blockade.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf6db90382a1eb08f63c4a831cadf8747148a432" target='_blank'>
              Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype
              </a>
            </td>
          <td>
            Pierre-Hubert Desimpel, P-F. Petit, Benoit J. Van den Eynde, Jingjing Zhu
          </td>
          <td>2025-12-04</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immunotherapy because of its highly immunosuppressive tumor microenvironment. Aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor, has emerged as a key regulator of immune homeostasis and inflammation. However, its systemic immunomodulatory role in PDAC, particularly outside the tumor microenvironment, remains poorly understood. Methods Peripheral blood mononuclear cells (PBMCs) from patients with PDAC and healthy donors were isolated and treated ex vivo with two AHR agonists (Carbidopa and Tapinarof) and one antagonist (BAY 2416964). The samples were stratified into Low and High/Medium AHR expression groups. Flow cytometry (FC), qPCR, ELISA, Luminex assays, and immunofluorescence imaging were used to evaluate immune checkpoint expression, cytokine secretion, monocyte polarization, and subcellular AHR localization. Overall survival analysis was performed based on the baseline AHR expression levels. Results Baseline AHR expression strongly influenced the immunological effects of AHR modulators. In High/Medium AHR PBMCs, Carbidopa increased PD-L1 and soluble PD-1 (sPD-1) levels, while IL10 expression was suppressed. In contrast, BAY significantly reduced PD-1 and sPD-1 levels in Low AHR PBMCs, whereas Tapinarof induced the highest IL10 expression. All modulators reduced the proportion of M2-like monocytes, indicating a shift toward less immunosuppressive phenotypes. Nuclear translocation of AHR protein varied across treatments and expression levels. Kaplan–Meier analysis revealed a non-significant trend toward improved overall survival in the High/Medium AHR group (log-rank p = 0.276). Conclusion Baseline AHR expression critically shapes the immune response to pharmacological modulation in PBMCs from PDAC patients. These findings suggest that AHR profiling may serve as a clinically relevant biomarker for stratifying patients and guiding personalized immunotherapy approaches for PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a46524e691b33034f74b47cfc886a57c3dea8c5c" target='_blank'>
              Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients
              </a>
            </td>
          <td>
            Arenida Bartkeviciene, A. Jasukaitienė, Inga Žievytė, Sandra Ivanauskienė, Gabija Stachnevičiūtė, Kornelija Jenceviciute, Gabrielė Karvelytė, Darius Stukas, Agne Sikarske, Daiva Urbonienė, T. Maimets, K. Jaudzems, A. Vitkauskiene, Jason Matthews, A. Gulbinas, Ž. Dambrauskas
          </td>
          <td>2025-11-20</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Immunogenic cell death (ICD) significantly boosts anti-tumor immunotherapy effectiveness; however, the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), driven by factors such as adenosine accumulation and oxygen depletion during ICD, impairs the overall therapeutic outcome as well as facilitates tumor development and metastasis. Recent studies identify CD300ld as a key regulator of PMN-MDSCs recruitment, making it a promising immunotherapeutic target. Here, an innovative strategy is developed to eminently amplify ICD while alleviating PMN-MDSC infiltration upon ultrasound (US) stimulation. A modified generation 5 (G5) poly(amidoamine) dendrimer (G5PBA) was employed to encapsulate hematoporphyrin (GH)—a widely used organic sonosensitizer—and modified the complex with pardaxin peptides (Par) to achieve precise endoplasmic reticulum (ER) targeting, and adsorbed the negatively charged siCD300ld (PGH@siRNA). Under US irradiation, PGH@siRNA precisely accumulates at ER to induce localized reactive oxygen species (ROS) bursts, and effectively silence CD300ld, thereby amplifying endoplasmic reticulum stress (ERS)-mediated ICD and reducing PMN-MDSCs infiltration to reshape the tumor microenvironment. This systematic preclinical evaluations demonstrated enhanced immune activation, suppressed metastasis, and improved therapeutic outcomes. This study introduces a sono-responsive synergistic strategy integrating ER-targeted sonodynamic therapy with gene silencing, offering a novel paradigm for targeting PMN-MDSCs and enhancing triple-negative breast cancer (TNBC) immunotherapy. Graphical Abstract Supplementary Information The online version contains supplementary material available at 10.1186/s12951-025-03852-7.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d8ace307e49ce92f9985bbbbae4accb311e36425" target='_blank'>
              Sono-triggered endoplasmic reticulum-targeted ROS burst silencing CD300ld to alleviate polymorphonuclear myeloid-derived suppressor cells for breast cancer treatment
              </a>
            </td>
          <td>
            Xuejun Chen, Shaoyue Li, Qing Lu, Yitong Li, Mingrui Zhu, Shen Zhang, Yan Fang, Congjian Wen, Daohui Yang, Peili Fan, Huixiong Xu, Haohao Yin
          </td>
          <td>2025-11-26</td>
          <td>Journal of Nanobiotechnology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Natural killer (NK) cells exhibit remarkable adaptability within the tumour microenvironment (TME), where dynamic shifts in phenotype, function and metabolism govern their dual roles in antitumour immunity and tumour immune evasion. In the TME, NK cells undergo receptor remodelling, which is characterised by upregulated inhibitory signals and suppressed activating receptors, leading to the formation of dysfunctional subsets, such as exhausted TIM-3⁺ NK cells or tissue-resident CD49a⁺ populations. Immunosuppressive factors within the TME drive a transition from cytotoxic activity to regulatory or senescent-like states, impairing tumour surveillance. Metabolic reprogramming further compromises NK cell effector functions, as nutrient deprivation and metabolic byproducts disrupt energy pathways and suppress immune responses. Therapeutic strategies targeting this plasticity include engineered natural killer (NK) cells with enhanced specificity, metabolic restoration approaches and microenvironment-modulating interventions. However, challenges persist because of TME heterogeneity and persistent dysfunctional states. Understanding these adaptive mechanisms provides a framework for developing NK cell-based therapies that leverage plasticity to counteract tumour resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/910259fba0614bb5440944e1a9be14c37f13989d" target='_blank'>
              Multidimensional plasticity of natural killer cells in tumours
              </a>
            </td>
          <td>
            Xinya Yang, Zhaoyang Song, Ligang Chen, Qingge Jia, Mingyang Li
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Understanding the tumor microenvironment (TME) requires a comprehensive exploration of the interactions between tumor cells and various stromal and immune cells, as these interactions significantly influence tumor growth and treatment response. Immunometabolism, which examines the relationship between immune cell metabolic processes and their behaviour, has become crucial in determining the effectiveness of anti-tumor immune responses. This review explores the intricate relationship between immunometabolism and TME, highlighting how metabolic changes in immune cells can either enhance or impair their capacity to fight cancer. It specifically investigates the metabolic reprogramming of T cells, macrophages, and dendritic cells within the TME and how these alterations affect their anti-tumor roles. The review also examines how tumors utilise metabolic pathways to establish an immunosuppressive environment that fosters tumor growth. Understanding these processes reveals potential therapeutic targets in immunometabolism to improve cancer treatment outcomes. By emphasising the dual role of immunometabolism in both aiding and inhibiting the immune response to cancer, this review underscores the necessity of integrating metabolic strategies into cancer immunotherapy research, which may lead to novel treatments that maximise the immune system's ability to combat cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ee6d9003c1d9ef5a52cbc4df38e206a7582a70a" target='_blank'>
              Immunometabolism in the Tumor Microenvironment: Dual Role in Modulating Anti-Tumor Immunity and Tumor Progression.
              </a>
            </td>
          <td>
            Casterland Marbaniang, Lakhon Kma, R. N. Sharan
          </td>
          <td>2025-11-20</td>
          <td>Asian Pacific journal of cancer prevention : APJCP</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Background Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer in Asian, Caucasian, and Hispanic populations and its aggressive form contributes to significant morbidity and mortality. Chronic ultraviolet B (UVB) exposure is a major environmental carcinogen that drives cSCC initiation, progression, and immune evasion. Regulatory T cells (Tregs) are known mediators of UVB-induced immunosuppression; however, their direct involvement in the establishment of cSCC remains elusive. Methods Flow cytometry was employed to quantify Treg populations in the skin and draining lymph nodes of UVB-exposed and untreated mice. The functional role of Tregs following UVB exposure was examined using a contact hypersensitivity assay, where Treg activity was modulated by anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4, anti-TIGIT, and anti-FR4 antibodies. The capacity of UVB to render mice susceptible to immunogenic cSCC tumor establishment was assessed under different UVB exposure regimens. Treg-modulating antibodies were administered following UVB treatment and prior to tumor implantation to explore whether UV-induced Treg manipulation can prevent cSCC tumor establishment. Results UVB irradiation for 5 consecutive days significantly increased the number of CD4+ Foxp3+ Tregs in both skin and skin-draining lymph nodes. These Tregs were shown to be suppressive in contact hypersensitivity assays. However, suppression was prevented following depletion of Tregs and/or avolition of their function using monoclonal antibodies. Consistently, chronic UVB exposure prior to tumor implantation permitted the establishment and growth of otherwise immunogenic cSCC tumors, which correlated with the expansion and recruitment of Tregs into the skin. Importantly, immunomodulation with anti-CTLA-4 or anti-FR4 after chronic UVB exposure effectively prevented cSCC establishment, indicating that the manipulation of UV-induced Tregs prevented the establishment and growth of immunogenic cSCC tumors. Conclusion Our findings show that the manipulation of UV-induced Tregs prevents early cSCC establishment. Thus, strategies aimed at modulating Treg function or abundance in the skin may represent a feasible therapeutic avenue for the prevention of cSCC tumor emergence in patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e9646d0ae217447d84ed31b1896b1daa87cf40c" target='_blank'>
              Immunomodulation of UVB-induced regulatory T cells prevents the establishment of squamous cell carcinoma
              </a>
            </td>
          <td>
            Shoaib Anwaar, Amina Ashraf, Sarah Jahfali, Joseph Yunis, Jazmina L Gonzalez Cruz, James W. Wells
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>1</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/928340f1c482d3cc3031b9813af988a397a41c2c" target='_blank'>
              Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma.
              </a>
            </td>
          <td>
            Zihao Zhao, Wenjing Zheng, Yang He, Han Zhang, Lingling Zhang, Yi Huo, Junwei Jiang, Chen Zhang, Haohan Lyu, Weiwei Qin, Chen Liu, Feng Chang, Lequn Shan, Tao Wang, Wenjie Song
          </td>
          <td>2025-12-13</td>
          <td>Molecular cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c515ee3e9e86703752ec072206a806bfdf0f76b3" target='_blank'>
              SLAMF1-peptide mediated epigenetic priming reprograms innate immune responses in sepsis
              </a>
            </td>
          <td>
            Sindre Ullmann, Birgitta Ehrnström, Jørgen Stenvik, S. Pinto, Yashwanth Subbannayya, Victor Boyartchuk, I. Mestvedt, Mahamaya Dhaware, Siddhesh S. Kamat, L. Ryan, Hilde Vagle, T. Dahl, B. Halvorsen, J. K. Damås, T. Espevik, Maria Yurchenko
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/08d4f1553d816ffed3bab56145c5586b7fe2e8fb" target='_blank'>
              Clec7a-mediated regulation of Killer-like Lectin Receptor expression controls T cell immunity
              </a>
            </td>
          <td>
            Ivy M. Dambuza, Fabián Salazar, Emily A. Sey, Stavrola L. Kastora, Cecilia Rodrigues, Annie Phillips-Brookes, Jamie Harvey, Rebecca A. Drummond, Jane Rush, Raif Yuecel, Shinobu Saijo, J. Willment, Daniel H. Kaplan, Salomé LeidundGut-Landmann, G. D. Brown
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72f3e3fb83d6da5da12fbd024325e0282875f616" target='_blank'>
              Single-cell analysis identifies monocyte signatures of disease activity and clinical subtypes in Behcet disease
              </a>
            </td>
          <td>
            E. Carmona, R. Deniz, C. Bes, H. Direskeneli, A. Gul, A. H. Sawalha
          </td>
          <td>2025-12-27</td>
          <td>None</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Early-onset colorectal cancer (EOCRC), CRC diagnosed before age 50, are rising with the global incidence of EOCRC predicted to double by 2030. Notably, this disease is more common in men and women have better survival outcomes. Changes in immunity with age and between sexes are postulated to contribute to these discrepancies, which warrants further investigation. Therefore, we used single-cell RNA sequencing to analyze peripheral blood mononuclear cells (PBMCs) from males and females with CRC. Our analysis revealed reduced proportions of circulating naïve and effector memory CD8+ T-cells in late-onset colorectal cancer (LOCRC) compared to EOCRC. Similarly, genes associated with proliferation were decreased in circulating CD8+ T-cells from LOCRC patients. Hallmark and GO BP pathway analyses revealed that T-cells isolated from patients with LOCRC have decreased transcriptional profiles associated with AKT/MTOR signaling, lymphocyte differentiation, and cell surface/antigen receptor-mediated signaling. Conversely, upregulated pathways were associated with TNF and interferon alpha signaling, apoptosis, DNA damage, oxidative stress, and RNA/protein homeostasis. Regarding NK cells, in LOCRC, the overall frequency of naïve and cytotoxic populations cells was also decreased while interferon-producing NK cells signatures were increased. Notably, pathway analyses revealed almost identical transcriptional immunosuppressive changes in NK and T-cells in LOCRC. Analysis of sex differences in the immune landscape of EOCRC and LOCRC revealed proliferative defects in CD8+ T-cells in males regardless of age. However, NK cells from males with EOCRC appear to be more functional as highlighted by the increased expression of genes associated with cytolysis and more naïve signatures associated with these cells. Conversely, NK cell signatures in females were robust in both the EOCRC and LOCRC, and did not exhibit age-dependent functional declines. Furthermore, in females, NK cells and T-cells in EOCRC had similar decreases in differentiation, intracellular signaling, decreased TNF activation, and apoptosis signatures but signatures associated with metabolism, protein homeostasis, and p53 activation were increased. Compared to females, pathway analyses of NK cells and T-cells from males with EOCRC revealed reduced gene signatures associated with differentiation and intracellular signaling but enhanced signatures associated with inflammation, oxidative stress, RNA processing, MYC activation, G2M checkpoint activation, and apoptosis. In summary, we reveal that circulating lymphocytes from female patients with EOCRC and LOCRC are more functional than those observed in males. Furthermore, T-cells from males with CRC become more dysfunctional with age, potentially due to increased sensing of pro-inflammatory cytokines like TNF and interferon alpha. Therefore, better survival outcomes for women with CRC may potentially be attributed to possessing a more robust immune system that exhibits minimal decline with aging.



 Timothy J. Kopper, Claire E. Pillsbury, Michael Kaufman, Clara Sánchez-Menéndez, María González-Sanmartin, Montserrat Torres, Mayte Coiras, Jose Perea Garcia, Curtis J. Henry. Transcriptional profiling of circulating immune cells from patients with early- and late-onset colorectal cancer reveals sex-specific differences [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers—Knowledge Gaps and Research Opportunities; 2025 Dec 10-13; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(23_Suppl):Abstract nr C012.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18bde8a985e5e049ae833ecf8777d4a97aaf142e" target='_blank'>
              Abstract C012: Transcriptional profiling of circulating immune cells from patients with early- and late-onset colorectal cancer reveals sex-specific differences
              </a>
            </td>
          <td>
            T. Kopper, Claire E Pillsbury, Michael Kaufman, Clara Sánchez-Menéndez, María González-Sanmartín, Montserrat Torres, M. Coiras, Jose Perea Garcia, Curtis J. Henry
          </td>
          <td>2025-12-10</td>
          <td>Clinical Cancer Research</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Brain tumors such as glioblastoma remain among the most lethal and immunologically resistant cancers, in large part due to epigenetic programs that sculpt the tumor–immune microenvironment. DNA methylation, histone modifications, and chromatin remodeling do not merely drive tumor-intrinsic changes; they also profoundly reprogram immune responses, shaping antigen presentation, cytokine signaling, and immune cell recruitment. At the center of this regulation are T cells, whose effector functions are suppressed through promoter hypermethylation of antigen-processing genes, silencing of interferon pathways, and the establishment of exhaustion-specific chromatin states. Mutations such as IDH1/2 and H3K27M further reinforce these epigenetic barriers, fostering immune-cold microenvironments that disable cytotoxic T-cell activity. Emerging evidence highlights both CNS-specific adaptations, including microglial and astrocytic epigenetic programs that reinforce immune privilege, and conserved features of T cell exhaustion that mirror those in peripheral cancers. This duality underscores the need for therapeutic strategies that dismantle CNS-specific barriers while leveraging shared exhaustion programs across tumor types. Epigenetic drugs, ranging from DNA methyltransferase and EZH2 inhibitors to BET degraders and CRISPR-based epigenome editors, are beginning to restore antigenicity, reverse T cell dysfunction, and sensitize tumors to checkpoint blockade. Yet these approaches carry the paradoxical risk of disrupting CNS immune tolerance, potentially triggering harmful neuroinflammation or autoimmunity. To our knowledge, this is among the first comprehensive reviews to integrate CNS-specific immune privilege mechanisms with peripheral exhaustion pathways, providing a unified perspective on how epigenetic regulation orchestrates immune dysfunction across central and peripheral contexts. By mapping the continuum between immune evasion and global immunosuppression, we propose a conceptual framework for tailoring epigenetic-immunotherapy combinations to achieve durable antitumor immunity in the CNS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d7202ed1c4ffc9d0ee982c0f1ad42403d845276" target='_blank'>
              Beyond the genome: epigenetic regulation of immune responses and T cells in brain tumors
              </a>
            </td>
          <td>
            Shuo Sun, Yu Han, Haiying Li, Chengyan Wang, Shu Zhou, Xiaowei Zhang, Shuhong Dai, Yao Peng, Zhuoqun Wang
          </td>
          <td>2025-11-18</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c675f620640f6b9595c20caba3018a269bcf7216" target='_blank'>
              Anoctamin-2-specific T Cells Link Epstein-Barr Virus to Multiple Sclerosis
              </a>
            </td>
          <td>
            Olivia G. Thomas, Urszula Rykaczewska, Marina Galesic, Rianne T. M. van der Burgt, Nils Hallén, Filippo Ferro, Mattias Bronge, Zoe Marti, Yue Li, Alexandra Hill Riqué, Jianing Lin, Aleksa Krstic, Alicja Gromadzka, András Levente Szonder, Chiara Sorini, María Reina-Campos, T. Sun, L. A. Rubio Rodríguez-Kirby, Özge Dumral, R. Berglund, M. P. Kakhki, Milena Z. Adzemovic, M. Zeitelhofer, Birce Akpinar, Katarina Tengvall, Ola B. Nilsson, Erik Holmgren, Chiara Starvaggi Cucuzza, Klara Asplund Högelin, G. Gafvelin, Katharina Fink, Gonçalo Castelo-Branco, Maria Needhamsen, Mohsen Khademi, Fredrik Piehl, Torbjörn Gräslund, Lars Alfredsson, Harald Lund, P. Uhlén, Ingrid Kockum, Roland Martin, Maja Jagodic, H. Grönlund, A. O. Guerreiro-Cacais, Tomas Olsson
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/73602df6625b44848edf1084a701c143743994eb" target='_blank'>
              Tumors Located in the Brain Impair the Frequency and Phenotype of Dendritic Cells in Blood and Tumor
              </a>
            </td>
          <td>
            B. Gardam, T. Gargett, E. Nam, Sidra Khan, Rebecca J Ormsby, Santosh I Poonnoose, Julie M Bracken, Anupama Pasam, S. Lenin, Briony L Gliddon, Melinda N. Tea, C. Shard, Stuart M. Pitson, Guillermo A Gomez, Katherine A. Pillman, Shahneen Sandhu, Michael P Brown, LM Ebert
          </td>
          <td>2025-11-07</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="ABSTRACT The human-specific gammaherpesviruses Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus infect >95% of all adults, establish lifelong infections, and are associated with multiple different cancers, including B-cell lymphomas. These viruses naturally infect B cells and drive a unique and robust germinal center response to establish their latent viral reservoir in memory B cells. The unique and robust nature of the virus-driven germinal center response increases the risk for B-cell transformation, which is why many gammaherpesvirus-associated cancers are derived from germinal center or post-germinal center B cells. We have previously reported that both global and T cell-specific host IL-17RA signaling is proviral in the context of gammaherpesvirus infection by promoting the virus-driven germinal center response and establishment of latent viral infection. In this study, we examine the role of B cell-specific IL-17RA signaling in the context of gammaherpesvirus infection, given these viruses’ reliance on B cells to establish and maintain lifelong infection. Similarly, to what we observed in the context of global and T cell-specific IL-17RA signaling, we found that B cell-intrinsic IL-17RA signaling supports the establishment of viral latency and reactivation in the spleen and peritoneal cavity, as well as promotes the virus-driven germinal center response. Our study reveals the proviral role of B cell-intrinsic IL-17RA signaling in supporting the establishment of chronic gammaherpesvirus infection. IMPORTANCE Gammaherpesviruses are lifelong pathogens that are prevalent in over 95% of all adults. These viruses are tumorigenic and associated with multiple cancers, including B-cell lymphomas. They are B-cell tropic viruses that manipulate the germinal center response to establish their latent viral reservoir in memory B cells. This manipulation of the germinal center response is thought to be the target of viral transformation, leading to lymphomagenesis as most gammaherpesvirus-associated cancers are germinal center or post-germinal center derived. In this study, we developed a new mouse model to understand the B cell-intrinsic role of IL-17RA signaling in gammaherpesvirus infection. Previous studies have shown that IL-17RA signaling is proviral in the context of gammaherpesvirus infection, and this study found that while B cell-intrinsic IL-17RA signaling is not the sole factor behind the systemic proviral role of IL-17RA signaling, it plays an important role in the virus-driven germinal center response, the expansion of B-1 B cells, and the establishment of chronic gammaherpesvirus infection. Gammaherpesviruses are lifelong pathogens that are prevalent in over 95% of all adults. These viruses are tumorigenic and associated with multiple cancers, including B-cell lymphomas. They are B-cell tropic viruses that manipulate the germinal center response to establish their latent viral reservoir in memory B cells. This manipulation of the germinal center response is thought to be the target of viral transformation, leading to lymphomagenesis as most gammaherpesvirus-associated cancers are germinal center or post-germinal center derived. In this study, we developed a new mouse model to understand the B cell-intrinsic role of IL-17RA signaling in gammaherpesvirus infection. Previous studies have shown that IL-17RA signaling is proviral in the context of gammaherpesvirus infection, and this study found that while B cell-intrinsic IL-17RA signaling is not the sole factor behind the systemic proviral role of IL-17RA signaling, it plays an important role in the virus-driven germinal center response, the expansion of B-1 B cells, and the establishment of chronic gammaherpesvirus infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1890fb6742f276fac3b4c0609bbeabf5b4059e28" target='_blank'>
              B cell-intrinsic interleukin 17 receptor A signaling supports the establishment of chronic murine gammaherpesvirus 68 infection
              </a>
            </td>
          <td>
            S. T. Majeed, Nicholas P. Huss, Samantha M. Bradford, C. Jondle
          </td>
          <td>2025-12-01</td>
          <td>Journal of Virology</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Ferroptotic tumor therapy is of highly significance to treat malignancies. Nevertheless, immune cells within the tumor immune microenvironment (TIME) are particularly susceptible to ferroptosis upon exposure to ferroptotic inducers, leading to the immunosuppression of TIME. In the present work, we report a dual activation strategy to initially pre-activate the T cells within TIME using genetically engineered cytolysin A-expressing outer membrane vesicles (OMVs) to enhance the interferon-γ (IFN-γ) production. We then deliver the homologous tumor cell membrane-hybridized liposomal nanovesicles containing arachidonic acid (MLipoAA) to the tumor cells for IFN-γ-potentiated ferroptosis. The combination treatment of OMVs and MLipoAA results in significant tumor destruction in colon CT26 tumor xenografts. This approach is also effective in combating tumor recurrence and metastasis. Mechanistically, the produced IFN-γ synergizes with arachidonic acid to trigger Acsl4-mediated tumor ferroptosis. The present work provides prominent immunopotentiations followed by selective tumor ferroptotic strategy with high effectiveness and biocompatibility, presenting a robust therapeutic strategy to conquer the immunosuppression drawback during in vivo ferroptotic therapy. Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5ea8aabf479b70bf359a2e32d2d9662ee7569509" target='_blank'>
              Pre-activation of T cell immunity potentiates ferroptotic cell death through arachidonic acid hybridized nanovesicles
              </a>
            </td>
          <td>
            Qi Lyu, Chang Liu, Shaoyue Li, Dandan Shan, Hong Han, Liying Wang, Huixiong Xu
          </td>
          <td>2025-11-18</td>
          <td>Journal of Nanobiotechnology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Glioblastoma is one of the most aggressive and therapeutically challenging brain tumors. It is characterized by a highly immunosuppressive tumor microenvironment and poor prognosis, requiring novel treatment strategies. Along this line, ferroptosis has been proposed. To study the impact of ferroptosis on glioblastoma cells and immune cell infiltration, we established a spheroid model using LN229 glioblastoma cells and verified ferroptosis by measuring lipid peroxidation and RNA expression of ferroptosis-related genes. We then co-cultured spheroids with human peripheral blood mononuclear cells to follow the infiltration of distinct immune cell subsets by flow cytometry and immunohistochemistry. T lymphocyte infiltration into ferroptotic spheroids compared to control spheroids became apparent with the notion that ferroptotic cells attracted T cells more efficiently compared to apoptotic or necrotic cells. Mechanistically, ferroptotic glioblastoma spheroids released high amounts of ATP, which caused T cell attraction, while ATP deprivation reduced this effect. Ferroptosis appears to be an interesting therapy approach but might need co-treatments to ensure proper T cell activation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0d8f9909cc48b7c49c46b992fe55c08f1c1b4fd5" target='_blank'>
              Ferroptosis Enhances T Lymphocyte Infiltration into Glioblastoma Spheroids
              </a>
            </td>
          <td>
            Anna Schwantes, Yara Shadid, V. M. Guerrero Ruiz, B. Aliraj, Anja Wickert, Megan A. Palmer, S. Meyer, Andreas Weigert, Bernhard Brüne, D. Fuhrmann
          </td>
          <td>2025-11-01</td>
          <td>Antioxidants</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/afc8fd0b9c370fcd3fe478613bb2d770e9cf4d40" target='_blank'>
              Clonal Hematopoiesis Associated with TP53 and DNMT3A Mutations Promotes Tissue Repair in Acute Cardiovascular Diseases
              </a>
            </td>
          <td>
            Yi Pan, XiaDuo Meng, Chen Wang, WenXuan Zhou, Qin Zhou, Jingshu Chi, Breton Barrier, Luis A Martinez-Lemus, De-Pei Li, Zhenguo Liu, Xunlei Kang
          </td>
          <td>2025-12-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="A recent publication by Qin et al. in Cell reported on the ﬁ rst-in-human application of anti-BCMA chimeric antigen receptor (CAR)- T cell therapy in patients with treatment-refractory progressive multiple sclerosis (MS) with a good tolerability and ef ﬁ cacy. 1 CAR-T cells rank among the breakthrough therapeutic approaches, transforming the ﬁ eld of cancer and autoimmune conditions including neuroimmunological disorders. B-cell maturation antigen (BCMA) and CD19 antigen are B-cell target antigens frequently used in CAR constructs for autoimmune diseases. 1,2 In addition to the B-cell depletion in the peripheral blood, CAR-T cells allow deep depletion of tissue-resident B cells e.g., in lymphoid tissues and hard-to-reach compartments such as the central nervous system (CNS), an effect that has not been observed with antibody-based B-cell depletion therapies. However, little is known about direct and indirect effects of CAR-T cells on microglia, even though CNS-resident microglial cells are involved as one of the key drivers and maintainers of the compartmentalized neuroin ﬂ ammation and neurodegeneration during MS progression. This is con ﬁ rmed by emerging evidence that smoldering neurodegenerative processes are hallmarked by chronic microglia-mediated neuroin ﬂ ammation with progressive axonal injury, resulting in disability progression independent of relapse activity (PIRA) and brain atrophy. 1 To date, none of the available therapies for MS are fully effective at preventing disease progression and PIRA. The emerging study by Qin et al. showed, for the ﬁ rst time, signi ﬁ cant functional improvement during a 9-month">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aadbe175bb178ba56f15991ba7d572d20c6623b1" target='_blank'>
              Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk
              </a>
            </td>
          <td>
            F. Ismail, Hans-Peter Hartung, Nico Melzer
          </td>
          <td>2025-12-20</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy can restore T cell function in tumors, but not all patients benefit, and the mechanisms behind this remain unclear. In this study, we used patient-derived organotypic (PDO) cultures from metastatic melanoma to examine transcriptomic and cellular changes following ex vivo T cell stimulation. Genomic and transcriptomic features were preserved during PDO formation, capturing melanoma heterogeneity. PDOs from ICB-responsive patients showed rapid T cell expansion upon T cell stimulation, unlike those from ICB-resistant tissue. Resistant tissue harbored T cells lacking activation and checkpoint markers, suggesting non-tumor-reactive T cells. A T cell-specific transcriptomic score, activated in responsive PDOs, correlated with improved overall and relapse-free survival in metastatic melanoma patients treated with ICB. These findings demonstrate that ex vivo analysis is a viable tool to investigate mechanisms of ICB response and may help identify predictive biomarkers for patient outcome. Supplementary Information The online version contains supplementary material available at 10.1007/s00262-025-04269-9.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ed50cf99fb67ea8136c8c566f1253db09fe9441" target='_blank'>
              Modeling anti-tumor immune responses using patient-derived melanoma organoids
              </a>
            </td>
          <td>
            Kamila Kaminska, B. Phung, Jacob Karlström, M. Lauss, K. Harbst, Teresa Svensson, Kristian Pietras, Kari Nielsen, Ana Carneiro, Henrik Ekedahl, K. Isaksson, G. Jönsson
          </td>
          <td>2025-12-23</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc692c3e1c7e0729bdb6f8b1c8d623d6f263acd5" target='_blank'>
              The impact of macrophage phenotype during Mycobacterium tuberculosis infection and in host-directed therapeutic interventions
              </a>
            </td>
          <td>
            Shamsuddeen Yusuf Ma'aruf, Suleiman Yusuf, Nelita du Plessis
          </td>
          <td>2025-12-01</td>
          <td>Mycobacteria</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d49a12e622b00e4ea5d3c549019f953f23ea2e3" target='_blank'>
              Therapeutic Inducers of NK cell Killing (ThINKK)-induced NK cell cytotoxicity against childhood acute lymphoblastic leukemia: unraveling the dual role of TRAIL leads to the establishment of an efficacy biomarker
              </a>
            </td>
          <td>
            Émilie Ollame-Omvane, Leila Ben Khemis, Paulo Cordeiro, Claire Fuchs, Alex Richard-St-Hilaire, K. Béland, Elie Haddad, D. Sinnett, S. Herblot, Michel Duval
          </td>
          <td>2025-11-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Background and Objectives Immune reconstitution therapies for multiple sclerosis (MS) are based on selective lymphocyte reduction, followed by repopulation and rescue of immune tolerance. Among these therapies, cladribine is an adenosine analog that interferes with cell division and depletes several lymphocyte subtypes. Regulatory T cells (Tregs), physiologically devoted to immune suppression, are dysfunctional in the context of MS. In this study, we explored the effects of cladribine on Treg dynamics and phenotype. Methods In vivo, deep immunophenotyping was conducted on peripheral blood of patients with MS (n = 11), longitudinally collected before and after 6 and 12 months of cladribine therapy. In vitro, expanded Tregs were treated with cladribine and analyzed for their phenotypic, molecular, and metabolic profiles. Results In vivo, Tregs were overall less sensitive than conventional T cells (Tconvs) to the depleting effects of cladribine. This phenomenon was particularly evident in the subset of the resting (rest) Tregs. At baseline, while activated (act) Tregs presented markers of proliferation, senescence, and survival, restTregs highly expressed the antiapoptotic protein Bcl2 and the quiescence marker Bach2. In vitro, cladribine strongly reduced Treg viability while inducing a program of senescence and dysfunction and compromising their metabolic fitness. When Treg dynamics were analyzed ex vivo in relation to neuroinflammation and response to therapy, restTregs exhibited resistance to depletion in nonresponders, in association with increasing expression of Bcl2. Discussion These results indicate that the efficacy of cladribine therapy may require reduction and repopulation of the Treg compartment, an event that may be hindered by restTreg resistance, which is supported by antiapoptotic signals.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/10d1219f8a5bdc236a5c9491a7524af25282a5a7" target='_blank'>
              Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis
              </a>
            </td>
          <td>
            Ilenia Cammarata, Giorgia Sartori, Tiziano Giacomelli, Valeria Pinna, A. Pinzon Grimaldos, G. De Rosa, G. Matarese, C. Procaccini, Divya Mishra, Diletta Di Mitri, C. Gasperini, G. Guerrera, Manolo Sambucci, Luca Battistini, Silvia Piconese
          </td>
          <td>2025-12-17</td>
          <td>Neurology® Neuroimmunology & Neuroinflammation</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Diffuse gliomas remain lethal primary brain tumors. Immune-checkpoint inhibitors have not delivered durable benefit for most patients, reflecting myeloid-dominant immunosuppression and spatially organized immune exclusion. In this mini-review we summarize ligand–receptor multi-omics—single-cell RNA/CITE-seq, single-cell chromatin accessibility, and spatial proteo-transcriptomics—that resolve microglia- and monocyte-derived TAM programs and malignant state continua, and we appraise translational opportunities spanning TAM reprogramming (CSF1–CSF1R), perivascular SPP1–CD44 disruption, and innate–adaptive combinations targeting CD47–SIRPα, CD39–CD73, and PD-1/PD-L1. We also discuss challenges—including ontogeny-aware state definitions, heteromer-aware databases, chromatin gating of receivers (requiring accessible regulatory DNA for the receptor and its program), spatial registration, and limited assay standardization—that temper implementation. By integrating myeloid-informed readouts (SPP1–TAM burden, CD39–CD73 proximity, HMOX1+ IL-10 niches, serum IL-8), emerging strategies aim to restore antigen presentation, enable effector ingress, and remodel vascular–stromal interfaces. Our synthesis provides an appraisal of reproducible communication architectures in glioma and outlines pragmatic reporting standards and trial-ready pharmacodynamic endpoints for myeloid-informed precision immuno-oncology. We hope these insights will assist researchers and clinicians as they design multi-omics pipelines and interventions to convert suppressive ecosystems into responsive ones.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e39bafbb89665949b18c8b3763ecd3648dcb8152" target='_blank'>
              Mapping TAM–tumor crosstalk in glioma via ligand–receptor multi-omics: mechanisms of immune evasion
              </a>
            </td>
          <td>
            Dong Zhang, Yiming Ma, Daxiong Feng
          </td>
          <td>2025-11-21</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Cellular senescence is a complex biological process that contributes to the progression of age-related diseases. Senescent cells accumulate over time and secrete proinflammatory factors that disrupt tissue homeostasis and promote chronic diseases. Initially created for cancer immunotherapy, chimeric antigen receptor (CAR) T cell therapy has recently been repurposed at the preclinical level to eliminate senescent cells by recognizing senescence-associated surface markers. Recent preclinical studies have demonstrated the feasibility of anti-uPAR and anti-NKG2D CAR T cell-based approaches for eliminating senescent cells in preclinical models of fibrosis, metabolic disorders, and natural aging, resulting in reduced fibrotic burden, improved metabolic parameters, and enhanced tissue function. However, several challenges remain in their clinical applicability, including the identification of specific and universal senescence markers, potential off-target effects, and long-term safety concerns. Additionally, immunosenescence, an age-related decline in immune function, poses challenges for CAR T cell therapy in elderly patients. This review discusses recent advancements in CAR T cell therapy for senescence clearance, highlighting key molecular targets, preclinical findings, and future research directions. Despite their promise, a significant translational gap persists, and further research is required to improve the specificity, efficacy, and readiness for future human clinical trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d113132250c19579664d9a3c7b6b4e41c0e7cbb7" target='_blank'>
              Above and beyond senescence and CAR T cell: advances and future perspectives
              </a>
            </td>
          <td>
            R. Rosas-Campos, Scarlet Arceo-Orozco, A. Sandoval-Rodríguez, Jose Alejandro Madrigal, Juan Armendariz-Borunda
          </td>
          <td>2025-12-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Background and Objectives In multiple sclerosis (MS), a variety of immunosuppressive treatments are available. While effective, these approaches often lead to sustained impairment of essential components of the immune system, posing long-term safety concerns. Consequently, there is a growing interest in alternative therapeutic approaches that selectively limit pathogenic B-cell functions while preserving their physiologic roles. In this study, we investigated the therapeutic potential of inhibiting the enzyme Bruton tyrosine kinase (BTK), a key signaling molecule in both B-cell and myeloid cell activation. Methods The effects of the BTK inhibitor evobrutinib were evaluated in various experimental in vivo models of CNS demyelination, each representing different aspects of disease pathology as well as a naïve healthy condition. The impact on disease onset and severity was determined, and phenotypical alterations in different cell populations were assessed via flow cytometry. Furthermore, functional changes in both murine and human myeloid cells induced by BTK inhibition under specific Fc receptor–dependent stimulation were analyzed in in vitro settings using flow cytometry. Results In a naïve, healthy environment, evobrutinib promoted the development of regulatory B-cell properties. In various experimental models of CNS demyelination, BTK inhibition limited the differentiation of proinflammatory B cells while supporting their regulatory properties. Beyond modulating B-cell responses, BTK inhibition also attenuated the activation of myeloid cells after Fc receptor–mediated antigen uptake, a process assumed to be of importance in conditions, such as neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–antibody associated disease. In addition, BTK inhibition was shown to suppress the secretion of proinflammatory cytokines and reduce antigen presentation, further dampening pathogenic immune responses. Discussion These findings highlight the potential of BTK inhibition as a selective and sustainable immunomodulatory strategy for both B cells and myeloid cells in the context of chronic CNS inflammation. Despite their efficacy, broad-spectrum immunosuppressive therapies often fail to provide targeted immune modulation. By contrast, BTK inhibition promotes regulatory B-cell properties while leaving other B-cell functions intact, providing the basis for its broad use—potentially in combination with established anti-inflammatory agents.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d45c864d650e75d6107915d1c803721a2b18f33f" target='_blank'>
              Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease–Driving Inflammation While Promoting Regulatory B Cells
              </a>
            </td>
          <td>
            Sarah Dybowski, Jacqueline Thode, Marie Freier, Darius Saberi, S. Nessler, Anastasia Geladaris, Silke Häusser-Kinzel, Marius Ringelstein, Sebastian Torke, Martin S. Weber
          </td>
          <td>2025-11-25</td>
          <td>Neurology® Neuroimmunology & Neuroinflammation</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Belimumab, a fully humanized B cell-activating factor (BAFF)-targeting monoclonal antibody, inhibits autoreactive B cell survival and improves systemic lupus erythematosus (SLE) clinical outcomes. However, its administration criteria remain unclear. To establish a basis for defining these criteria, we characterized the immune cell subpopulation alterations post-belimumab treatment and elucidated the underlying mechanisms. We hypothesized that belimumab modulates specific cell subsets and investigated the post-therapy changes. Flow cytometry and correlation analysis revealed that the frequency of B- and T-lymphocyte attenuator (BTLA)high memory B cells in peripheral blood and clinical improvement after belimumab treatment. Western blotting analysis of healthy control B cells revealed that BTLA engagement suppressed Bruton tyrosine kinase and phospholipase C-gamma 2 phosphorylation, which was enhanced by B cell and BAFF receptor co-stimulation. BTLA-expressing memory B cells, which positively correlate with disease improvement, possibly contributed to SLE improvement via BTLA-mediated signaling that attenuated B cell- and BAFF receptor-induced intracellular pathways. To validate these findings, we plan to further assess the effects of belimumab on BTLA expression and B cell signaling pathways in treatment-naive patients with SLE by western blotting. Collectively, our results provide a novel foundation for establish appropriate belimumab administration criteria.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/880eb36783ff2268c61f3e800cf1e6431737d419" target='_blank'>
              BTLA-Expressing Memory B Cells Are Associated with Belimumab-Induced Improvement in Systemic Lupus Erythematosus
              </a>
            </td>
          <td>
            T. Nishi, Kunihiro Hayakawa, K. Ikeda, M. Fujishiro, Yuko Kataoka, Ken Yamaji, Kenji Takamori, N. Tamura, Iwao Sekigawa, Shinji Morimoto
          </td>
          <td>2025-11-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="CD38 is a transmembrane glycoprotein involved in NAD+ metabolism, calcium signaling, and immune cell activation. Its role in the inflammatory response has been studied extensively in innate immune cells; however, its contribution to the activation of memory T lymphocytes under inflammatory conditions is less understood. Additionally, recent studies have shown an age-related increase in the expression of the protein CD38 in various human and murine tissues. Moreover, CD8+ bystander T cells have been shown to contribute to inflammation during the aging process. Given the importance of its potential role in age-related pathologies, we examined the effect of CD38 on bystander activation of CD8+ memory T cells in aged mice following lipopolysaccharide challenge. CD38-deficient mice exhibited attenuated serum cytokine responses (IL-1β, IL-6, IFN-γ, and IL-10) and a distinct CD8+ T cell profile, characterized by a decrease in activated T cells. Wild-type mice displayed a significant expansion of CD69+TCM cells after LPS inoculation, an effect that was absent in CD38-deficient animals. LPS also promoted the expression of CD69 and CD38 in TEM/EFF subsets. Thus, our findings reveal a CD38-dependent mechanism underlying bystander activation of memory CD8+ T cells in aging. Highlighting the potential contribution of CD38 to age-related diseases, such as autoimmunity, and in the face of inflammatory conditions in aged people.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2543f635ae92595d3f140c2ea47a35fc4eab9dd" target='_blank'>
              CD38 promotes LPS-induced innate-like activation and proliferation of CD8+ T lymphocytes in aged mice
              </a>
            </td>
          <td>
            Wendolaine Santiago-Cruz, Enrique Espinosa, Jocelyn C Pérez-Lara, Héctor Romero‐Ramírez, Priyadharshini Devarajan, Fabio García-García, J. C. Rodríguez-Alba
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Aging</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Highlights What are the main findings? We find that under inflammatory conditions, B cells from streptococci-infected tonsils and blood of HLA-C*06:02-positive psoriasis patients activate a melanocyte-reactive T-cell receptor from a pathogenic psoriatic CD8+ T cell clone and also have autostimulatory properties for CD8+ T cells. We identify several self-peptides from the complex HLA-C*06:02 immunopeptidomes of B cells that may serve as autoantigens to activate the lesional psoriatic autoimmune response against melanocytes due to T-cell receptor polyspecificity. What is the implication of the main finding? The proinflammatory environment of streptococcal tonsillopharyngitis, as an important trigger for psoriasis, might break the tolerance of pathogenic psoriatic CD8+ T cells to autoantigens presented by HLA-C*06:02 on B cells that subsequently react against melanocytes, inducing psoriasis. The findings open up potential avenues for the development of therapies targeting the pathogenic B-T cell interaction in psoriasis. Abstract Psoriasis vulgaris is a T-cell-mediated skin disease that may involve an autoimmune response against melanocytes. It develops through still unexplained pathomechanisms. Streptococcal tonsillopharyngitis is a major trigger of psoriasis onset and relapses. HLA-C*06:02 is the main psoriasis risk gene. Here we find that B cells isolated from streptococci-infected tonsils or peripheral blood of HLA-C*06:02+ psoriasis patients stimulate an HLA-C*06:02-restricted melanocyte-reactive Vα3S1/Vβ13S1 T-cell receptor (TCR) from a lesional psoriatic CD8+ T cell clone in an IFN-γ-enhanced manner. Patients’ B cells furthermore induce proliferation of autologous blood CD8+ T cells. We identify several HLA-C*06:02-presented self-peptides in the immunopeptidomes we had isolated from four HLA-C*06:02 homozygous B-cell lines that stimulate the Vα3S1/Vβ13S1 TCR and differ from the melanocyte autoantigen recognized by this TCR. These data suggest that the proinflammatory environment of streptococcal tonsillopharyngitis may enable B cells to activate autoreactive CD8+ T cells that, owing to the polyspecificity of T-cell receptors, recognize several B-cell self-peptides presented by HLA-C*06:02 and subsequently cross-react against melanocytes in the skin, thereby triggering psoriasis. The capacity of B cells to stimulate a cross-reactive autoimmune response through HLA class I-presented B-cell peptides is a previously unknown mechanism in the induction of autoimmunity that could explain psoriasis onset and persistence.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5d7a0f1489f4e873304e188edfedc3bb70c48a78" target='_blank'>
              B Cells Can Trigger the T-Cell-Mediated Autoimmune Response Against Melanocytes in Psoriasis
              </a>
            </td>
          <td>
            Mengwen He, Melissa Bernhardt, Akiko Arakawa, Song-Min Kim, S. Vollmer, B. Summer, Yukiyasu Arakawa, Tatsushi Ishimoto, A. Schlosser, J. C. Prinz
          </td>
          <td>2025-12-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Abstract Marek’s disease virus (MDV) is an alphaherpesvirus responsible for the development of T-cell lymphoma in chickens. Despite the identification of several pro-oncogenic viral molecules encoded by MDV, the processes leading to tumourigenesis remain poorly understood. Extracellular vesicles (EVs) are important mediators of intercellular communication, carrying bioactive molecules that can elicit profound physiological changes in recipient cells. Tumour cells can release significant amounts of EVs, which influence tumour development and growth, metastatic processes and resistance to cancer therapies. These EVs favour cancer cells to evade the immune response, particularly by establishing an immunosuppressive microenvironment. Here, we investigated whether EVs produced by MDV-transformed T lymphocytes affect the proliferation of avian immune cells, a determining feature in neoplastic processes. EVs were purified from an MDV-transformed cell line cultured in vitro. Using a proteomic approach, we confirmed the presence of specific markers and identified a panel of cellular proteins enriched in these EVs. Notably, no viral proteins were detected in the purified EVs. We also demonstrated that EVs are rapidly internalized by recipient chicken cells. Moreover, these EVs can induce a decrease in primary chicken B-cell proliferation, while promoting primary chicken T-cell proliferation. Our findings suggest that EVs released by MDV-transformed cells may contribute to immunosuppression and potentially facilitate lymphoma progression by enhancing T-cell proliferation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43b084989accf17a6783519e76506e135a588a03" target='_blank'>
              Extracellular vesicles released from Marek’s disease virus-transformed T-cells impact immune cell proliferation
              </a>
            </td>
          <td>
            Laetitia Trapp-Fragnet, Julien Burgaud-Gaillard, Valérie Labas, S. Remy, Ana-Paula Texeira-Gomes, C. Denesvre
          </td>
          <td>2025-12-01</td>
          <td>The Journal of General Virology</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) are a unique subset of dendritic cells specialized in rapid and robust type I interferon (IFN) production, playing critical roles in the pathogenesis and pathomechanisms of many human diseases. Accurate identification of pDCs in peripheral blood mononuclear cells (PBMCs) is challenging due to dynamic and non-exclusive specific expression of surface markers such as blood dendritic cell antigen (BDCA)-2 and BDCA-4. Although BDCA-4 is generally more stably expressed than BDCA-2, prolonged stimulation or inflammatory conditions can induce its expression on multiple non-pDC cell types, reducing the accuracy of pDC identification. Here, we thoroughly investigated BDCA-4 expression dynamics on pDCs and other PBMC subsets following prolonged activation with Toll-like receptor (TLR) 7 and TLR9 agonists. Our flow cytometry analysis revealed a significant increase in BDCA-4-positive non-pDC populations after extended stimulation, primarily corresponding to CD14+ monocytes. To overcome this limitation, we performed a gating strategy combining BDCA-4 positivity with a cocktail of non-pDC markers, enabling the exclusion of non-pDCs and accurate identification of pDCs. This approach enables the reliable identification of pDCs within heterogeneous cell populations using only two fluorescent channels in healthy conditions and even during strong activation or pathological states characterized by chronic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77ace1a1894f18ae4a0a60d310c2f608f595a199" target='_blank'>
              Flow Cytometric Challenges in Plasmacytoid Dendritic Cell (pDC) Identification: Limitation of BDCA-4 (CD304)-Based Gating
              </a>
            </td>
          <td>
            Sarolta Demeter, Tünde Fekete, Beáta Scholtz, Zoltán Veréb, L. Kemény, Attila Bácsi, Kitti Pázmándi
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Primary glomerulopathies share common immune dysregulation but differ in their predominant pathways. We compared immune checkpoint profiles in minimal change disease (MCD) and membranous nephropathy (MN) with those in healthy volunteers (HV). In a cohort of 90 individuals (MCD, n = 30; MN, n = 30; HV, n = 30), we performed multiparameter flow cytometry of PBMCs to assess the expression of PD-1/PD-L1, CTLA-4/CD86, and CD200/CD200R on CD4+and CD8+ T cells, CD19+ B cells, and natural killer cells (NK cells). ELISA measured serum soluble checkpoint concentrations, and transcript levels in PBMCs were measured by qPCR. Nonparametric statistics and ROC analysis were used. In MCD, a skewed T cell pattern was observed, characterized by dominant expression of PD-1 and CTLA-4, whereas in MN, a humoral predominance was observed with higher PD-L1 expression and attenuated CD200/CD200R axis. Across diseases, expression profiles and correlations between markers differed between HV and between MCD and MN. Soluble checkpoints (sPD-1, sPD-L1, sCD200, sCD200R) showed potential discriminatory value for GN compared to HV and for differentiating MCD from MN in ROC analyses. These findings indicate that the mechanisms maintaining immune tolerance in primary GN are standard but pathway-specific, consistent with the dominant immunological component of each disease. A significant implication of this study is the need to conduct tissue-level studies to confirm clinical utility and provide insights into personalized immunomodulatory strategies targeting PD-1/PD-L1, CTLA-4/CD86, and CD200/CD200R.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3979f761edab8871f9f50cf62fee2a1c082d57d3" target='_blank'>
              Immune Checkpoint Signatures in Minimal Change Disease and Membranous Nephropathy: Divergent Pathways of a Shared Imbalance
              </a>
            </td>
          <td>
            Sebastian Mertowski, Paulina Mertowska, Milena Czosnek, Iwona Smarz-Widelska, Wojciech Załuska, E. Grywalska
          </td>
          <td>2025-11-25</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="This work introduces stem cell activity as a central factor contributing to the pleiotropic effects of IFN-γ and TGF-β1, as well as to the fluctuations of autoimmune diseases (AIDs) between flares and remissions. Analysis of published data on hair follicle immune privilege indicates that immune protection is not an inherent feature of quiescent stem cells, as previously proposed, but instead depends on the specific pathways that regulate quiescence. While both IFN-γ and high levels of TGF-β1 induce stem cell quiescence, they exert opposite effects on immune privilege: IFN-γ upregulates MHC-I expression, whereas TGF-β1 downregulates it. Similar mechanisms apply to hematopoietic stem cell niches in the bone marrow. Moreover, cytokines such as IGF-1 and α-MSH, which enhance stem cell activity, also downregulate MHC-I. Different concentrations and combinations of these cytokines can promote or suppress stem cell activity and preserve or disrupt immune privilege, underscoring their multifaceted nature. Two mechanisms may contribute to the pleiotropic effects of IFN-γ and TGF-β1: opposing effects on bone marrow activity, with IFN-γ and high TGF-β1 acting in contrast, and differential effects of IFN-γ on immune attack intensity in the bone marrow versus the target tissue during AID. Stem cell dynamics also shape the course of AIDs: high stem cell activity supports tissue regeneration and remission, whereas quiescence together with tissue destruction by autoimmune attacks drives flares. A clear correlation emerges between the effects of various agents on stem cell activity and clinical outcomes in AIDs, highlighting the central role of stem cell activity in their pathogenesis. A proposed TGF-β1 gradient between protected stem cell reservoirs (hair follicle bulge, bone endosteal niches) and less protected regions enables simultaneous preservation of stem cells and regeneration of damaged tissue.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/15bdfa965dff52976114b7b94e175ba62d9e398c" target='_blank'>
              Stem cell activity shapes the pleiotropic effects of IFN-γ and TGF-β in autoimmune diseases, infections, and cancer, and drives autoimmune flares and remissions
              </a>
            </td>
          <td>
            Z. Elkoshi
          </td>
          <td>2025-11-26</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Abstract Regulatory T cells (Treg cells) play a crucial role in maintaining immune tolerance and regulating immune responses, especially in cancer, where their immunosuppressive function is highly significant. Treg cells accumulate in the tumor microenvironment (TME), interact with tumor cells and other immune cells, and suppress anti-tumor immunity through various mechanisms, including secretion of immunosuppressive cytokines, direct contact with target cells, and depletion of key nutrients and signaling molecules. Regulating Treg cells has become a novel approach for enhancing cancer immunotherapy. Extracellular vesicles (EVs) are small vesicles with a lipid bilayer membrane secreted by all cells and play an important role in tumor biology as communication mediators by transmitting proteins, RNA, and other bioactive molecules in TME. In the past years, an increasing amount of research has uncovered the effects of EVs on Treg in TME, greatly enriching our understanding of Treg in tumor progression. Additionally, due to the potential of EVs as “natural nanoparticles” for drug and gene delivery, targeting Treg via an EV-delivery system has become a hotspot. Therefore, we comprehensively summarized the updates on the effects of EVs on Treg in TME and EV-related therapy for tumor treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7632449f7f61cc5a360dd919993a4c692375d8d4" target='_blank'>
              Crosstalk Between Extracellular Vesicles and Regulatory T Cells Across Cancers: From Interaction to Therapeutic Potential
              </a>
            </td>
          <td>
            Di Liu, Zhixiong Hao, Guangpeng He, Ye Huang
          </td>
          <td>2025-12-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by desmoplastic stroma, immunosuppressive tumor microenvironment (TME), and resistance to standard therapies. Natural killer (NK) cell-based immunotherapies have shown limited efficacy due to impaired persistence, infiltration, and function in PDAC. We established a direct reprogramming strategy to generate cytotoxic NK cells (1 F-NKs) by targeting BCL11B, a transcription factor essential for T cell lineage commitment, using shRNA or CRISPR/Cas9 in peripheral blood mononuclear cells (PBMCs). A genome-wide CRISPR/Cas9 screen identified tumor-intrinsic modulators of NK resistance. Functional and in vivo studies assesses the efficacy of 1 F-NKs alone and in combination with mesothelin (MSLN)-CAR engineering and PKMYT1 inhibition. BCL11B depletion enabled the generation of CD56brightCD16bright 1 F-NKs with potent cytotoxicity and elevated NKG2D and CX3CR1 expression. Site-specific integration of a mesothelin (MSLN)-CAR into BCL11B locus generated MSLN-1 F-NKs with stable antigen specific activity. A genome-wide screen identified PKMYT1 as a modulator of tumor resistance to NK cell-mediated killing; its inhibition by RP6306 upregulated NKG2D ligands (MICA/B) and CX3CL1, sensitizing PDACs to 1 F-NK cytotoxicity. In PDAC xenograft models, 1 F-NKs alone or combined with CAR engineering and RP6306 significantly reduced tumor growth and prolonged survival. Notably, this triple combination elicited a synergistic antitumor effect, outperforming each monotherapy or dual combination. This study presents a synergistic immunotherapy platform that integrates NK reprogramming, CAR engineering, and tumor sensitization. The combinatorial approach significantly enhances antitumor efficacy in PDAC and offers a promising strategy for overcoming immune resistance in solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b23a48bf88b5abc5a8f64c5caf88ab8a3e6e72ed" target='_blank'>
              Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma
              </a>
            </td>
          <td>
            Han-Seop Kim, Jae Yun Kim, Ji-Young lee, Binna Seol, Ji Eun Choi, Yee Sook Cho
          </td>
          <td>2025-11-13</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Background: The clinical significance and mechanistic role of immune checkpoints (ICs) in B-cell lymphoma remain underexplored. This study investigates peripheral IC expression as prognostic biomarkers and their interaction with Tregs and IL-10. Methods: Peripheral blood from 140 B-cell lymphoma patients was analyzed using flow cytometry (PD-1, CTLA-4, LAG-3, TIM-3 on CD4 + /CD8 + T cells) and ELISA. Comparisons were made across disease aggressiveness, extranodal involvement, and treatment response (complete remission [CR] vs relapse/progression [R/P]). Results: Aggressive lymphomas and cases with multiple extranodal sites showed significantly elevated IC expression (all p < 0.05). R/P patients demonstrated markedly higher PD-1 expression (CD4 + : 26.1% vs 8.2%; CD8 + : 25.2% vs 7.1%; p < 0.001) and elevated CTLA-4, LAG-3, TIM-3 versus CR patients. PD-1 and CTLA-4 showed significant prognostic value (AUC > 0.7), unlike LAG-3/ TIM-3. R/P patients had increased Treg proportions (7.84% vs 3.58%, P<0.0001) and IL-10 levels (10.5 vs 5.44 pg/mL, p < 0.0001). PD-1 on CD4 + T cells correlated positively with Treg frequency (r = 0.539, p < 0.0001) and IL-10 levels (r = 0.457, p < 0.0001). Conclusion: Peripheral T-cell ICs, particularly PD-1 and CTLA-4, are significant prognostic biomarkers in B-cell lymphoma. The correlation between PD-1 + CD4 + T cells, Treg expansion, and IL-10 elevation is consistent with a mechanism whereby PD-1 signaling may contribute to immunosuppression through Treg differentiation and JAK2/STAT3 pathway activation, providing insights for therapeutic targeting.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/df92404b80cc201bf6515dfacb503bd9fc5828ff" target='_blank'>
              Flow Cytometric Profiling of Peripheral Immune Checkpoints Predicts Prognosis and Reveals PD-1/Treg/IL-10 Crosstalk in B-Cell Lymphoma
              </a>
            </td>
          <td>
            Bing Pan, Sijia Li, Ruyu Ye, Jie Zhu, Yawei Tang, Li Li
          </td>
          <td>2025-12-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e-4). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e08f1dd96dd018add58f7a79b8066098738fcfe" target='_blank'>
              Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
              </a>
            </td>
          <td>
            Denis J Ohlstrom, William C. Pilcher, Marina E. Michaud, Chaitanya R. Acharya, Sarthak Satpathy, Edgar Gonzalez-Kozlova, R. Jayasinghe, Katherine E. Ferguson, Hope L. Mumme, Shivani Nanda, Yizhe Song, Sowmitri Mantrala, Dimitra Karagkouni, Jessica Schulman, Nick Pabustan, Junia Vieira Dos Santos, Daniel W. Sherbenou, J. Keats, Alex Gout, Steven Foltz, A. Laganà, T. Kourelis, Ravi Vij, M. Dhodapkar, D. Avigan, H. Cho, L. Baughn, Ajay K Nooka, S. Lonial, Shaji K. Kumar, Mehmet K Samur, Ioannis S Vlachos, Li Ding, Sacha Gnjatic, George Mulligan, Manoj K. Bhasin
          </td>
          <td>2025-12-09</td>
          <td>Blood cancer discovery</td>
          <td>0</td>
          <td>112</td>
        </tr>

        <tr id="Recent studies underscore herpesvirus-associated risks, especially HHV6 and Epstein–Barr virus (EBV), in CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, partly due to ex vivo cell manipulation. EBV-driven B cell outgrowth can occur during TIL expansion, and EBV-transformed B cells may exert immunomodulatory functions, potentially impacting TIL therapy efficacy and safety — areas that remain underexplored. Here, we characterized a spontaneously arising wild-type EBV-transformed B cell line, lcl_burn0214, established during ex vivo culture of a tumor specimen from a rectal cancer patient who was EBV-negative. The lcl_burn0214 cell line has undergone 70 passages and was confirmed as a monoclonal B cell line of patient origin via HLA genotyping, immunophenotyping (CD19, CD20), B cell receptor clonotype analysis. RNA-seq analysis revealed that lcl_burn0214’s gene expression closely resembles that of lymphoblastoid cells (r = 0.88) rather than malignant B lymphomas. In immunocompromised mice, lcl_burn0214 exhibited limited tumorigenicity. Autologous TILs were negative for B cells and exhibited a strong interferon-gamma response in the ELISPOT assay during coculture with lcl_burn0214 or with the EBV peptide pool (1000–1800 spots per million of TILs). Our findings underscore the importance of monitoring TIL products for EBV-positive B cell contamination during manufacturing to ensure safety and therapeutic efficacy even for EBV-negative patients. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-025-29456-7.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f04e3cd64b2f34b7fbf2d233e4200ffee769364" target='_blank'>
              Latent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue
              </a>
            </td>
          <td>
            Tatiana V. Petrova, Daria V Kuznetzova, Alexandra V Kanygina, Liubov O Skorodumova, Viktor A Ivanov, T. Astrelina, S. Varlamova, E. A. Zerkalenkova, E. Sharova
          </td>
          <td>2025-11-24</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a81a04ed656834e3dbf3e26c295c4c2f5db6951" target='_blank'>
              M2 macrophage polarization in allogeneic skin transplantation: from intrinsic mechanisms to clinical prospects for immune tolerance
              </a>
            </td>
          <td>
            Tengxiao Ma, Haoxinai Wang, Yunbin Liu, Lei Li
          </td>
          <td>2025-11-26</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e72fd69c1e9854128cc0a45768d08ad1fc1e6761" target='_blank'>
              In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma.
              </a>
            </td>
          <td>
            Morgane Krejbich, Emilie Navarro, Judith Fresquet, Marine Cotinat, Valentin Isen, Hortense Perdrieau, Virginie Forest, Aurélie Doméné, Tiphaine Delaunay, Hala Awada, Vincent Dochez, David Roulois, Nicolas Boisgerault, R. Redon, Christophe Blanquart, Isabelle Corre, Lucas Treps
          </td>
          <td>2025-11-27</td>
          <td>Journal of experimental & clinical cancer research : CR</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Extramedullary multiple myeloma (EMM) is a high-risk feature of multiple myeloma (MM) associated with increased resistance to treatments, including modern immunotherapies, and shorter survival. Composition and functional state of immune cells within the EMM tumor microenvironment (TME) remain poorly understood. Using single-cell RNA sequencing, flow cytometry, and spatial transcriptomics, we revealed significant differences in the EMM TME compared to MM bone marrow. T and NK cells were verified as the most abundant immune subsets in the EMM TME. Compared to the bone marrow counterparts, we found these tumors to have a significantly reduced effector-to-tumor cell ratio, significantly lower number of CD4⁺ T cells, and increased proportion of regulatory CD16⁻ NK cells. We observed a high proportion of exhausted, tumor-reactive CD8+ T cells in roughly half of EMM tumors. Furthermore, we identified elevated expression of immune checkpoints, such as PD-1 on CD8⁺ T cells and KLRC1 (NKG2A) on CD16⁻ NK cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47739f0fa51cdc733ee363855805ca043c1fdeb9" target='_blank'>
              Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironment.
              </a>
            </td>
          <td>
            A. Anilkumar Sithara, V. Kapustová, D. Žihala, O. Venglar, D. Bilek, Moutaz Helal, Maria John, Eva Radova, L. Broskevičová, J. Vrána, G. Havlova, L. Muroňová, T. Popková, J. Mihalyova, H. Plonkova, S. Nenarokov, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Sandra Charvátová, Ivo Demel, M. Kascak, Milan Navrátil, M. Havel, J. Bago, M. Šimíček, Angela Riedel, Leo Rasche, T. Ševčíková, O. Landgren, R. Hájek, T. Jelínek
          </td>
          <td>2025-11-14</td>
          <td>Blood cancer discovery</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Extracellular vesicles (EVs) are central mediators of intercellular communication in both healthy and malignant states. In normal B lymphocyte (cell) biology, EVs derived from B cells, mast cells, T cells, and mesenchymal stromal cells regulate maturation, antigen presentation, and activation. B cell-derived EVs can either suppress excessive activation to maintain immune homeostasis or amplify responses during an active immune response. Modulation of these responses often occurs via phosphoinositide 3-kinase signaling pathways in recipient cells. In B cell malignancies, such as leukemias, lymphomas, and multiple myeloma, EVs play pivotal roles in disease progression and therapy resistance. Tumor- and stromal-derived EVs can transfer pro-survival proteins, regulatory RNAs, and drug-resistance factors to directly promote tumor progression. In addition, EVs can shape the tumor microenvironment to indirectly promote tumor progression through macrophage polarization, stromal cell reprogramming, and suppression of anti-tumor immunity. Conversely, under certain conditions, B cell EVs can enhance immune surveillance by stimulating T cells and presenting antigen, highlighting their dual potential in cancer biology. Clinically, B cell-derived EVs represent promising liquid biopsy biomarkers: increases in EV abundance, expression of surface antigens, altered protein cargo, and distinct RNA signatures have been associated with disease stage, treatment response, and patient outcomes. Despite this potential, variability in EV isolation and analysis methods remains a barrier to clinical translation. Moving forward, identifying robust biomarker signatures across platforms and clarifying mechanisms of cargo selection and EV uptake will be critical for advancing diagnostic and therapeutic applications. Overall, B cell-derived EVs act as contextual regulators of immune function and malignancy, positioning them as both modulators of disease progression and promising clinical tools.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62930a7e9c707674957a1f9402a815a0e545b47b" target='_blank'>
              Extracellular vesicles in malignant and normal B lymphocyte growth and development
              </a>
            </td>
          <td>
            Kaitlyn E. Mayne, Rashid Jafardoust, Hong-Dien Phan, S. L. Christian
          </td>
          <td>2025-12-10</td>
          <td>Extracellular Vesicles and Circulating Nucleic Acids</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="ABSTRACT The immune system is tasked with mounting effective responses to pathogens while preventing inflammation triggered by innocuous antigens, including those derived from self, food, and commensal microbes. This balance is especially critical in the intestine, where dietary and microbial antigens are constantly encountered. Peripherally induced regulatory T cells (pTreg or iTreg) play a key role in suppressing inappropriate immune activation and maintaining gut homeostasis. Elucidating how pTreg cells are generated along the gastrointestinal tract is therefore critical to understanding peripheral tolerance. Recent studies have revealed that intestinal antigen‐specific pTreg cell differentiation is induced by a distinct lineage of antigen‐presenting cells (APCs) requiring expression of the transcription factors RORγt and PRDM16. Genetic perturbation of these APCs results not only in microbiota‐specific proinflammatory T cell responses but also in the breakdown of oral tolerance, which in turn predisposes to allergic inflammation. In this review, we summarize the discovery of these tolerance‐inducing APCs, highlight their role in instructing pTreg cell differentiation in response to microbiota and dietary antigens, and discuss the regulatory networks that support their function during intestinal immune tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3da30c377152a2f5e064e9a65d6e95246713e092" target='_blank'>
              Specialized Dendritic Cells Mediating Peripheral Tolerance to Intestinal Antigens
              </a>
            </td>
          <td>
            Liuhui Fu, Dan R. Littman
          </td>
          <td>2025-12-02</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/63d8dac4d5a8e2866e49d323e545a58bba863203" target='_blank'>
              TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS
              </a>
            </td>
          <td>
            J. Huuhtanen, S. Forstén, B. Ford, J. Smolander, O. Bruck, S. Lundgren, A. Kreutzman, O. Dufva, M. Kankainen, M. Ilander, H. Lahteenmaki, T. Kasanen, J. Klievink, J. Leitner, P. Steinberger, M. Kontro, M. Pelletier, H. Lahdsemaki, C. Sabatos-Peyton, M. Rinne, K. Porkka, K. Peltonen, S. Mustjoki
          </td>
          <td>2025-11-19</td>
          <td>None</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Immunologically mediated clearance of senescent cells has been demonstrated in several model systems. Given increasing evidence for these cells promoting tumor pathology and immune escape, we sought to examine whether a vaccine against senescent cells can lead to tumor regression. A senolytic dendritic cell (DC) immunotherapy (“SenoVax™”) was created by pulsing DCs with lysate from in vitro generated syngeneic senescent fibroblasts. Prophylactic and therapeutic activity of SenoVax on tumor growth and metastasis was assessed in the Lewis Lung Carcinoma (LLC) model. The immunogenicity of SenoVax™ was measured using cytotoxicity, proliferation, and cytokine assays. Adoptive transfer of lymphocytes from vaccinated mice into naïve mice was performed in a prophylactic tumor challenge model. Assessment of plasma senescence associated biomarkers IL-11, IL-6, IL-23 receptor, and YLK-40 was performed by ELISA. Synergy of SenoVax™ with immune checkpoint inhibitors and the universality of the vaccine’s effects against other tumors was assessed. Furthermore, induction of autoimmunity was assessed by complement activation and autoantibody formation. SenoVax™ was created by pulsing DC with cell lysate from senescent fibroblasts, producing DCs that expressed co-stimulatory molecules, stimulated T cell proliferation, and expressed the senescence antigen p16. SenoVax™ induced prophylactic and therapeutic tumor regression in LLC primary and metastatic murine tumor models. T cell proliferative and cytokine recall responses towards senescent cells but not to control stromal cell pulsed DCs were detected in vaccinated mice. Additionally, reduction in senescence associated biomarkers IL-11, IL-6, IL-23 receptor, and YLK-40 were observed. Adoptive transfer experiments revealed a role for CD8+ T cells in transplanting protection. When SenoVax™ was administered in combination with anti-PD-L1 or anti-CTLA-4 antibodies, the data showed synergistic effects in reducing tumor growth. SenoVax™ also demonstrated reduction of GL281 glioma, Pan01 pancreatic cancer, and 4T1 breast cancer cell growth. No significant activation of complement or induction of autoantibodies was observed. Vaccination with DC pulsed senescent cells resulted in reduction of tumor growth in a CD8+ T cell and interferon gamma-associated manner in lung cancer as well as other tumor models. The data provide mechanistic support for advancement of senolytic immunotherapy as a novel form of cancer therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a319f213855b5647ee19bcdf7566aa5d37fe5379" target='_blank'>
              Reduction of solid tumors by senescent cell immunization
              </a>
            </td>
          <td>
            Thomas E. Ichim, Gilberto Lopes, Robert Reznik, Vladyslav Bykoriz, Christian A. Fortunati, Karenjan A. Pascual, Boris Minev, Roman A. Ramos, Anil Bajnath, Emma Lin, Joyce Hu, Francesco M. Marincola, Armin Rath, Boris N. Reznik
          </td>
          <td>2025-11-28</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune checkpoint inhibition (ICI) is a promising therapeutic strategy for counteracting tumor immune evasion. The therapeutic response largely depends on interactions between cancer cells and the tumor immune microenvironment (TIME). This study aimed to characterize the TIME and its relationship with the immune checkpoint ligand Programmed Death-Ligand 1 (PD-L1) in canine urothelial carcinomas (UCs). UCs were retrospectively selected and tested for PD-L1 using single-antibody immunohistochemistry. Multiplex immunohistochemistry was performed using anti-CD3, -CD20, and -IBA1 antibodies, to co-localize the immune cells (ICs). Both ICs and PD-L1 expression were quantified with computer-assisted image analysis (QuPath software). Based on the spatial distribution and density of ICs, tumors were classified in three distinct immune phenotypes: immune-inflamed, immune-excluded, and immune-desert. Among the 49 UCs analyzed, 11 (22%) were PD-L1+. Forty carcinomas were classified as immune-inflamed (9 PD-L1+; 31 PD-L1-), 7 as immune-excluded (2 PD-L1+; 5 PD-L1-), and 2 as immune-desert (PD-L1-). Macrophages and T-cells were the most numerous ICs, while B-cells were significantly fewer (p < 0.0001). PDL1 + tumors exhibited a significantly higher number of macrophages compared to PD-L1- tumors (p = 0.003). Immuno-inflamed tumors showed a higher density of T cells (p = 0.01) and a lower macrophages-to-T lymphocytes ratio (p = 0.02) compared to immune-excluded and immune-desert phenotypes. In summary, most UCs were immune-inflamed and T-cell rich; a subset of tumors was PDL1 + and associated with a higher number of macrophages. Further characterization of T lymphocytes and macrophages polarization is necessary to better stratify the immune response.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0f6172b43b76cfce875e0fae8833322bf20367e8" target='_blank'>
              Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma
              </a>
            </td>
          <td>
            L. Muscatello, G. D’Annunzio, T. Franceschini, C. Tugnoli, A. Grillini, B. Bacci, G. Avallone, P. Valenti, A. Giuliano, M. Fiorentino, D. Volpatti, G. Sarli
          </td>
          <td>2025-11-24</td>
          <td>BMC Veterinary Research</td>
          <td>0</td>
          <td>2</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025', '2026'],
    y: [3, 0],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>